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ABSTRACT
Metallothioneins (MT) are a family of small cysteine rich proteins, which since their
discovery in 1957, have been implicated in a range of roles including toxic metal
detoxification, protection against oxidative stress, and as a metallochaperone involved in
the homeostasis of both essential zinc and copper. The most well studied member of the
family is the mammalian MT, which consists of two domains: a β-domain with 9 cysteine
residues, which sequesters 3 Cd2+/Zn2+ or 6 Cu+ ions, and an α-domain with 11 cysteine
residues, which sequesters 4 Cd2+/Zn2+ or 6 Cu+ ions. Despite over half a century of
research, the exact functions of MT are still unknown but must be related to its metalation
status. Several areas that are not well studied, but that could lead to the assignment of
function include 1) the determination of the exact mechanism of metalation and the
structural characterization of 2) submetalated and 3) supermetalated forms of MT.
Together these three areas of study will provide a more comprehensive understanding of
the potential metalation chemistries of MT in vivo.
Towards this goal, the following thesis presents electrospray ionization mass
spectrometric (ESI MS) data showing that the mechanism of metalation of MT is
noncooperative. That is metalation events occur independently of each other, allowing
for partially metalated species to exist in vivo. Further metalation studies using the
isolated domains of MT as metal ion competitors against the full MT protein have yielded
evidence that a new Zn5-MT exists in which both domains ‘coalesce.’ In addition, NMR
and CD spectroscopy, coupled with ESI mass spectrometric data, have shown the
existence of a new ‘supermetalated’ Cd8-MT, which also results in a ‘coalescence’ of
both domains. Taken together these results indicate that 1) partially metalated forms of
the protein are in fact stable and 2) the traditional structural view of MT, where both
domains act in isolation, is in fact the exceptional case and that under conditions of metal
ion deficiency and excess, both domains interact with each other.
Keywords: Metallothionein, cadmium, zinc, mechanism of metalation, competitive
metalation,

metal-induced

folding,

supermetalated

spectrometry, NMR spectroscopy, CD spectroscopy
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Chapter 1.

Introduction1

1.1 Metallothionein
Metallothioneins (MTs) are a group of metalloproteins characterized by their small
size (~6,000 – 7,000 Da), high cysteine content, an absence of disulfide bonds, and a lack
of aromatic amino acids (1). Metallothioneins bind strongly to the monovalent Group 11
and the divalent Group 12, d10 metals. The effect of binding to these soft Group 11 and
12 metals on the cysteinyl thiols is to reduce the pKa of the cysteines by up 6 orders of
magnitude. As a consequence, the cysteine sulphurs bind to the metals as thiolates. Key
to the discussion is that the formation of these metal-thiolate (cysteine) bonds dominates
the secondary structure of the protein, so that we may describe the secondary and tertiary
structures present in the native metalated protein as arising primarily as a result of metalinduced folding.
MT was initially isolated by Margoshes and Vallee in 1957 from samples of horse
kidney cortex that through progressive purification showed an increase in relative
cadmium content (2). The protein was named metallothionein for its unusually high
metal (metallo) and sulphur (thiol) content (3). Since its discovery, members of the MT
family have been isolated from a wide array of sources including all animal phyla, fungi,
plants, as well as cyanobacteria (4). Owing to both the high cysteine content of these
proteins (~30%) and their presence in all organisms, MT is implicated in a number of
physiological processes. The most commonly cited processes are metal ion homeostasis,
toxic metal detoxification, and protection against oxidative stress.
Mammalian MTs comprises 20 cysteine residues that act to encapsulate two metalthiolate cores (β and α) using a combination of bridging and terminal thiolates (where
terminal defines coordination to only a single metal ion) from the cysteinyl residues
(Figure 1-1). The two separate domains form a dumb-bell-like structure in the crystal
first described from analysis of the X-ray diffraction data from rat liver MT (5). The β-

1

A version of this work has been published:
Reproduced with permission from D.E.K. Sutherland and M.J. Stillman Metallomics 3
(2011) 444-463. Copyright 2011 Royal Society of Chemistry.
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domain with 9 cysteine residues is capable of binding 3 Cd2+ or Zn2+, or 6 Cu+ and an αdomain with 11 cysteine residues capable of binding 4 Cd2+ or Zn2+, or 6 Cu+. Molecular
modeling and later experimental data from solution studies suggests that the two domains
are not isolated but rather somewhat coalesced. MT binds a wide range of metals with
similar stoichiometries, but we may consider them not to be ‘natural’. We describe these
additional binding motifs below. A common thread in the mammalian MTs is, however,
the formation of the two metal-thiolate clusters where a mixture of metals can bind in
each domain and where the metals in either domain can be different. The question of the
extent of domain interaction in the function of MTs is a current topic of intense research.

Figure 1-1.
Molecular model structure of Cd7-βα-rhMT. (A) Space filling
structure of cadmium metalated recombinant human MT-1a (Cd7-βα-rhMT 1a) calculated
using molecular modeling. The N-terminal β domain is located on the left hand side,
while the C-terminal α domain is located on the right-hand side. (B) The cadmiumcysteinyl-thiolate connections, both terminal and bridging, in Cd7-βα-rhMT 1a are
presented as a ball-and-stick model: β domain (left) and α domain (right). The α domain
has one bridging and one terminal thiolate labeled to clearly illustrate the different modes
of coordination. (C) Connectivity diagram of human metallothionein 1a, which shows
that each of the seven cadmium atoms is connected to exactly four cysteine amino acids
in a tetrahedral arrangement. In the nomenclature used here, the 'recombinant' source is
noted by a prefix of 'r', and the origin of the sequence is indicated by the second prefix,
here 'h' for human. Molecular modeling data from Chan et al. (6).
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The MT family contains a number of isoforms (and subisoforms) where the
complement of these is organism dependent. In particular, mammals contain four MT
subfamilies that have been proposed to exhibit specific roles (7): MT-1 and MT-2 in the
liver and kidneys, which are induced by a number of stimuli including metal ions,
glucocorticoids, cytokines and oxidative stress (4, 8-9), MT-3, primarily found in the
central nervous system (10), and MT-4, found in certain stratified squamous epithelial
tissues (11). While a number of stimuli can induce expression of both MT-1 and MT-2,
the expression of MT-3 and MT-4 is more strictly controlled. Presumably, differences in
expression are the result of both MT-3 and MT-4 having specific biological functions.
To support the proposal for specificity of function, disruption of the natural expression of
MT-3, through ectopic expression in mice, has been shown to cause pancreatic acinar cell
necrosis and death (12).

1.2 Function
1.2.1 Metal ion homeostasis
Naturally occurring MTs are usually isolated as either Zn-MT, Cu-MT or as the mixed
metal species Zn,Cu-MT and Zn,Cd-MT.

In the case of mammals, Zn-MT is the

dominant form (13), however, Cu-MT has been isolated from several sources including
fetal liver MT (14-15), bovine calf liver MT (16), rat kidney (17), as well as brain
specific MT-3 (10). Elevated Cu-MT levels have also been found in patients suffering
from Wilson’s disease (18). While in the case of yeast and fungi, Cu-MT is the dominant
species (19).
At the cellular level both toxic and nontoxic metals are tightly controlled and estimates
of free Cu+ and Zn2+ suggest that neither is available in the cytosol (20-21). The absence
of freely available Cu+ and Zn2+ suggests that an organism is able to exist in this state by
using metallochaperones to transport these ions in a controlled manner. MT is considered
one such metallochaperone, which is capable of transporting essential Zn2+ and Cu+ to
apo-enzymes (22-25). Indeed metal exchange experiments have been conducted in which
Zn2+ from Zn7-βα-MT has been transferred to Zn-dependent enzymes, for example, maconitase (22), carbonic anhydrase (23), and the prototypical transcription factor (24),

4

Gal4.

Removal of Zn2+ from the zinc finger-containing transcription factor Sp1

demonstrates that MT may also act as a Zn2+ acceptor (25). It should be noted that zinc
fingers are structural motifs that coordinate one or more Zn2+ ions to stabilize their
protein fold. Thus this natural association of MT with the biologically essential Zn2+ and
Cu+ has suggested that one of the functions of MT is the maintenance of metal ion
homeostasis. While metal exchange to apo-enzymes requiring these metals has been
reported, no mechanistic details have emerged yet about how the metal transfer takes
place.
Support for the role of MT as a metallochaperone is found in the transcription of DNA
to RNA, which has been shown to be strongly controlled by exposure to metal ions, for
example in yeast (26-27), Drosophila (28) and mammals (29-31).

In the case of

mammals, of the four isoforms (MT-1 to -4) only two (MT-1 and MT-2) are strongly
upregulated by metal ions.

Induction of inducible MT isoforms requires both the

interaction of a metal response element (MRE) with a metal response element binding
transcription factor 1 (MTF-1). MREs are cis-acting DNA sequences necessary and
sufficient for metallothionein expression under heavy metal load (29, 32). MTF-1 is a
zinc binding protein that contains six Cys2-His2 zinc fingers, the presence of these zinc
fingers, along with differences in their respective affinity, make MTF-1 exquisitely
sensitive to changes in the concentration of zinc in a cell (33-34). Cell free transcription
experiments have shown a number of stresses, including exposure to Cd2+, Cu+ and H2O2
function by displacing naturally bound Zn2+ from MT (35). These free Zn2+ ions bind to
MTF-1 leading to a translocation of MTF-1 from the cytoplasm to the nucleus where the
Zn-MTF-1 interacts with MREs leading to upregulation of MT. In this way, MT is
capable of countering and deactivating a wide range of insults in order to return an
organism to homeostatic balance.

1.2.2 Toxic metal detoxification
The proposed detoxifying properties of MT were inferred from metal analysis of
samples isolated from human kidneys (36). These samples contained significant amounts
of excess Cd2+ and some Hg2+, the presence of Hg2+ being traced back to the use of
therapeutic mercurial diuretics. In addition to Cd2+ and Hg2+, MT is generally understood
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to coordinate all the group 11 and 12 metals, and is also capable of binding to other
metals including: Co2+, Pb2+, Pt2+/4+, Fe2+, As3+, Bi3+ and Tc5+ (37-41). The binding
affinities of MT for metal ions follows closely with the association constant of metal ions
for inorganic thiolate ligands (Hg2+ > Cu+ > Cd2+ > Zn2+). Thus MT preferentially
coordinates many toxic metals and ultimately this coordination leads to the release of
Zn2+, which acts to upregulate the production of MT and returns an organism to
homeostatic balance.
The requirement for and the toxicological effects of excess Zn2+ have been well
documented (42). MT knockout studies have highlighted the importance of this protein
in the homeostasis of Zn2+ (43). For example, MT-null mouse pups fed severely deficient
Zn2+ diets, showed delays in kidney development when compared to wild-type controls.
These pups lacked a hepatic reservoir of zinc critical for proper development. On the
other hand, MT-null adult mice challenged with increased Zn2+ showed a greater
incidence of pancreatic acinar cell degeneration. In this case, MT is able to act as a
temporary sink to accommodate the influx of Zn2+. These results demonstrate that MT is
critical in protecting an organism from the extremes of Zn2+ exposure, acting as both a
source and a sink for Zn2+ during deficiency and excess, respectively.
Copper toxicity is also of considerable interest, because unlike zinc, free copper is able
to catalyze the formation of hydroxyl radicals through Haber-Weiss and Fenton reactions
(42). Significant regulation of copper transport in humans relies on two homologous
copper transport proteins: namely, ATP7A and ATP7B (44). Mutations to ATP7A result
in Menkes disease, where copper accumulates in the kidneys and intestinal wall, while
the brain, serum and liver do not receive adequate amounts (45). A murine model of
Menkes disease involving MT-1 and -2 knockout mice demonstrated that in the absence
of inducible MT, knockout mice were more susceptible to copper toxicity (46). The
second disorder, Wilson’s disease, resulting from mutations to ATP7B, is characterized
by the accumulation of copper in the liver leading to cellular damage and release of free
copper into the blood serum (44).

Cellular damage is somewhat mitigated by the

accumulation of copper in the form of Cu-MT (18, 47). In this manner, MT is able to
sequester Cu+, and with 20 thiol groups can act as a reducing agent to further protect
against oxidative stress (48-49).

6

Chronic cadmium poisoning significantly affects the kidneys.

Traditionally, the

2+

nephrotoxicity of Cd exposure was thought to be the result of a transfer of Cd-MT from
the liver to the kidneys with subsequent degradation leading to a high local concentration
of Cd2+. Indeed liver transplant studies aimed at monitoring Cd-MT levels have shown a
time dependent decrease in Cd-MT present in the liver with concomitant increase of CdMT present in the kidneys (50). Further complicating the problem, recent studies have
demonstrated that MT knockout mice are hypersensitive to Cd2+, while only
accumulating 7% Cd2+ compared to their wild-type mice. However, it is not a paradox
that MT-knockout mice only accumulate little Cd2+, but are sensitive to Cd2+. Little
accumulation in knockout mice would suggest that free Cd2+ is travelling directly to the
kidneys and subsequently harming the organ. These results indicated that MT enhances
the accumulation of Cd2+ in the kidneys but that it also significantly reduces the
associated toxic effects (51). It should be noted at this point that retention of Cd2+ in
humans is primarily attributed to MT and that the biological half-life of Cd2+ in the
human body is on the order of several decades (52-53).
MT knockout mice, in which both MT-1 and MT-2 were inactivated, experience
enhanced hepatic Cd2+ poisoning, but under control conditions these MT-null mice were
viable and reproduced normally (54). These results suggest that MT acts to buffer the
toxic effects of Cd2+ to an organism by sequestering the Cd2+, likely leading to the release
of Zn2+, which would act to upregulate MT. To further support the buffering role of MT,
wild-type mice given increasing doses of Cd2+ developed a tolerance to Cd2+ lethality, as
evidenced by a 7-fold increase in the LD50 (55). While under the same conditions, the
LD50 of MT-null mice was unaffected. These pretreatment experiments underscore the
importance of not only MT in toxic metal detoxification, but also the total MT pool in an
organism.
The ability of methylmercury (MeHg+) to induce neurotoxic effects in a cell is related
to the amount of MT present, with increasing amounts directly attenuating the associated
toxic effects. The astrocyte is thought to play a pivotal role in MeHg+ mediated death,
because it expresses three times as much MT as its associated neurons and could
potentially function as a buffer to protect these neurons, and consequently the organism,
from toxic insult (8-9, 56). Surprisingly MeHg+ is not capable of directly inducing MT in
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spite of its large affinity for thiol groups. We consider that MT, binding metals in a
noncooperative fashion, will coordinate MeHg+ through the available thiols found in any
of the partially metalated forms (57-59).

1.2.3 Protection against oxidative stress
The high thiol content of MT makes it an ideal molecule to interact with and inhibit
reactive oxygen species (ROS). Indeed, animal studies, in which cardiac specific MT is
overexpressed, have shown that MT functions to protect against oxidative stress,
specifically in the inhibition of ischemia-reperfusion induced myocardial injury (60-61).
MT is upregulated by ROS through the antioxidant response element (ARE), a promoter
region on the MT gene, ARE-binding transcription factors, as well as MTF-1. Perhaps
the most well known reactivity of MT is that with air leading to oxidation of the cysteine
residues and subsequent formation of sulfonic acid and disulfide bonds. Metal free (apo-)
MT is particularly susceptible to oxygen, and metalation experiments should be carried
out under strictly anaerobic conditions.
Nitric oxide has also been shown to increase the intracellular release of Zn2+ through
the oxidation of Zn-MT in mouse lung fibroblasts (62). In vitro analysis of the oxidation
products of the three isoforms (MT -1, -2, and -3), suggests the mechanism of oxidation
of each is different. In the case of mouse MT-1, the β-domain metals are exclusively
released (63), while the products from the oxidation of rabbit MT-2 show a more
distributed release pattern (64), and finally, for human MT-3 a long lived Cd2-α-domain
intermediate exists when nitric oxide induces oxidation of the protein (65). It is probable
that these differences in metal release are the result of the distinct functions of each
isoform under nitrosative stress. Both cell free and cell culture studies of Zn-MT in the
presence of H2O2 have also shown that MT is capable of acting as an antioxidant leading
to release of Zn2+, which acts to upregulate MT through MTF-1 (35, 66-67).
Metal ions are a significant source of ROS cellular chemistry with both copper and
iron capable of producing hydroxyl radicals (68). Zn-MT is capable of inhibiting the
production of copper catalyzed hydroxyl radicals in vitro. With 20 cysteine residues, MT
is capable of reducing Cu2+ to Cu+, after which it can be coordinated with high affinity to
MT.
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As a reducing agent that readily coordinates Zn2+, a proposed function of MT is
sensing the presence of incoming oxidants. In this redox cycle, an ROS oxidizes MT
leading to Zn2+ release (49, 69). This Zn2+ is responsible for upregulating Zn-dependent
proteins through MTF-1.

Either reduction of the previously oxidized MT with

glutathione, or complete replacement with de novo MT then leads to a reestablishment of
zinc homeostasis. In this manner, MT may either directly interact with the ROS, or in
cases where ROS production is the result of a metal ion that readily coordinates MT, such
as copper, MT may act to sequester the metal ion and effectively neutralize ROS activity.

1.3 Structural Characterization
X-ray diffraction results have been reported from just two crystals, the first successful
example was for rat Cd5Zn2-MT-2 (5), and the second was for yeast Cu8-MT (70). It
should be noted that MT has been described as being notoriously difficult to crystallize,
and much of our structural knowledge is the result of the many NMR-based studies
reported. Structures based on analyses of the NMR data have been reported from several
mammalian sources (71-74). These structures provide the absolute connectivities of all
atoms and their spatial relationship with the metal-thiolate core but not the alignment of
the linkage between the two domains. The domain alignments were determined from the
X-ray diffraction studies for the rat liver Cd5,Zn2-MT (5). In the case of the X-ray crystal
structure of rat Cd5Zn2-MT-2 species, all metal centres were tetrahedrally coordinated by
cysteinyl-thiolates; later, when compared to the NMR structure, both showed identical
molecular architectures (75). A comparison of the NMR-based structures of human Cd7and Zn7-MT-2 has shown overall maintenance of cluster geometry and demonstrated that
MT can accommodate metal ions of varying size (76). The ability of Cd2+ to replace Zn2+
isomorphously is exploited in many experiments due to several advantageous properties
of the cadmium-thiolate cluster, such as the availability of 113/111Cd NMR active isotopes,
as well as the red shifted ligand-to-metal charge transfer band in the optical spectrum.
Copper(I) is capable of coordinating with a range of geometries depending on the
Cu(I) : MT stoichiometric ratio. Digonal and trigonal geometries were found in the Xray diffraction structure of the Cu-MT from yeast (70). While no mammalian Cu-MT Xray diffraction structure exists, spectroscopic data have demonstrated the existence of
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both a Cu12-MT and a Cu15-MT for the two-domain, rabbit liver MT 2a, the former likely
being mainly copper coordinated in a trigonal geometry, while the latter is likely a
mixture of trigonal and digonal geometries (77). In addition to these fully metalated
structures, a copper folding intermediate in the β-domain, Cu4-MT, has been isolated for
both rat liver MT-1 and mouse MT-3 but is of unknown coordination geometry (78). It is
probable that this intermediate is related to the mixed metal species, Cu4Zn4-MT-3,
thought to a critical product in controlling the oxidative damage caused by the Cu+/Cu2+
redox cycle in Alzheimer’s disease (79). Previous NMR metal exchange experiments, in
which Cd2+ was reacted with calf liver Zn4,Cu3-MT-1 and -2 have shown that cadmium
ions could only displace the zinc ions (16). Based on the NMR chemical shifts, it was
concluded that these zinc ions were almost exclusively located in the α-domain, while the
copper ions were located preferentially in the β-domain. From these results it has been
proposed that MT is capable of separating metal types into different domains, essentially
isolating the chemistry of both essential zinc and copper.
While NMR spectroscopy and X-ray diffraction studies have yielded the most
significant information about the structure of MT, other techniques have also greatly
contributed including CD, emission and Raman spectroscopy.

In the case of CD

spectroscopy, the ligand-to-metal charge transfer is strongly affected by the chirality of
the protein and changes to the chirality can affect the signal observed (80-81). For
example, due to exciton coupling in mammalian MT, a typical spectrum has the crossover of the derivative envelope centered at ~250 nm, however upon supermetalation
exciton coupling is broken and a CD band maximum at ~250 nm is now observed (8283). In this way, one is able to infer that the metal coordination of both clusters is
symmetric and that supermetalation results in a loss of this symmetry.

Emission

spectroscopy is also useful and in the case of copper emission is most intense when 12
equivalents of Cu+ have been added forming Cu12-MT. Loss of emission intensity past
12 equivalents of Cu+ added to rabbit liver MT demonstrates that the protein is opening
and assuming a less compact and more porous form (84). Raman spectroscopy is also
gaining interest because of its ability to determine the oxidation state of cysteine residues,
the identity of coordinating ligands and finally identification of cysteine residues that
could be modified by radical attack (85). These techniques, while not as structurally
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specific as NMR spectroscopy, X-ray absorption spectroscopic methods or X-ray
diffraction studies, provide useful information that help in the determination of the
dynamic structures of MT and further our understanding of its overall function(s).

1.4 Zinc and Cadmium binding to MT
Zinc is critical to the continued health of an organism and is required for the proper
functioning of a number of enzymes and transcription factors. With 5-20% of all cellular
Zn associated with MT, structural motifs of Zn-MT are of critical importance (86).
Exposure of an organism to cadmium will negatively affect the health of an individual,
including both liver and kidney damage. Cadmium is also a known carcinogen, capable
of both inhibiting several DNA repair systems, as well as indirectly producing ROS to
further DNA damage (87-88). Perhaps the most well known disease associated with
cadmium poisoning is Itai-Itai, made famous by mass cadmium poisoning in Toyama
Prefecture, Japan, and most strikingly characterized by an increase in bone brittleness
leading to an increased incidence of fractures (89). While it may seem initially odd to
include Zn2+, an essential element, with Cd2+, a toxic metal, both share similar
coordination geometries.

This is best demonstrated by NMR spectroscopy that has

shown an almost identical protein fold when either metal is bound and a significant
portion of the structural information known is derived from Cd-MT (76).
For both Zn2+ and Cd2+, the most well characterized form of MT is mammalian, with
an N-terminal β-domain containing 9 cysteine residues and a C-terminal α-domain
containing 11 cysteine residues. The traditional number of metals bound to the full
protein are 7 metal ions, 3 in the β-domain (Zn3- or Cd3-β-MT) and 4 in the α-domain
(Zn4- or Cd4-α-MT). More recent evidence points towards a new supermetalated form of
the protein that is discussed in Chapters 5 and 6.
Several studies have together provided compelling evidence that the two domains of
mammalian MT are structurally independent. To illustrate, the
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Cd chemical shifts of

the isolated α-domain are remarkably similar to those of the full protein indicating that
the complete loss of the β-domain does not affect, to a large extent, the environment of
the α-domain (90). While NMR structural studies from several MT sources, including
mouse (74) and human (72), show a lack of interdomain peaks associated with the

11

nuclear overhauser effect (NOEs), which would strongly suggest that the fully metalated
domains are independent of each other. It is possible that the independence of the two
domains is critical to the function of MT.
The initial proton NMR studies of MT demonstrated that in the absence of metal
binding the structure was a random coil (although we note that proposed models of the
apo-MT support the presence of a motif-like structure), however, upon addition of either
Cd2+ or Zn2+ the structure became significantly more rigid (91-93). Further analysis of
the chemical shifts of cadmium atoms, as well as the splitting pattern, lead to the
determination of the stoichiometry of the polynuclear clusters: Cd3S9 and Cd4S11 (90, 9497). Since these initial studies, solution structures have been determined from a number
of MT sources including mammalian (human, rat, rabbit and mouse) (71-76), plant (98)
and cyanobacteria (99). The critical step in the determination of the overall structure of
mammalian MT was the X-ray crystallographic structure showing an identical molecular
architecture to the previously determined NMR structure but with the alignment of the
two domains now defined (5).

1.5 Copper binding to MT
Copper is vital for the continued health of all organisms. Copper induced toxicity is of
considerable interest and its dyshomeostasis can lead to a number of diseases including
Wilson’s disease and Menkes disease (44). Unlike zinc, free copper is redox active and
able to catalyze the formation of hydroxyl radicals through Haber-Weiss and Fenton
reactions (42). A murine model of Menkes disease involving MT-1 and MT-2 null mice
have shown enhanced sensitivity to copper toxicity (46). In the case of Wilson’s disease,
a marked increase in Cu-MT has been demonstrated (18, 47). These two examples
emphasize the importance of MT in maintaining health through the control of transient
fluctuations in Cu+ availability (42, 100).
In the case of copper, it has been reported that there exists a preference for its
accumulation in the β-domain of mammalian MT before binding under thermodynamic
control in the α-domain. In essence, this would allow simultaneous involvement of both
Zn2+ and Cu+ in the homeostatic functioning of the organism. This dual nature of the
metal-binding properties of MTs could be critical to the brain specific MT-3 and its
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interactions with the protein Aβ1-40-Cu2+, a producer of reactive oxygen critical to
Alzheimer’s disease (79, 101). In this fashion Zn7-MT-3 is capable of deactivating Aβ12+
40-Cu

by exchanging Cu2+ for Zn2+. Following this exchange Cu2+ is reduced and

sequestered specifically into the β domain of MT-3.
Emission spectroscopy has been particularly useful in studying Cu+ binding to MT.
The first such study was for the fungus Neurospora crassa (102). Since this initial study,
both equilibrium and kinetic emission data have been reported for both Cu+ and Ag+
binding to different MTs. In these studies, excitation of Cu+ at 300 nm leads to a spin
forbidden transition of 3d103d94s1, or alternatively 3d103d94p1, with subsequent
emission from a long-lived state at a wavelength significantly red shifted from the initial
excitation band (near 600 nm for Cu+ and 570 nm for Ag+). Because the emission
intensity is dependent on the environment of the metal ion, any changes in this intensity
as a function of metal stoichiometry is the result of the dynamics of protein folding.
The spectroscopic data (absorption, CD and emission) indicate that for the twodomain βα-MT-2a protein that there exist two significant saturation points, the “magic
numbers” of copper binding, with Cu(I) : MT ratios (i) of 12 and (ii) of 15 (77). Each
domain is independently capable of binding 6 Cu+ ions leading to the formation of metal
clusters with the stoichiometry Cu6S9 and Cu6S11 for the β- and α-domains, respectively
(103-104). Domain mixing experiments have shown the fluctionality of these clusters as
Cu+ ions located in the α-domain migrate to the β-domain displacing metal ions of
weaker affinity in the process. Interestingly, the emission of Cu12-βα-MT formed by the
stepwise addition of Cu+ to a solution of Zn7-βα-MT is very time and temperature
sensitive (77, 84). These results demonstrate that the initial Cu+ binding is distributive
without particular preference for either the α- or β-domain, which is the kinetic product of
metalation. Given sufficient time and thermal energy, rearrangement of the protein leads
to preferential accumulation of Cu+ in the β-domain.
An unusual species was identified during titrations of Cd7-MT 2 with Cu+. The
spectroscopic maxima were found for a mixed metal species with 12 Cu+ and four Cd2+,
Cd4Cu12-MT. It was proposed that the 4 Cd2+ were mixed with 6 Cu+ in the α domain
and the remaining 6 Cu+ were bound in the β domain (77). Like Hg18-MT 2 (see below),
it is possible that this species is in fact a single domain species.
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To summarize, “the magic numbers” of the metalation of MT with Cu+ are 6 for the
isolated β- and α-domains and 12 and 15 for the full protein. When multiple metals are
present both Cu9Zn2-MT and Cu12Cd4-MT form. Interestingly, Cu+ has a preference of
the β-domain, which has been used to interpret the location of Cu+ in many of these
species.

1.6 Mercury binding to MT
Mercury has no known physiological role and environmental exposure can come in
several forms including elemental mercury (Hg0), inorganic mercury (Hg2+ and Hg22+)
and organic forms of mercury, such as methylmercury (CH3Hg+), and toxicity is greatest
for the alkylated species.

Mercury has long been associated with MT, with early

copurification attributed, in part, to the therapeutic use of mercurials (36). MT-null mice
have been instrumental in demonstrating the protective role of MT against Hg induced
toxicity (105-108). It should be noted that like CH3Hg+, Hg0 is lipid soluble and can
cross the blood brain barrier, where it can be oxidized to Hg2+ with catalase and H2O2
(109).

MT has a critically important role in protecting an organism against

methylmercury poisoning, and pretreatment experiments in which administration of MT
inducers (Zn2+ and Cd2+) caused an increase in the tolerance of astrocytes against toxic
methylmercury insult (56, 110-111). The above examples highlight the importance of
MT in the maintenance of neurological health.
A significant body of work has been produced describing not only the structurally
significant stoichiometries of Hg-MT, but also the factors that influence their formation,
such as time, temperature, presence of MT coordinated metals and the identity of the
counter ions used in Hg2+ addition (112-115).

Four saturation points have been

spectroscopically observed including Hg7-, Hg11-, Hg18-, and Hg20-MT.

The latter,

having a very weak CD spectrum, is likely the result of a complete unwinding of the
protein leading to a random coil with Hg2+ coordinated in a linear fashion. The most
notable technique used in titrations of MT with Hg2+ to date is CD spectroscopy. The
technique measures the difference between left and right circularly polarized light caused
by the chirality of the chromophore. In this case, the chirality of the ligand-to-metal
charge transfer of each mercury-thiolate cluster is measured. Because the metals that
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bind MT form predefined structures that exhibit specific chirality, CD spectroscopy is
extremely sensitive in monitoring the metalation of MT. The CD bands specifically
probes the metal-cysteine binding site structure because the chirality arises from a
combination of the chiral wrapping of the peptide chain around the binding site and the
exact energy of the ligand-to-metal charge transfer band (LMCT band). The energies of
the LMCT depend on the coordination number of the Hg2+ and, therefore, on the structure
adopted at a each specific Hg(II) : MT stoichiometric ratio. Changes in the wavelength
of bands and the band morphologies in the CD spectrum as a function of Hg2+ loading
indicate changes in binding site geometry as a function of the Hg2+ stoichiometric ratio.
While the metalation reactions of MT by Hg2+ have been studied for apo-MT, Zn-MT
and Cd-MT, the importance of MT in zinc chemistry suggests that the displacement of
Zn2+ by Hg2+ in MT is the most biologically relevant.
displacement of Cd

2+

It should be noted that: 1)

in Cd-MT is the result of a distributive metalation, in which Hg2+

binds statistically to both the β- and α- domain, and 2) the metalation of apo-MT with
Hg2+ follows a very similar pattern to that measured when Hg2+ is added to Zn-MT with
the singular exception that in the early stages of the reaction no isolated HgSR4 units are
observed.
Hg18-βα-MT-2 from rabbit liver has been reported to be a structurally significant
species, where it was proposed that each Hg2+ atom adopts a pseudotetrahedral structure,
each with two bridging thiolates and outlying chloride anions (113, 115). The necessity
for Hg2+ to be coordinated to two cysteine residues and chloride ions has been confirmed
by XAFS measurements (116). In this way, each Hg2+ atom is effectively stacked on the
others leading to the formation of one large domain instead of two smaller ones.
Interestingly this species may only be formed from isoform 2, unless isoform 1 is first
lyophilized and then dissolved in acid. Formation of Hg18-βα-MT-2 has been attributed
to residues 38-40, where the unique presence of two consecutive proline residues allows
the twisting of the protein to accommodate a single domain structure. In the case of
lyophilized protein, breaking of the solvent-protein bonds allows an alternate
conformation to be adopted in acid, which upon addition of Hg2+ leads to the formation
of Hg18-βα-MT-1. We will return to the formation of a single-domain species in Chapter
6, but to summarize the “magic numbers” of Hg2+ to MT binding are 7, 11 and 18.
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1.7 The mechanism of metalation of MT
In recent years there has been considerable debate regarding the mechanism of
metalation of MT (57-59, 117-118). Specifically, do the metals bind in a noncooperative
manner, that is one at a time, or do they bind in a cooperative manner, that is all-ornothing? Briefly a noncooperative mechanism of metalation implies that the binding of
one metal ion is independent of the others, and as such, throughout metalation a decrease
in the association constants is related to a decrease in the number of available sites.
While a cooperative mechanism of metalation implies that binding of one metal
facilitates the binding of further metals leading to an increase in the association constants.
The mechanism of metalation has significant consequences for our understanding of the
protein and its interactions with the cellular environment. For example, several MT
polymorphisms have been linked to the longevity of certain human groups, with both low
Zn-MT levels and satisfactory Zn2+ bioavailability being good markers for human health
(119-121). Exposure of this mutant MT to nitric oxide, resulted in less Zn2+ release
compared to the wild-type. If the Zn2+ binds to MT in a cooperative fashion, then one
can infer that the mutant is inherently less reactive, however if Zn2+ binds to MT in a
noncooperative fashion, then there is potential that a large pool of partially oxidized MT
exists.

In both cases, the mechanism of metalation, and the potential for partially

metalated species taking part in cellular chemistry has significant consequences in the
understanding of the relationship between Zn2+ bioavailability, MT and the overall health
of an individual.
Early research supported a cooperative mechanism of metalation. For example, a
titration of 113Cd2+ with MT, as monitored by 113Cd-NMR, demonstrated the apperance of
only fully metalated MT and no intermediates (118).

If the metals were to bind

sequentially, then one would have predicted the appearance and disappearance, as a
function of the amount of
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Cd2+ added to solution, of

with isolated tetrahedral cadmium-thiolates.

113

Cd-NMR signals associated

The absence of those signals, and the

presence of only signals associated with fully metalated Cd7-MT, would suggest a
cooperative mechanism of metalation.

However, this assumes that the isolated

tetrahedral cadmium-thiolate units are not significantly mobile.

16

A significant problem with studying metalation reactions with metals that are
biologically relevant to the chemistry of MT, such as Zn2+, Cd2+ and Cu+, is that these are
d10 metals, and consequently are chromophorically silent in many spectroscopies. In such
cases, researchers have, until recently, been limited to the ligand-to-metal charge transfer
bands in the optical spectrum (using absorption, emission, circular dichroism (CD) and
magnetic circular dichroism (MCD) techniques) making their coordination properties
difficult to study.

One way to overcome this problem, involves using Co2+ as a

spectroscopic probe for Zn2+. The metalation of apo-MT to form Co7-MT is of interest,
because the results indicate that for the binding of at least the first three Co2+ atoms, the
spectroscopic signature indicates the presence of isolated Co-tetrathiolate units within the
MT binding site. As further Co2+ is added, both electronic absorption, EPR and 1H NMR
spectra indicate thiolate bridging occurs as the coordination remains tetrahedral by
sulphur (122-123). These results are significant in that if MT were to bind metal ions in a
cooperative fashion then cluster formation would be immediate upon addition of Co2+
leaving a significant fraction of the protein in the unmetalated apo-MT state.

The

experimental data indicate that cluster formation requires the addition of several
equivalents, and consequently binds Co2+ in a noncoooperative manner.
Recently the technique of ESI-mass spectrometry, which detects each unique protein
species with a different mass-to-charge ratio, has allowed the study of dilute protein
solutions as a function of metal loading; data that complements the optical spectroscopic
data. Using this technique, two papers have provided evidence for the mechanism of
metalation of MT to occur in a noncooperative fashion. Specifically, the addition of Cd2+
to MT-3 (59), the brain specific isoform, and the α-domain of MT-1 (58). This data,
however, cannot be immediately generalized to all mammalian MTs, because unlike MT1, -2 and -4, MT-3 has an additional threonine (Thr5) in a TCPCP motif, and a glutamaterich hexapeptide near the C-terminal that have both been shown to be critical to its
function (124-125).
determined.

Consequently, the mechanism of MT-1 or -2 will need to be

17

1.8 Scope of the Thesis
The metalation chemistry of MT has typically focused on its fully metalated states,
that is Zn7- and Cd7-MT. Consequently the overall structure of this state is well known,
but such questions as the mechanism of metalation and the mechanism of metal exchange
have been largely overlooked. In addition, the respective structures of these submetalated
and metal exchange intermediates have not been characterized.
This thesis is composed of seven Chapters. The first Chapter gives on overview of
MT, both its functions and its metalation chemistry, with an emphasis placed on the wide
array of metals that are capable of binding. Chapter two gives a complete description of
the recombinant preparation methods of the MT, both the full protein and its isolated
domains, as well as a brief description of the instrumental techniques (UV absorption,
CD and NMR spectroscopy, as well as ESI-mass spectrometry and molecular
mechanics/dynamics) used to probe the metalation reactions of MT. The remainder of
this thesis focuses on determining the mechanism of metalation, as well as the metalated
structures that may exist in vivo.
Chapter three describes an equilibrium study in which the cooperative nature of the
metal binding mechanism is explored by examination of the speciation of both the
isolated β-domain, as well as the full MT protein, using electrospray ionization mass
spectrometry. While Chapter four describes the first ever competition reaction between
the isolated domains and the full MT protein, as well as provide metalation evidence for a
new Zn5-MT structure that may be a partially metalated stable intermediate. The results
from this study are necessary to allow for a generalization of the noncooperative
mechanism of metalation to all mammalian MT isoforms.
Chapter five discusses the structural determination of a new Cd4-β-rhMT-1a structure
by examination of the domain speciation under metal ion excess. This novel cluster
arrangement is characterized by CD and UV absorption spectroscopy, ESI mass
spectrometry and
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Cd NMR spectroscopy. Chapter six extends these excess metal ion

studies to the full MT protein, and provides evidence for the existence of a novel Cd8-βαrhMT-1a structure, in which both domains act to coordinate the eighth metal ion.
Finally, Chapter seven draws together the result of these studies, presented in Chapter
three through six, and discusses them with respect to the known functions of MT.
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Chapter 2.

Methods for Preparation and

Characterization of Recombinant MT2
2.1 Introduction
Metallothionein (MT) was first isolated from horse kidney cortex in 1957. This first
isolation of MT relied upon retaining the cadmium content present in kidney homogenate
following a series of purifications. In fact, early in vitro studies of MT relied upon
purification from natural sources, the most well studied of which were those from
mammalian sources including, human, rabbit, and horse. These purification protocols
relied upon rigorous and time consuming metal ion injection procedures, where the lab
animal was euthanized and the organ of interest, usually the liver or the kidney, was
isolated with subsequent MT extraction. Studies on human MT were further complicated
by the necessity to isolate MT from cadavers. The above described procedure, while
inefficient, is well suited for studying MT isoforms -1 and -2, because both can be
induced by a number of stimuli including metal ions, glucocorticoids, cytokines and
oxidative stress. However expression of other MT isoforms, MT-3 and MT-4, are more
strictly controlled. This restriction is a contributing factor to their relatively late isolation
and discovery.
Modern studies rely heavily on recombinant protein expression systems, where the
MT of interest is grown and isolated from a non natural source, for example human MT
grown and purified from Escherichia coli (E. coli). In these systems, the MT gene has
been inserted into a host organism, which will produce significant quantities of the
protein. There are several advantages when compared to isolation from natural sources,
including enhanced purity and efficiency. MT from natural sources is composed of a
mixture of isoform that must be separated using lengthy chromatographic methods.
Since only a single isoform is inserted into the host system, these purification steps are
avoided. By using recombinant protein expression systems, unusual MT proteins have
2
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been designed, including single domain studies (β or α-rhMT) and different domain
combinations (αβ-, ββ-, βββ-, αα- and ααα- rhMT).

There are, however, several

disadvantages to these systems including necessary alterations of the MT-protein
sequence to enhance expression and addition of peptide sequences, for example S-tag
purification system, to the protein in order to allow for efficient purification from the cell
lysate. Finally, there is also the potential for post-translational modifications that may
significantly alter the chemical properties of the protein.
In this Chapter, the recombinant protein preparation is described for the production of
the isolated β- and α-domains, and full MT protein of isoform 1a referred to as β-rhMT,
α-rhMT and βα-rhMT, respectively. A brief description of the instrumental techniques
used to characterize MT and its domains are also provided.

2.2 Recombinant Expression and Purification of MT 1a
2.2.1 Materials and solution preparation
Materials
Table 2-1 provides a list of the chemicals and biological agents used in the preparation
of MT and its isolated domains. All experiments described throughout this thesis used
these compounds.
Solutions preparation
All solutions were prepared with deionized water (di-H2O) with a resistivity greater
than 14 MΩ•cm (Barnstead, Dubuque, IL, USA). The kanamycin antibiotic solution was
prepared by adding di-H2O to 0.5 g of solid kanamycin to a final volume of 10 mL (50
mg/mL final conc.).

Large particulate was then removed by filtering the kanamycin

solution through 0.2 μm syringe filters. The filtrate was separated into 1 mL aliquots in
sterile Eppendorf tubes and stored in a freezer at -20 ⁰C.

The isopropyl-β-D-

thiogalactoside (IPTG) was prepared by adding di-H2O to 2.38 g of solid IPTG to a final
volume of 10 mL (1 M final conc.). This solution was then separated into 0.7 mL
aliquots in sterile Eppendorf tubes and stored in a freezer at -20 ⁰C. The LB Miller Broth
was prepared by adding 25 g to each of the 4-Fernbach flasks containing 1 L of di-H2O
and lightly sealed with aluminum foil. The LB Agar gel was prepared by adding di-H2O

29

to 4 g of agar to a final volume of 100 mL. This solution was lightly sealed with
aluminum foil. In order to sterilize the solutions, both the LB Miller Broth and Agar
were autoclaved for 20 min at 121 ⁰C. When the LB Agar was warm to the touch,
kanamycin antiboitc solution was added (final conc. 50 μg/mL). The LB Agar was
poured into disposable sterile Petri dishes and the gel was allowed to solidify to room
temperature. These dishes were parafilmed and stored in a fridge at 4 ⁰C.
Table 2-1.

Chemical and biological reagents used.
CHEMICAL
F. W.
GRADE

SUPPLIER

(g/mol)
Ammonium Formate, NH4COOH

63.06

Reagent

J. T. Baker

Ammonium Hydroxide, NH4OH

35.05

Reagent

Caledon

BL21(DE3) Strain of E. coli

Biotech

Cadmium sulfate, 3CdSO4•8H2O

769.56

ACS

Fisher

Cadmium(113)chloride, 113CdCl2

183.9

>96%

Trace Sciences
International

Formic Acid (88%), HCOOH

46.03

Reagent

Caledon

Hydrochloric Acid, HCl

36.46

Reagent

Caledon

Isopropyl-β-D-thiogalactoside

238.31

Biotech

Fisher

Kanamycine, monosulfate,

582.58

Biotech

EMD

LB Agar, Miller

Biotech

Difco Laboratories

LB Broth, Miller

Biotech

Fluka Analytical

Sephadex G-25 Fine

Biotech

Amersham

C18H36N4O11•H2SO4

Biosciences
Thrombin CleanCleave™ Kit
Tris(2-carboxyethyl)phosphine (TCEP),

Biotech

Sigma-Aldrich

286.65

Reagent

Sigma-Aldrich

121.14

Reagent

EMD

287.56

ACS

Caledon

C9H15O6P
Tris(hydroxymethyl)aminomethane (Tris),
(CH2OH)3CNH2
Zinc sulfate, 3ZnSO4•7H2O

MT was purified from the cell homogenate by using an SP ion exchange column and
required four solutions: 10 mM Tris-HCl, pH 7.4 (Solution A), 10 mM Tris-HCl + 1 M
NaCl, pH 7.4 (Solution B), 350 mM ammonium formate (Solution C), and di-H2O

30

(Solution D). All four buffers were prepared by dissolving the appropriate amount of
chemical into di-H2O and the pH was adjusted using either concentrated hydrochloric,
formic acid, or ammonium hydroxide. The pH of the solutions was monitored using a pH
meter (Accumet Basic AB15, Fisher Scientific, Ottawa, ON, Canada) with an Accumet
Semimicro pH electrode. MT can readily oxidize upon exposure to oxygen. To impede
oxidation of the cysteine residues to disulfide bonds by oxygen, all solutions were
rigorously evacuated and argon saturated.
Metallothionein Transformed Bacterial Cells
The MT DNA was provided by Peter Kille (Cardiff, Wales) and transformed by Jayna
Chan, Christie Vermieren and Thanh Ngu (U.W.O). The following sections briefly
discuss the MT construct and describe in detail, the growth, isolation and purification of
MT from bacterial cells.
The DNA constructs of the isolated β- and α-domains and the full MT protein
engineered from human MT 1a (Table 2-2). The pET-29a plasmids (Novagen/EMD
Biosciences, San Diego, CA, USA), which the MT protein and its isolated domains were
transformed into, contained a kanamycin-resistance gene allowing selective growth of
bacteria that have taken up the plasmid.

This plasmid contains an S-tag™

(Novagen/EMD Biosciences) upstream of the MT DNA sequence. Consequently, all
expressed protein will be S-tag fusion proteins with the tag attached to the N-terminus.
Plasmids were transformed into competent E. coli BL21(DE3) cells (Novagen/EMD
Biosciences). All transformed cell lines were grown to an optical density of 0.6 and
stored in a 50% (v/v) solution of glycerol at -80 ⁰C.
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Table 2-2.
Amino acid sequences used in study. Amino acid sequence of human
MT 1a (hMT-1a), recombinant human MT 1a (rhMT-1a), the isolated β-domain of
human MT 1a (β-rhMT-1a), the isolated α-domain of human MT 1a (α-rhMT-1a) and
finally the S-tag used to stabilize the expression of the MT protein. The N-terminus is
located on the left hand side, while the C-terminus is located on the right. Colour legend:
Red – cysteine residues, Green – inserts to align sequences of different lengths, blue –
modified amino acids found in constructs.

2.2.2 Overexpression of Recombinant Cd-Metallothionein
The protocol for MT, and its isolated domains, preparation is presented in Figure 2-1.
It should be noted that this protocol allows for the production of metalated Cd-MT,
specifically Cd7-βα-rhMT, Cd3-β-rhMT and Cd4-α-rhMT. From the glycerol stocks, a
small portion of frozen cells were plated onto room temperature agar plates containing 50
μg/mL (final conc.) kanamycin sulfate. The presence of the antibiotic ensures that only
cells that have been transformed with the MT plasmid will grow. These plates were kept
overnight at 37 ⁰C. To four 2 L Fernbach flasks, 1 L of sterilized LB liquid media was
added, as well as kanamycin and CdSO4 to a final concentration of 50 μg/mL and 50 μM,
respectively. The CdSO4 was added to ensure that any MT grown prior to induction
would be stabilized and it also provided a secondary selective pressure for bacteria that
express MT. The cells were transferred into the LB liquid media and placed in an
incubator-shaker at 37 ⁰C and 150 rpm to facilitate aeration of the cells.

Protein

expression was induced at an optical density of 0.5-0.6 at 600 nm, which corresponds to
the mid-log phase of the bacterial growth cycle. At this point, IPTG was added to a final
concentration 0.7 mM to induce MT expression. The cells were allowed to express MT
for 30 min, at which point additional CdSO4 was added to solution to a final total CdSO4
concentration of 200 μM.
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2.2.3 Isolation and purification of recombinant Cd-metallothionein
Following growth, the cells were isolated by centrifugation at 8,983 g for 15 min using
an Avanti J-series centrifuge (Beckman-Coulter, Mississauga, ON, Canada) with a JLA9.1000 rotor. At this point the LB broth supernatant was discarded and the cell pellet was
resuspended in a deoxygenated 10 mM Tris-HCl solution, pH 7.4. The cells were lysed
using a French press and were centrifuged at 20,442 g for 1 hr using a JLA-25.50 rotor to
remove the cellular debris. Typical yields were 10 mg of protein per 1 L of LB broth.
The supernatant was loaded onto a Hi Trap™ SP Sepharose™ HP cation exchange
chromatographic cartridge. The elution was monitored using the ligand-to-metal charge
transfer (LMCT) transition of SCd of MT by UV absorption spectroscopy.

The

cartridges were washed with solution A that had been argon saturated to remove the
cellular components that were weakly associated to the column. Following this wash, a
stepwise increase in the amount of solution B from 0% to 5% in 1% increments removed
more tightly bound complexes. Cd-MT elutes at 5% (50 mM) NaCl. At this point, the
salt concentration is increased to 30% in order to remove the protein in as small a volume
as possible. A small aliquot of the protein was desalted into 5 mM ammonium formate in
order to determine the purity by electrospray ionization mass spectrometry. The protein
was subsequently concentrated to an 8 mL fraction using the stirred ultrafiltration cell
(Amicon Bioseparations/Millipore, Bedford, MA, USA) with a YM-3 cellulose
membrane (3,000 MWCO) under pressure by an inert gas (in this case nitrogen) to avoid
oxidation of the protein through oxygen exposure.
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Figure 2-1.

Protein preparation protocol for all metallothioneins used.

2.2.4 Cleavage of the S-tag from recombinant Cd-metallothionein
Both the isolated domains, and the full MT protein, were expressed with a 27 amino
acid S-tag (Table 2-2 Figure 2-2) attached to the N-terminus of the recombinant protein.
This tag has been observed to aid in the stability of the MT protein during expression
(personal communication with Professor Peter Kille). For all subsequent experiments,
the S-tag is cleaved using a Thrombin CleanCleave™ Kit. This kit contains bovine
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Thrombin immobilized onto agarose beads. There are two optimal cleavage sites for the
thrombin enzyme: The first is P4-P3-Pro-Arg/Lys•P1’-P2’, where P4 and P3 are
hydrophobic residues and both P1’ and P2’ are non-acidic residues. The scissile bond is
the Arg/Lys•P1’. The second is P2-Arg/Lys•P1’, where P2 or P1’ is a glycine residue
and Arg/Lys•P1’is the scissile bond.

Figure 2-2 shows that the Thrombin enzyme

cleaves M7-βα-rhMT 1a at an Arg-Gly bond. One consequence of this cleavage site is
that there remain 2 amino acids, glycine and serine, from the S-tag.
The thrombin suspension was purchased as immobilized agarose beads (Thrombin
CleanCleave™, Sigma) to facilitate separation from the recombinant protein without the
need for chromatographic steps. The thrombin-agarose slurry was stored at -20 ⁰C in a
50 % (v/v) solution of glycerol and 20 mM Tris-HCl, pH 8.0. Use of the thrombinagarose beads requires two cleavage buffers, 500 mM Tris-HCl, pH 8.0, 100 mM CaCl2
(10X cleavage buffer) and a 50 mM Tris-HCl, pH 8.0, 10 mM CaCl2 (1X cleavage
buffer), both of which were rigorously bubbled with argon and evacuated immediately
prior to use. The resin was washed by pelleting the beads by centrifugation at 500 g for 5
min using an Eppendorf centrifuge 5418 (Eppendorf North America, Inc., Westbury,
NY). The supernatant was removed and the beads were resuspended in an equal volume
of 1X cleavage buffer. The cells were again pelleted and resuspended in 1X cleavage
buffer to insure complete removal of glycerol.
To the resuspended beads, 10% (v/v) of 10X deoxygenated cleavage buffer was added
directly to the Thrombin slurry. The protein and a magnetic stir bar were added to the
Thrombin solution, evacuated and sealed under Argon. The mixture was stirred at 4 ⁰C
overnight. The beads were removed by centrifugation at 500 g for 5 min and were
washed with deoxygenated 1X cleavage to ensure complete removal of the beads. The
supernatant from both the initial cleavage and the wash, which contained the protein and
the S-tag, were pooled.
A fine G-25 Sephadex size-exclusion column was equilibrated with deoxygenated 10
mM Tris-HCl, pH 7.4. The protein solution was loaded onto this column and desalted.
The protein/S-tag mixture was subsequently loaded onto the SP ion exchange column at a
rate of 3 mL/min. All solutions used for the SP ion exchange column are identical to
those used to purify the recombinant MT from the cell homogenate. The column was
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washed with solution A and monitored using UV absorption spectroscopy. While MT
requires a solution of 10 mM Tris, pH 7.4 and 50 mM NaCl to elute from the column, the
S-tag does not adhere strongly and can be eluted by simply washing the column with
solution A. Once the UV absorption profile showed that no peptide was being eluted, the
composition of solution B in the eluent was increased from 0% to 5%, with a concomitant
decrease in the composition of solution A from 100% to 95%. This increase facilitates
the removal of any remaining S-tag, as well as other proteins that may bind weakly to the
column. At 5% solution B both the full MT protein, or the isolated fragments, begin to
elute from the column. This is observed by an increase in the absorption at 250 nm
corresponding to the LMCT of the S  Cd bonds in the metal-thiolate clusters. The
composition of solution B in the eluent is immediately increased to 30%. This allows
complete removal of either MT or its isolated clusters in a minimum volume. The
cleaved protein collected from the SP column was concentrated using stirred
ultrafiltration cell model 8200 (Amicon Bioseparations/Millipore) with the YM-3
membrane (3,000 MWCO) to 8 mL.
All cleaved protein was subjected to both mass spectrometric and UV absorption
spectroscopic analysis.

In the former, electrospray ionization mass spectrometry

provided the mass of the protein plus any bound Cd2+ ions. The observed mass always
corresponded well with the theoretical mass. There were several instances in which a
loss of amino acids was observed. In these cases, ESI-mass spectrometric analysis
revealed the identity of the missing amino acids. UV absorption spectroscopy provided
an estimate of the concentration of either of the isolated domains, or the full MT protein.

2.2.5 Preparation of metal-free recombinant metallothionein
A sample of thrombin cleaved metal-free (apo-) MT was prepared by decreasing the
pH of metalated Cd3-β-, Cd4-α- and Cd7-βα-rhMT to 2 through the stepwise addition of
concentrated HCl. The pH was monitored using pHydrion® pH paper (Micro Essential
Laboratory, Inc.). A deoxygenated fine G-25 Sephadex size-exclusion column was used
to remove the previously bound Cd2+ ions. The eluent buffer was chosen to suit the final
experiment. For example, apo-MT prepared for electrospray mass spectrometry, was
exchanged into di-H2O pH adjusted to 2.7 with concentrated formic acid. Unlike Cd-
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bound MT, apo-MT has no LMCT and metal free fractions were monitored by UV
absorption at 220 nm. A small aliquot of buffer exchanged MT was remetalated using
CdSO4 and the LMCT was monitored in order to determine the apo-protein
concentration. The demetalated MT was subsequently evacuated, capped and backfilled
with argon in order to remove the bulk of oxygen in the sample. Exposure to oxygen
oxidizes MT and samples prepared in this manner may last for up to several weeks.

Figure 2-2
A connectivity diagram of MT 1a. This shows that each of the seven
cadmium atoms is connected to exactly four cysteine amino acids. The connectivity
diagram has been renumbered to accommodate the amino acids glycine and serine, both
of which are a product of S-tag cleavage with Thrombin, located on the N-terminal of the
β-domain.

2.2.6 Preparation of

113

Cd-recombinant metallothionein

To a sample of deoxygenated metal-free (apo-) MT 1a, solid

113

CdCl2 was added

directly to the solution at a ratio that would lead to complete metalation for either of the
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isolated domains (3 or 4 Cd2+ per β or α-rhMT, respectively), or the full MT protein (7
Cd2+ per βα-rhMT 1a).

The solution was neutralized by the stepwise addition of

deoxygenated concentrated ammonium hydroxide. MT spontaneously remetalates when
neutralized. The solution is then rigorously evacuated to remove any oxygen that may
have entered the solution. A fine G-25 Sephadex size-exclusion column was buffer
equilibrated with 5 mM ammonium formate that had been pH adjusted to 7.4 with
deoxygenated concentrated ammonium hydroxide. The isotopically enriched MT sample
was then desalted into the 5 mM ammonium formate solution, pH 7.4 in order to remove
any excess salt of
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Cd2+ ions that may be present. The solution was then concentrated

to 8 mL using an Amicon stirred ultrafiltration cell model 8200. The MT solution was
further concentrated to 1-2 mL using an Amicon stirred ultrafiltration cell model 8010.
The final concentration was determined by UV absorption spectroscopy through a
thousand fold dilution of an aliquot of the isotopically enriched MT sample.

2.3 Instrumental Techniques
Metallothionein binds a wide array of metals, ranging from physiologically crucial
metals, such as Zn2+ and Cu+, to the toxic metals, such as Cd2+ and Hg2+. We outline
several techniques, which have been critical to the understanding of metal binding.
Critical to this thesis include UV absorption, circular dichroism and nuclear magnetic
resonance spectroscopy, as well as electrospray ionization mass spectrometry. A brief
overview of these techniques and the information that can be extracted from them is
discussed. A section describing the computational modeling that was used to calculate
the qualitative models of supermetalated MT is also presented.

2.3.1 UV absorption spectroscopy
Metallothionein exhibits a number of characteristic spectroscopic signatures that
depend on the type of metal bound. Because of the lack of either aromatic amino acids or
a defined secondary structure, such a β sheet or an α helix, in the apo-form (1-2) it is far
easier to measure spectroscopic properties that are entirely dependent on both the type
and number of metals bound, than is the case with many metalloproteins (3-5). UVvisible absorption and circular dichroism spectroscopies have been the key techniques in
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the determination of the relative affinities of metallothioneins for metal ions, the mode of
metal coordination and possible stoichiometries of these metals. In particular, the lack of
aromatic amino acid residues allows UV absorption spectroscopy to monitor the ligandto-metal charge transfer bands above 220 nm without interference. These techniques are
widely used to monitor metalation reactions of d10 metals, such as Zn2+, Cd2+, Hg2+, Cu+
and Ag+ (6-11). Typically, a titration with a metal ion leads to a change in the UV
absorption spectrum of the solution demonstrating either binding of the metal to the metal
free protein, or, alternatively displacement of an already present metal. The former is
used to determine binding stoichiometries for high affinity metals, while the latter can be
used to determine binding affinity and possible mixed metal species. If, however, the
incoming metal ion has a low binding affinity, then caution should be taken in directly
correlating a spectroscopically-determined maximum with a particular metal binding
stoichiometry.

Figure 2-3. UV absorption spectroscopy of rabbit liver metallothionein 2 (βαrlMT-2) as a function of increasing additions of aliquots of Cd2+. The concentration
of protein was 10 μM, while spectra were recorded at pH 7. There are 11 lines: line 1,
apo-βα-rlMT-2 at pH 2; line 2, apo-βα-rlMT-2 at pH 7; lines 3-11 for apo-βα-rlMT-2
with different concentrations of Cd2+ (1.06, 2.14, 3.5, 5.0, 5.95, 6.05, 6.92, 7.61, and 8.82
molar equivalent). It should be noted that as the amount of Cd2+ added to the solution
increases, the absorbance at 250 nm increases as well. The inset represents changes in
the intensity as monitored by the ligand-to-metal charge transfer band of cadmium
thiolate at 250 nm, as a function of molar equivalents of Cd2+ added. Adapted from (12)
with permission from ASBMB Copyright 1987.
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Figure 2-3 shows a classical titration of rabbit liver apoMT-2 with Cd2+ monitored by
UV-absorption spectroscopy between 210 and 290 nm (12). Initially, the absorbance is
associated with the protein backbone, the metal-free apo-MT. However, upon addition of
Cd2+ a shoulder forms at 250 nm, which corresponds to the ligand-to-metal charge
transfer of cadmium-thiolate bonds. The UV absorbance at 250 nm is at a maximum at 7
Cd2+ atoms, corresponding to fully metalated Cd7-βα-MT-2. Complete binding of the
Cd2+ ions is the result of the high affinity of cysteinyl sulfurs for Cd2+, 6.0x1021 – 1025.6
M-1 (13-14). While the stoichiometry of metal binding may be extracted from UV
absorption spectra, it is the CD spectra that clearly show changes in the metal-binding
sites indicative of a transition from individual CdS4 sites to the formation of the
polynuclear clusters (15). The maximum of seven Cd2+ per βα-MT has been confirmed
by ESI-MS measurements for MTs from many different mammalian sources, for
example, human MT (16-17). In the case shown in Figure 2-3, we see a slight reduction
in absorbance at 250 nm, which has been interpreted as due to non-specific Cd2+
associating with the protein. That these ions do not change the CD band envelope
morphology is strong evidence that the Cd7S20 domain structure is not directly affected.
While metallothionein is key in the cellular homeostasis of both Zn2+ and Cu+, as d10
metals, their spectroscopic signatures are essentially limited to the ligand-to-metal charge
transfer bands (thiolate to Zn2+ and thiolate to Cu+). On the other hand, metalation of
metallothionein using metal ions with an incomplete d shell allows dd transitions to be
monitored. These transitions are sensitive to the coordination geometry of the metal
atom, and coupled with information provided by the ligand-to-metal charge transfer
bands, can allow assignment of both the coordinating ligands and the metal binding
geometry. In the following three examples of Co2+, Ni2+ and Fe2+, a maximum metal
binding stoichiometry of 7 metal atoms has been determined spectroscopically. The
spectral data for the binding of Co2+ to metallothionein demonstrates that the protein
enforces a distorted tetrahedral arrangement in which the α-domain has more tetrahedral
character than the β-domain (18-21).

The spectroscopic data for Ni2+ binding to

metallothionein does not have distinct dd transitions, however, the spectrum was
similar to Ni2+ bound to azurin, and this suggests a tetrahedral coordination. Fe2+ has also
been shown to bind in a tetrahedral manner, with a dd transition in the near infrared
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region (22). While these metals may not be naturally associated with the protein, their
spectroscopic characteristics are useful in determining the flexibility of the protein in
accommodating different metals.

2.3.2 Circular Dichroism (CD) spectroscopy
CD spectroscopy is an extremely valuable method used to measure the difference in
absorption between left- and right-circularly polarized light caused by chirality in the
chromophore as a function of the wavelength of light used. This method is highly
sensitive to conformations of optically active chiral molecules.

Traditionally in

biochemistry, the CD technique has been used to determine the extent of secondary
structure of a protein, such as α-helices, β-sheets and turns in the protein, or the status of
complexation based on the relative differential absorbance of the amino acids in the
peptide chain. In this manner the effects of denaturing agents, temperature, potential
ligands and mutations can be readily and reliably monitored.
In MT much greater structural sensitivity is found in the CD spectrum, because the
metals that bind form structurally significant binding sites that exhibit specific chirality
and cause the protein to fold into a predefined structure (Figure 2-2). These chiral
structures are composed of the metal ion and the thiolate donor atoms of the cysteine
residues. The ligand to metal charge transfer transitions in MTs are easy to measure
above 230 nm because they occur in the region of the electronic spectrum devoid of the
usual transitions associated with aromatic amino acids. This window region has allowed
detailed spectroscopic analyses of the metalation reactions of MT to be carried out for the
d10 metals that are otherwise chromophorically-silent. The CD spectrum of MT to the red
of 220 nm is completely dependent on the binding of metal ions.
Possibly the first CD spectrum of MT was published for Zn,Cd-βα-MT (23). In
subsequent studies of the rabbit liver Cd7-βα-MT-2a, it was reported that the morphology
of the CD spectrum resembled a derivative shape with the cross-over point aligned with
the 250 nm band of the SCd2+ ligand-to-metal charge transfer (12, 24-25). The origin
of this morphology was explained by Stillman et al. as resulting from exciton coupling
between pairs of Cd2+ ions in the α-domain through the interpretation of CD spectral
changes that took place following the titration of Cd2+ into rabbit liver Zn7-βα-MT-2a
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(12). That this CD band envelope represented a specific metalated structure was again
demonstrated when the supermetalated Cd5-α-hMT-1a was formed (26). Figure 2-4
shows the titration of human Cd3-β-MT-1a with excess Cd2+ to form the Cd4-β-MT-1a
species, also the associated ESI-MS and
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Cd NMR support the formation of a new

species. It is in this way that CD data may act as a fingerprint for the determination of
specific metalated species in MT.
Because of the utility of the CD technique, CD spectroscopic studies have been
reported for a wide variety of metals (11), including Ag-MT (27-28), Cu-MT (6, 24, 2931), Zn-MT (6, 12, 25, 31-32), Cd-MT (6, 12, 24-25, 29), and Hg-MT (8, 33-34). In this
thesis, CD spectroscopy is used to investigate changes in the chirality of both the isolated
β-domain and full MT protein upon binding of an additional Cd2+ ion to form Cd4-βrhMT (Chapter 5) and Cd8-βα-rhMT (Chapter 6), respectively.

Figure 2-4
Circular dichroism spectral changes observed upon titrating human
Cd3-β-rhMT with an additional 4.4 molar equivalents of Cd2+ to form Cd4-β-rhMT.
Adapted from Sutherland et al.(35).

2.3.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectroscopy is one of the most powerful techniques used to analyze the
structure and dynamics of metalloproteins.

It should be noted that MT has been

described as being notoriously difficult to crystallize, and much of our structural
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knowledge is the result of many NMR-based studies. Structures based on analyses of the
NMR data have been reported from several mammalian sources.

These structures

provide the absolute connectivities of all atoms and their spatial relationship within the
metal-thiolate core. Specifically, structural studies of metallothionein have focused
largely on

111/113

Cd binding. There are several advantages to using Cd2+ to study the

metalation of metallothionein including the natural presence of Cd2+ in metallothionein
(36), Cd2+ having a similar coordination geometry to Zn2+, and enhanced resistance to
oxidation due to Cd2+ having a high affinity for thiolates.
Both isotopes (111/113Cd) have a spin of ½:

111

Cd has a natural abundance of 12.75%

but a relative sensitivity to 1H (1H = 1) of only 9.54×10-3, while

113

Cd has a natural

abundance of 12.26% and a relative sensitivity of 1.09×10-2. The increased relative
sensitivity of

113

Cd compared with

The chemical shift range of
characterized

113

113

111

Cd makes the former isotope more widely used.

Cd has been recorded for a number of structurally

Cd-substituted metalloproteins (37). With a chemical shift range of

roughly 900 ppm (relative to 0.1 M Cd(ClO4)2), each

113

Cd is extremely sensitive to the

coordinating ligands: heptacoordinate oxygen ligands are the most shielded, while
tetrathiolate ligands are the most deshielding.
Enrichment with

113

Cd leads to an eight-fold enhancement of sample sensitivity over

those measurements based upon natural abundance

113

Cd. This enhancement allows for

data acquisition on low concentration (mM) samples in a reasonable amount of time.
Samples can be prepared by demetalation at low pH, followed by removal of metal ions
using gel filtration, and finally, remetalation using isotopically enriched

113

CdCl2. It

should be stressed at this point that the high concentrations of a typical NMR sample
have been reported to cause dimerization. Further complicating this issue are reports
suggesting that demetalation through the use of strong acid leads to structural changes in
metallothionein itself. As such, NMR spectral data should be correlated with other
spectroscopic techniques (above), as well as spectrometric techniques, such as ESI-MS
(below), which do not necessarily rely on either acid-induced demetalation or the large
concentrations necessary for this technique (38-40).
Through an analysis of both the 1-D 113Cd-NMR chemical shifts and splitting patterns,
the structures of the polynuclear clusters within MT were determined. These experiments
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identified the coordinating ligands as cysteinyl-thiolates and formulated the polynuclear
centers as Cd3S9 and Cd4S11, corresponding to the β-domain and α-domain, respectively
(41-44). While 1-D

113

Cd-NMR spectroscopy provides key information regarding the

number of Cd2+ ions bound and their respective coordinating ligands, these experiments
are resource intensive, requiring several days of acquisition.
A newer NMR method that is being used extensively in MT studies is Heteronuclear
Single Quantum Coherence (HSQC), which provides increased sensitivity by using easily
observed nuclei, such as 1H, to obtain NMR information on insensitive nuclei, such as
113

Cd.

A 1H{113Cd} HSQC experiments polarizes a 1H nuclei and transfers that

polarization to

113

Cd J-coupled nuclei. The signal is then allowed to evolve, and the

polarization is transferred back to the 1H nuclei, where acquisition occurs. A sensitivity
increase of γ1H/γ113Cd, where γ is the magnetogyric ratio of the nuclei in question, is
theoretically possible. 1H nuclei have a magnetogyric ratio, γ1H, of 267 radians/Tesla and
113

Cd nuclei have a magnetogyric ratio, γ113Cd, of 59.6 radians/Tesla.

From this

combination of nuclei one can theoretically expect an additional 4.5-fold increase in
sensitivity. Additionally, it may be possible to determine some of the terminal and
bridging cysteine residues, where terminal coordination defines a cysteine residue bound
to a single Cd2+ ion. The experiment may also provide some discriminatory evidence
towards either a one- or two-domain model. Perhaps most importantly, good quality
spectra are possible within a 12 hr period, as opposed to the much longer timescales of
the 113Cd 1-D NMR.
In this thesis, both 1-D and 2-D NMR spectroscopies are used to investigate Cd3- and
Cd4-β-rhMT 1a (Chapter 5) and Cd7- and Cd8-βα-rhMT 1a (Chapter 6). Specifically, 1-D
NMR spectroscopy provides the number of unique Cd2+ ions, while 2-D NMR
spectroscopy is used to determine the identity of different Cd2+ ion. In both cases, the
chemical shift provides information about the identity of the coordinating ligands.

2.3.4 Electrospray Ionization Mass Spectrometry (ESI-MS)
Electrospray ionization mass spectrometry (ESI-MS) measures the mass-to-charge
ratio (m/z) of analytes, and because the ionization method allows the infusion of the
analyte directly from solution, this method has become critical to many metallothionein
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binding experiments. Unique to this technique is its ability to determine not only the
number of metals bound but also the types of metals bound, which allows for a direct
correlation between the spectroscopy and speciation of a sample. A brief description of
the technique, followed by how data is interpreted, will allow for a better understanding
of its usefulness in studying the complex metal binding properties of metallothioneins.
In the ESI-MS experiment, a sample in solution is introduced, under atmospheric
pressure, into the tip of the electrospray capillary (Figure 2-5). This tip is electrically
charged to several thousand volts and causes the solution to accumulate positive charge.
Enrichment of the tip with positive ions leads to the formation of a Taylor cone, which
ejects small positively charged droplets. Solvent evaporation decreases the radius of the
droplet, while the charge remains constant. When Coulombic forces, due to the nearness
of positively charges ions, overcome the surface tension, fission of the droplet occurs.
Evaporation-fission events repeat until very small charged droplets are produced.
Eventual formation of the multiply charged protein is thought to occur via the charged
residue model (CRM) (45-46). The CRM mechanism of gas phase ion formation states
that the small highly charged droplet will evaporate to dryness leaving any unpaired ions
as adducts to the protein. Since each droplet will have varying numbers of charges, a
distribution of mass-to-charge ratios will be observed. The charge state distribution is
directly related to both the number of basic sites on the protein, as well as the size of the
protein, as such any alterations to this size, or site exposure, through folding or through
denaturation, will lead to changes in the charge state distribution.
Charged proteins are separated by differences in the m/z ratio; common analyzers
include the quadrupole and time-of-flight mass analyzers, allowing detection of species
even with very similar m/z values. The ESI-MS technique allows for the introduction of
samples in aqueous solution and at physiological pH.

Folding experiments can be

conducted, in which the charge state distribution can be directly related to changes in
sample conditions, such as pH or metal added, and changes in metalation status can be
monitored by mass changes.

By knowing the concentration of protein, from

spectroscopic techniques, accurate quantification is possible through a comparison of the
deconvoluted peaks. This, however, assumes that all species in solution ionize at the
same rate, and may not always be true.
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In the case of MT, metal induced folding experiments may be performed by the
addition of small aliquots of metal ions to apo-MT (17, 47). In this way both the number
of metals bound and changes in the folding of the protein may be observed. For example,
Figure 2-6 compares the ESI-mass spectral data for metal-free (apo-) MT 1a recorded
when 0 and 7.3 eq. Cd2+ have been added to solution. It is immediately obvious that apoMT possesses a greater number of charge states (+8 to +5) than Cd7-MT (+6 and +5) and
indicates that a folding event has occurred. The speciation of MT in solution may also be
observed from the deconvoluted spectra, Figure 2-6 (right). These spectra are the result
of the analysis of the m/z data, and allow slight shifts in the charge state of the protein to
be interpreted as the relative populations of differently metalated species. Consequently,
the folding of the protein is the result of metalation and has decreased the overall volume
of space occupied by MT and/or the solvent exposed residues.

Figure 2-5. Electrospray ionization mass spectrometer.
(A) Instrumental
configuration of the electrospray ionization mass spectrometer. Depicted is the ‘Z-spray’
configuration of Waters Micromass ESI-MS operating in positive ion mode. (B) The
charged residue model for analyte desolvation, where evaporation leads to the deposition
of unpaired protons on the surface of the protein.
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Figure 2-6. ESI mass spectra recorded during the titration of MT with Cd2+. (A)
metal-free (apo)-MT 1a at 0 eq. Cd2+ added to solution and (B) Cd6/7/8-MT 1a at 7.3 eq.
Cd2+ added to solution. Charge states +5’ to +8’ correspond to a less prevalent truncated
species.
In this thesis, mass spectrometric analysis of MT and its isolated domains is present in
all Chapters. Specifically in the Chapters 3 and 4, metal binding reactions of MT 1a
under equilibrium conditions is used to determine both the mechanism of metal binding
and the relative affinity of the isolated domains. A great strength of this technique is in
allowing the correlation of spectroscopic data with speciation in solution. In Chapters 5
and 6, ESI-MS is used to rationalize distinct changes in the spectroscopy of β-rhMT 1a
and βα-rhMT 1a.

2.3.5 Computational modeling
MT is notoriously difficult to crystallize and while structural information has been
made available in the form of NMR data, these studies require a complete backbone
assignment of the protein. The particular isoform studied in this thesis, isoform 1a, has
not had a complete backbone assignment performed. Consequently, a complete structure
for either Cd4-β- (Chapter 5) or Cd8-βα-rhMT 1a (Chapter 6) is not possible at this time.
In order to circumvent this problem, the work included in this thesis has produced
tentative models based upon the modified crystal structure of MT isoform 2 reported by
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Chan et al. (16). This thesis has used both molecular mechanics and molecular dynamics
to produce the qualitative structures of supermetalated MT and below is a brief
description of the computational techniques used.
Molecular mechanics (MM) uses Newtonian physics to model molecular system. All
atoms in the system are treated as hard spheres with a defined radius and the bonds
between these atoms are treated as a series of springs with associated lengths and force
constants. As an empirical technique, MM relies upon experimental data to construct the
force field necessary to calculate the structure of the molecule. The CACHE system used
for all calculations is based upon parameters published by Allinger for the MM force
field directly for all elements, except metals (48). The total energy of the system is given
by the following equation:
Etotal = Ebonding + Etheta + Ephi + Eimprop + Eelec + Evdw + EH-bond
The above terms describe the energies involved in the bond, angles, dihedral angles,
improper torsions, electrostatic potential, van der Waals interactions, and hydrogen
bonding, respectively. Common force fields used for biological molecules are Allinger’s
MM2/3/4 (48-52), CHARMM (53) and AMBER (54-55).

However in bioinorganic

chemistry, the presence of metal ions necessitates modification of the above force fields
to account for their presence. Thus the difficulty lies in obtaining an accurate force field
for the metal ion, specifically the metal-thiolate bonds found in metallothionein. The
force field used in this study was specifically tailored by Chan et al. to take into account
the cadmium-thiolate bonds present in MT (16, 56).
Molecular dynamics (MD) uses a classical mechanics approach to simulate the motion
of the atoms as a function of time according to the temperature and the calculated forces
exerted on the atoms. This method allows the user to search for energy minima by
injecting energy directly into the bonds, causing motion. At every time-step of the
dynamic simulation, the potential energy is calculated using molecular mechanics
(MM/MD). Conformational slices can be extracted and structurally relaxed by MM. The
lowest energy conformer of the supermetalated Cd4-β- and Cd8-βα-rhMT is presented in
both Chapter 5 and 6.
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Chapter 3.

Noncooperative Cadmium binding to
human MT 1a3

3.1 Introduction
Metallothionein (MT) is a ubiquitous metalloprotein found in bacteria, mammals and
invertebrates (1-3). Characteristic features of MT include its small size, high cysteine
content, and lack of aromatic amino acids. Although the exact in vivo function of MT is
unknown, it has been implicated as a metallochaperone involved in essential zinc and
copper homeostasis, as a detoxifying agent of toxic metals, and as a protective agent
against oxidative stress (4-7). The most well characterized member of the MT family is
mammalian MT and structural analysis of its fully metalated form by NMR and X-ray
crystallography have shown it to contain two separate metal binding domains: the Nterminal β-domain with 9 cysteine residues capable of binding three Cd2+/Zn2+, or 6 Cu+
and the C-terminal α-domain with 11 cysteine residues capable of binding four Cd2+/Zn2+
or 6 Cu+ (8-11). Both the isolated β- and α-domain encapsulate a metal thiolate core as
shown in Figure 3-1, and the metalation chemistry of each is thought to be independent.
Specifically, the β-domain of MT has been shown to have a preference for Cu+
coordination, while the α-domain has been shown to have a preference for Zn2+/Cd2+
coordination. In this manner, MT is thought to be able to separate the redox active Cu+
chemistry from the redox inactive Zn2+ chemistry.
While Cu-MT has been isolated from a number of sources including, fetal liver (1213), bovine calf liver (14), rat kidney (15), brain specific MT-3 (16), as well as patients
suffering from Wilson’s disease (17), it is the zinc form that is most commonly found in
healthy adult mammals. These observations have led to a long association of MT with
zinc homeostasis. Specifically, MT is thought to act as a robust metallochaperone,
capable of donating Zn2+ ions to apo-enzymes and accepting Zn2+ in cases of excess.
Indeed metal exchange experiments have been conducted in which Zn2+ from Zn7-βα-MT
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has been transferred to Zn-dependent enzymes, for example, m-aconitase (18), carbonic
anhydrase (19), and the prototypical transcription factor, Gal4 (20). Removal of Zn2+
from the zinc finger-containing transcription factor Sp1 demonstrates that MT may also
act as a Zn2+ acceptor (21). Thus this natural association of MT with the biologically
essential Zn2+ and Cu+ has suggested that one of the functions of MT is the maintenance
of metal ion homeostasis. To support this view a recent report by Krezel & Maret
demonstrated the presence of three sets of binding affinities (22): four Zn2+ ions that
bind strongly (logK = 11.8), 2 with intermediate affinity (logK~10) and finally a single
weakly bound Zn2+ (logK = 7.7). Thus MT is able to act as a dynamic metallochaperone
capable of binding and donating Zn2+ ions over a range of concentrations.
Several MT polymorphisms have been linked to the longevity of certain human
groups, with both low Zn-MT levels and satisfactory Zn2+ bioavailability being good
markers for human health (23).

Mutations of MT-1a (Asn27Thr) have also been

associated with diabetes type 2 and cardiovascular complications (24-25), where nitric
oxide, an oxidizing agent, was used to determine the availability of Zn2+ from Zn-MT.
Exposure of the mutant MT to nitric oxide, resulted in less Zn2+ release compared to the
wild-type, suggesting that either the mutant is inherently less reactive, or that a large pool
of partially oxidized MT exists. In both cases, the mechanism of metalation, and the
potential for partially metalated species taking part in cellular chemistry has significant
consequences in the understanding of the relationship between Zn2+ bioavailability, MT
and the overall health of an individual.
Specifically, if the mutant is inherently less reactive to NO, then one would
predict the mutation has affected the most weakly bound Zn2+ ion.

However, this

mutation may have also affected the stability of the protein leading to the accumulation of
partially oxidized MT, where loss of Zn2+ ions from weakly bound sites has led to an
accumulation of stronger binding sites.

These strong binding sites would decrease

cellular availability of Zn2+ and impede the health of the individual. It should be made
clear that while this was an in vivo study and no information about the metal loading of
the mutant MT is available, the final result of the individual is the same: only tightly
bound Zn2+ exists and cannot be released easily either because of an increase in the
stability of a weaker binding site, or partial oxidation and subsequent loss of a weaker
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binding site. In either case, MT impacts pathogenesis through both Zn buffering and
antioxidant dysfunction, which in turn rely on the metalation status in vivo. It is clear that
knowledge of the mechanism of metalation is needed to establish the metal status in vivo,
which will aid in determining the exact involvement of MT in these disorders.

Figure 3-1. Molecular model structure of Cd7-βα-rhMT. A) space filling; B) Balland-stick with the domains in space filling form; C) Ball and stick models of Cd3-β- (left)
and Cd4-α- (right) rhMT cadmium-cysteinyl-thiolate clusters. Cysteinyl sulphurs are
coloured yellow, while cadmium atoms are coloured green. Data of Chan et al. (26).
Surprisingly, while the stoichiometric ratios of 3 (β) and 4 (α) for Zn2+/Cd2+ ions are
well known, there has been considerable debate regarding the mechanism of MT
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metalation. It has been frequently proposed that the mechanism occurs in a cooperative
fashion, that is, the binding of one metal facilitates the binding of the next metal (27-28).
In this mechanism, one would expect only the metal free (apo-MT) and fully metalated
(holo-MT) forms to be relevant. Several experiments support this viewpoint. Most
notably in an NMR titration of apo-MT with 113Cd2+, the appearance of four 113Cd-NMR
peaks associated with the α-domain could be clearly observed at 2.8 equivalents of
113

Cd2+ per MT molecule, and the remaining 3 peaks, associated with the β-domain,

appeared at 5.3 equivalents of

113

Cd2+ per MT molecule (28). It should be noted that at

2.8 equivalents of Cd2+ per MT molecule, a broad peak is observed at 685 ppm and could
be the result of chemical exchange or overlap of peaks in the sample.
Contrary to a cooperative mechanism of metalation, a noncooperative mechanism is
also possible in which metalation events occur independently of each other (29-31). In
this alternate hypothesis, it would be expected that apo-MT, partially metalated MT and
completely metalated MT would coexist.

In this situation, the mechanism of MT

metalation determines the number of possible physiologically relevant structures that can
be present in the cell. Several studies support this alternative mechanism of metalation
including Zn7-MT titration, where chelator agents were used to determine the presence of
three distinct binding sites with log(K) affinities of 11.8, ~10 and 7.7 (22). In addition,
S-nitrosylation studies of brain-specific MT-3, as monitored by NMR spectroscopy,
demonstrated the persistence of two α-domain-Cd2+ atoms, even in the presence of excess
nitric oxide (32). If the mechanism of metalation were cooperative then in the first case,
one would predict increasing log(K) affinities as metalation progressed, and in the latter
case oxidation would lead to a destabilization of partially metalated β- and α- clusters. In
addition, enhanced resistance to S-nitrosylation has been reported in MT-1a mutants
(Asn27Thr) (24-25). These results may be reasonably interpreted if a noncooperative
mechanism is in effect; however this has not been proven experimentally to date.
A recent report has provided convincing evidence for noncooperative binding of
cadmium to the isolated α-domain of human MT-1a (33) but not the complete protein or
the isolated β-domain.

Determination of the mechanism of the β-domain and the

complete protein is important, because in a recent paper by Palumaa et al. (34) the
authors comment that while the brain-specific MT-3 exhibits noncooperative binding, β–
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MT domains from other species bind cooperatively. For this reason, we have studied the
step-wise metalation of the isolated β-domain and the two-domain βα human protein so
that the metalation properties of this human protein can be firmly established.
This chapter provides the necessary data establishing unambiguously the
noncooperative nature of cadmium binding to both the isolated domains and the
combined βα-MT protein (βα-rhMT) of human MT-1a.

Section 3.2 describes the

experimental details used to study the mechanism of metalation. Mass spectrometric
results are presented in section 3.3 and, finally section 3.4 discusses these results in the
context of current research and its implications. Briefly, the dominant metalation state
(1-3 for β- and 1-7 for β-) was directly dependent on the stoichiometric ratio of Cd2+
added, and interestingly, titration of apo-MT (β or βα) with excess CdSO4 yielded
supermetalated (metalation in excess of the normal maximum levels) species for the βand full-MT protein not previously reported.

3.2 Experimental Methods
In this section, the details of the protein preparation protocol for the metal-binding
studies (Section 3.2.1) and the instrumental parameters (Section 3.2.2) will be described,
as well as a detailed account of the experimental design for the metalation of apo-β- and
apo-βα-rhMT 1a with Cd2+ at pH 9.4 and 8.4, respectively (Section 3.2.3).

3.2.1 Protein preparation for metal binding studies
Chemicals
CdSO4 (J.T. Baker Chemical Company). All chemicals used in this study were of the
highest-grade purity from commercial sources.

All solutions were made with

>14MΩcm-1 deionized water (Barnstead Nanopure Infinity). Protein purification steps
were performed on Hi Trap SP ion exchange columns, fine G-25 Sephadex (Amersham
Biosciences) and a stirred ultrafiltration cell (Amicon Bioseparations/Millipore) with a
YM-3 membrane (3000 MWCO).
Protein preparation
The expression and purification methods have been previously described in detail in
chapter 2. The β-rhMT and βα-rhMT proteins used in this study were based on the 38-
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residue

and

ATGGSCTCTG

72-residue

sequences,

SCKCKECKCN

respectively:

SCKKAAAA,

β-rhMT

MGKAAAACSC

βα-rhMT

MGKAAAACSC

ATGGSCTCTG SCKCKECKCN SCKKAAAACC SCCPMSCAKC AQGCVCKGAS
EKCSCCKKAA AA. There are 9 and 20 cysteine residues present in β-rhMT and βαrhMT, respectively, and no disulfide bonds. The expression system included, for stability
purposes, an N-terminal S-tag (MKETAAAKFE RQHMDSPDLG TLVPRGS).
Recombinant β-rhMT was expressed in BL21(DE3) Escherichia coli (E. coli.), while βαrhMT was expressed in ER2566 E. coli.. Both cell lines were transformed using the
pET29a plasmid. Removal of S-tag was performed using a Thrombin CleanCleaveTM Kit
(Sigma). To impede oxidation of the cysteine residues to disulfide bonds, all protein
samples were argon saturated and rigorously evacuated.
A general description of the demetalation procedure can be found in chapter 2 (Section
2.2.6). In this experiment, concentrated formic acid was used to lower the pH of the MT
sample to 2 with concomitant demetalation. Previously bound Cd2+ ions were removed
by buffer exchange using a G-25 (Sephadex) column into deoxygenated di-H2O pH
adjusted to 2.7. The solution was evacuated, septum capped and backfilled with argon.
Small aliquots of both the apo-β- and apo-βα-rhMT 1a were remetalated using Cd2+
and their concentrations were determined to be 18.0 and 18.4 μM from the ligand-tometal charge transfer band (LMCT band) centered at 250 nm (ε250β = 36,000 and ε250βα =
89,000 M-1cm-1). Cadmium solutions were prepared as the sulfate salt in di-H2O to a
final concentration of 7.1 mM as determined by atomic absorption spectroscopy (AAS).

3.2.2 Mass spectrometric measurements
ESI-MS procedures.
All data were collected on an electrospray ionization time-of-flight (ESI-TOF) mass
spectrometer (Waters Micromass Inc.) in the positive ion mode. NaI was used as the
calibrant, because of its ability to form salt clusters that cover the m/z range of the
protein. The scan conditions for the spectrometer were: capillary, +3000.0 V; sample
cone, 15 V; extraction cone, 10 V; RF lens, 450 V; desolvation temperature, 20.0 °C;
source temperature, 80.0 °C; cone gas flow, 52 Lhr-1; and desolvation gas flow, 514 Lhr-1.
The m/z range was 500.0-2000.0; the scan mode was continuum, with a scan time of 2.4 s
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and an interscan delay of 0.10 s. Spectra were constructed and deconvoluted using the
MASSLYNX v.4.0 software package.

3.2.3 Metalation of apo-β- and apo-βα-rhMT 1a with Cd2+
The pH of the apo-β- and apo-βα-rhMT 1a solutions were raised to 9.4 and 8.4,
respectively, through the stepwise addition of concentrated NH4OH.

This stepwise

addition was initially monitored through the use of pHydrion® pH paper (Micro Essential
Laboratory, Inc.) and immediately following the titration, the pH was determined using a
pH meter (Accumet Basic AB15, Fisher Scientific, Ottawa, ON, Canada) with an
Accumet Semimicro pH electrode.
After the addition of each aliquot of Cd2+, the solution was thoroughly mixed and
allowed to equilibrate for 5 min. Mass spectra were then acquired of the MT solution.
Following the ESI-MS titration, AAS was used to calibrate the exact equivalents added to
solution at each step of the titration.

3.3 Results
In this section, the ESI mass spectral results for the titration of the isolated apo-βdomain and full MT 1a protein with Cd2+ are outlined. Specifically, the effects of
metalation on the isolated β-domain (Section 3.3.1), the full MT protein (Section 3.3.2)
and an analysis of the deconvoluted mass spectral data as a function of Cd2+ added to
solution (Section 3.3.3).

3.3.1 Metalation of apo-β-rhMT 1a with Cd2+ at pH 9.4
The mass spectra recorded during the titration of apo-β-rhMT are shown in Figure 3-2.
The data clearly show that stepwise addition of Cd2+ to the initially metal-free protein
results in the formation of partially-metalated (β<3 Cd2+) species until saturation occurs
with the fully metalated species at 2.8 equivalents Cd2+ added to solution. It should be
noted that there is some error in the measurement of Cd2+ added to solution and that 2.8
equivalents represents complete metalation, either because of an overestimation of the
protein content or an underestimation of the Cd2+ added to solution. In Figure 3-2, the
observed charge states (A-E) and their corresponding deconvoluted spectra are shown as
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a function of increasing concentration of Cd2+. Cleavage of the S-tag leaves the residues
GS attached to the N-terminal of the protein. Theoretical mass values for β-rhMT are as
follows: apo-β-rhMT 3753.46 Da, Cd1 3863.85 Da, Cd2 3974.24 Da, Cd3 4084.63 Da and
Cd4 4195.02 Da.
In more detail, Figure 3-2 shows the bound-metal speciation for β-rhMT as a function
of the number of Cd ions added at pH 9.4. One Zn2+ is bound to about 25% of the total
protein.

The binding persists until the Zn2+ is displaced at the Cd3 point, (D).

Surprisingly, addition of five molar excess led to the quantitative formation of a new
species Cd4-β-rhMT forms (E). Metal free apo-β-rhMT exhibits significant intensity in
charge states corresponding to +5, +4, and +3 at the 0 Cd2+ added point (A1). The +5
charge state intensity is no longer apparent when Cd1-β-rhMT forms. The loss of the +5
charge state clearly indicates some degree of folding has occurred as a result of the
conformational changes required following binding of just the first Cd2+ or the Zn2+ to the
apo-β-rhMT to form Cd1-β-rhMT or Zn1-β-rhMT (B1). After the disappearance of the +5
charge state, there is very little change in the charge state distribution with further
additions of Cd2+, indicating that the most significant folding occurs upon binding of the
first metal ion.

3.3.2 Metalation of apo-βα-rhMT 1a with Cd2+ at pH 9.4
The mass spectra recorded during the titration of apo-βα-rhMT Cd2+ are shown in
Figure 3-3. As in the case of apo-β-rhMT 1a, the data show that stepwise addition of
Cd2+ to the initially metal-free protein species results in the formation of partiallysaturated (β- <7 Cd2+) metalated species until saturation occurs with the fully metalated
species, which forms when stoichiometric amounts of Cd2+ are added. In Figure 3-3, the
observed charge states (A-E) and the corresponding deconvoluted spectra are shown as a
function of increasing concentration of Cd2+. Cleavage of the S-tag leaves the residues
GS attached to the N-terminal of the protein. However, the mass spectra show that
several amino acids of βα-rhMT were truncated either during the cleavage, or in the mass
spectrometer itself producing two different species: one in which the N-terminal G
residue and C-terminal AA residues were truncated, and a second in which the Nterminal GSMGK as well as A from either the N-terminal or C-terminal were truncated.
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None of the highly conserved cysteine residues were truncated. By assuming both
species of βα-rhMT are equivalently ionized, the first species is more prevalent.
Theoretical mass values for the predominant βα-rhMT species are as follows: apo-βαrhMT 6874.37 Da, Cd1 6984.76 Da, Cd2 7095.15 Da, Cd3 7205.54 Da, Cd4 7315.93 Da,
Cd5 7426.32 Da, Cd6 7536.71 Da, Cd7 7647.10 Da and Cd8 7757.49 Da.

Figure 3-2.
ESI mass spectral titration of apo-β-rhMT with CdSO4. The protein
concentration was 18.0 μM and a pH of 9.4. Mass spectral data (Left) and the
corresponding deconvolutions (Right) were recorded as aliquots of Cd2+ (7.1 mM) were
titrated into the solution at 22 °C. The * refers to a +5 m/z minority species
corresponding to slight dimer formation of β-rhMT.
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Figure 3-3. ESI mass spectral titration of apo-βα-rhMT with CdSO4. The protein
concentration was 18.4 μM and a pH of 8.4. Mass spectral data (Left) and the
corresponding deconvolutions (Right) were recorded as aliquots of Cd2+ (7.1 mM) were
titrated into the solution at 22 °C. Two sets of m/z refer to the presence of two βα-rhMT
species, see text.
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Cd-loading of the two-domain protein is shown in Figure 3-3 with the metalspeciation in βα-rhMT measured as a function of added Cd2+. Cd-species from 1 to 8 at
pH 8.4 are observed with stoichiometric addition of Cd2+. A single Zn2+ persists in 25%
of the protein as the Zn1-βα-rhMT species in (A). The Zn2+ is only displaced when Cd7species forms. The important feature in Figure 3-3 is the step-wise increases in Cd2+loading as a function of added Cd2+ and the appearance of Cd8-βα-rhMT with excess
added Cd2+. Apo-βα-rhMT (A) exhibits charge states corresponding to +8, +7, +6, and
+5 (+5’ to +8’ correspond to the less prevalent truncated βα-rhMT species). Addition of
1 Cd2+, data in (B), causes a significant reduction in the intensity of the +8 and +7 charge
states, again, indicating that a conformational change takes place reducing the exposed
basic amino acids. Complete loss of the +8 charge state occurs with formation of Cd 2βα-rhMT, which corresponds to the complete loss of apo-βα-rhMT species. As the
titration proceeds, up to 7 equivalents of Cd2+ are added, the intensity of +6 relative to +5
increases. This reversal in trend in the charge state intensity indicates an increase in
volume of the structure. The deconvoluted spectra in (E) show that this corresponds to
the emergence of Cd8-βα-rhMT. The appearance of the lower mass signals at the end of
the titration, Cd3/Cd4/Cd5-βα-rhMT, are due to the presence of metalated, truncated βαrhMT.

3.3.3 Relative abundance of apo-β- and apo-βα-rhMT 1a with Cd2+
Assembled in Figure 3-4 are the relative abundances of each metalated protein species
shown in Figure 3-2 and 3-3. Because there is a small fraction of Zn2+ bound, it has
shown that Zn2+ and Cd2+ bind isomorphously, all Zn2+ species are counted as if Cd2+
were bound (35). Of course, Cd2+ binds with a greater KF and so displaces the Zn2+ when
no other binding sites are available in the noncooperative model, as observed here. The
value of Figure 3-4 is that it clearly demonstrates that partial metalation occurs; hence the
extent of metalation is directly dependent on the amount of metal in solution. At low
equivalents of metal only partially metalated species are observed and addition of excess
Cd2+ to β-rhMT and βα-rhMT lead to the formation of Cd4-β-rhMT and Cd8-βα-rhMT,
respectively.
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Figure 3-4.
The metalation state as a function of Cd2+ added. This plot assumes
that the binding of zinc and cadmium are equivalent and treats them interchangeably. (A)
refers to the metalation of β-rhMT, whereas (B) refers to the metalation of βα-rhMT. The
second βα-rhMT truncation, accounts for 13% of total signal, which must be spread over
several species, no adjustment was made to metal speciation.
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3.4 Discussion
3.4.1 Cooperative

versus

noncooperative

metalation

of

metallothionein
Mammalian metallothioneins bind metals in metal-cysteinyl-thiolate clusters with
stoichiometries dependent on the associated metal: Cd7-MT, Zn7-MT, Ag12-MT, Cu12MT, Hg18-MT, and As6-MT (9, 11, 36-38). The details of the metal binding mechanisms
are important because of implications in the possible metalation status of the protein in
vivo, especially, whether partially metalated species exist under normal conditions. There
are two overall mechanisms (i) a cooperative mechanism in which only the metal-free
(apo-MT) and the metal-saturated (holo-MT) are significantly populated and a
noncooperative mechanism, which would allow for the presence of partially metalated
species that could potentially serve a biological function, such as controlling the
bioavailability of zinc (4, 22).

Previous attempts to determine the mechanism of

metalation have relied on techniques that do not produce direct evidence for the
absence/presence of intermediate species (28-31) or may be more sensitive to specific
species, for example, the CD spectrum of Cd4--domain dominates the spectrum
compared with the partially metalated Cd1-3 (33). ESI-MS data reported over several
years, and the specific recent results for the metalation of the α-domain of rhMT 1a (33,
39) show that ESI-MS data exhibit the discriminating power required to detect and
quantify the presence of partially metalated metallothioneins.
Cooperative metalation
A cooperative mechanism of metalation implies that the binding of one metal ion, for
example Cd2+, affects the binding of subsequent metal ions. There are two cases of
cooperative metalation: positive cooperativity, where the binding of one ligand facilitates
the binding of subsequent ligands (Kn+1> Kn, where n is the number of ligands bound),
and negative cooperativity, where the binding of one ligand hinders the binding of
subsequent ligands (Kn> Kn+1, where n is the number of ligands bound). The traditional
view of MT is that metalation occurs in a positive cooperative fashion with only the fully
metalated (holo-) and metal free (apo-) MT taking part in cellular chemistry. As such,
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research of the metalation properties of MT have focused primarily on the metal free, and
fully metalated forms.
Noncooperative metalation
A noncooperative mechanism of metalation implies that the each binding event is
independent of the others. In this model, one would expect the binding affinity to
decrease as a function of metals bound, because as each metalation site becomes
occupied the number of available sites decreases. Kinetic experiments involving As3+
binding to MT have supported the noncooperative mechanism of metalation.
Specifically, by studying the ESI-mass spectral metalation of the triple MT mutants (βββand ααα-rhMT) and comparing it to the isolated β- and α-domains, as well as the full MT
1a protein, it was shown that the rate of metalation is directly dependent upon the number
of available sites. This experiment was possible, because metalation of MT with As3+
occurs on the order of minutes to hours. Unlike As3+, Cd2+ metalation is complete in the
4 ms of the dead time of a stopped-flow machine, and ESI-mass spectral data on the
metalation of MT with Cd2+ is not currently available. Recent ESI-mass spectral studies
of the isolated α-domain of MT-1 by Rigby and Stillman, and full MT-3 protein by
Palumaa et al. have shown that partially metalated Cd-MT species are in fact stable and
that the dominant metalation state is directly dependent on the equivalents of Cd2+ added
to solution. These results support a noncooperative mechanism of metalation. However,
in the former case no metalation data are available without the metalation properties of
the isolated β-domain and the full MT protein no mechanism can be conclusively
supported.

3.4.2 Noncooperative metalation: ESI-mass spectral evidence
Many of the previous MT metalation experiments were based on optical techniques
and included CD, EPR, and UV spectroscopy. These techniques, while sensitive to the
metal-thiolate bond, provide an average of the metalation state of MT, and consequently
do not have the discriminating power necessary to determine the mechanism of
metalation.

ESI-mass spectrometry, a unique technique in that it is able to

simultaneously determine the number and type of metals bound to the protein.

In

addition, by monitoring changes to the charge state profile, protein folding information
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may also be extracted. Recently, ESI-MS has been extensively used to analyze the
metalation of MT through both the kinetics of metal binding and the discovery of a new
low affinity binding site. Specifically, the metalation of the isolated α-domain of human
MT-1a and the full MT-3 both support a noncooperative mechanism of metalation.
The present study demonstrates that the partially metalated species of the isolated βdomain and the two-domain protein of MT 1a are stable. Following the step-wise
addition of 1 to 4 (β) or 1 to 7 (βα) equivalents of Cd2+, all metalated species are observed
ranging from apo-MT to holo-MT depending on the amount of Cd2+ added, Figure 3-2
and 3-3. When combined with the kinetics of As3+ metalation and the stability of the
partially metalated species in the α-domain of MT 1a, we can now conclusively say that
both the isolated domains and full protein of metallothionein isoform 1a bind metals in a
noncooperative manner. It is very likely that noncooperative metalation applies to all
metals capable of binding metallothionein although this has yet to be proven.
Significantly, a noncooperative mechanism allows for partially metalated and metal
exchange intermediates to be stable and, therefore, to be able to take part in cellular
chemistry.
In addition to the metalation status, information from the charge state populations,
specifically changes in these populations, provides conformational information about the
protein. These charge state distributions are directly dependent on both the number of
basic sites and size of the protein. As such, any alterations to this size, or site exposure,
through folding or through denaturation, will lead to changes in the charge state
distribution.

Higher charge states correspond to a more open, solvent exposed,

conformation, while lower charge states correspond to more closed, solvent unexposed,
conformation.
The ESI-mass spectral data presented in Figures 3-2 and 3-3 show that the addition of
the first metal ion to both β-rhMT and βα-rhMT result in loss of intensity in the highest
charge states, +5 for the β-domain and +8 for the full protein, which indicates that
binding of this first metal leads to significant folding of the protein. The lack of change
in the distribution of the intensity in the charge states with further Cd2+ addition up to 3
(β) or 7 (β) indicates the first metal locks the structure in place and that, unexpectedly,
further metalation does not require significant rearrangement of the polypeptide backbone
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to occur. This compares well the α-domain of MT 1a, which upon binding the first Cd2+
ion losses the +7 and +6 charge states after which there is very little change to the charge
state spectra.
The dominant charge state of both fully metalated Cd3-β-rhMT and Cd4-α-rhMT is +4,
while the dominant charge state of the full MT protein is +6. One would predict that the
dominant charge state of the full MT protein would be the sum of the isolated domains.
This prediction is based upon the traditional view of the individual domains acting in
isolation of each other and is supported by a number of NMR studies, most convincingly
the almost identical location of the
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Cd-NMR peaks associated with the isolated α-

domain when compared to the full MT protein (10). However, contrary to this traditional
view, the dominant charge state of the fully folded MT protein is in fact +6 and is
significantly lower than the expected charge state of +8. This finding would suggest that
there is, in fact, some domain-domain interactions, which act to attenuate to total charge
that the protein is capable of holding. These domain-domain interactions, while not well
characterized may be critical in the equilibration of metal ions within each domain and
may help to explain the metal-ion preference of each domain (Zn2+ and Cd2+ in the αdomain and Cu+ in the β-domain) (40-41).

3.4.3 Implications of a noncooperative mechanism of metalation
The most significant consequence of a noncooperative mechanism of metalation is the
prospect of the existence of stable partially metalated MT species. For example, a recent
isolation of partially oxidized cardiac-specific MT from overexpressing transgenic mice
was somewhat surprising because in a cooperative mechanism partial oxidation of the
MT protein would act to labilize the remaining metal ions and facilitate complete
oxidation (42).

Prior to this study, isolation of partially metalated MT could be

interpreted as an artifact of purification and of no biological relevance. However, this
data establishes a noncooperative mechanism of metalation, which allows for the stability
of partially metalated intermediates. Under this mechanism, partially metalated MT is
likely to have several free thiol groups that can oxidize without interfering with the
remaining thiol-bound metal ions.
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The traditional functions of MT include the protective roles as a buffering agent
against both toxic metal exposure and oxidative stress. In both cases, interaction of MT
with the insult leads to a release of naturally bound Zn2+, which coordinates to metalregulatory transcription factor 1 (MTF-1). Zn-MTF-1 translocates to the nucleus and
upregulates MT, allowing the cell to deal with the insult. In the former case, MT has
been shown to protect an organism against a wide range of metals including Cd2+, Hg2+
and As3+ (43-44). In the latter case, exposure of MT to oxidizing agents, such as H2O2,
facilitates the oxidation of cysteine thiols to disulfide bonds (45).
A significant exception to this pattern of protection is methylmercury (MeHg+) (46).
The neurotoxicity of MeHg+ is well known and the expression of MT has been shown to
protect an organism against it. However induction of MT in vivo and in vitro with
MeHg+ using both astrocytes and neurons has not been possible (43-44). An analysis of
the binding affinities suggests that MeHg+, binding thiols with an association constant
ranging from 1015 to 1023 (46), would be able to effectively outcompete zinc, which has
an association constant ranging from 107 to 1012 (22). Taken together, these results
suggest that while at equilibrium MeHg+ should be able to displace Zn2+ from Zn-MT, in
a cellular environment it is not able to effectively compete. It has, however, been shown
that a pretreatment of the cell with either zinc or cadmium, both known to induce MT-1
and -2, is capable of aiding in metal-induced resistance to neurotoxicity (47-48). A
noncooperative mechanism is critical since it affords stability to partially metalated
species in the cellular environment. These partially metalated species, having several
non-coordinating thiols, would likely be more susceptible to MeHg+ binding. Without
the necessity for Zn2+ to dissociate from MT, MeHg+ coordination acts to sequester the
toxic metal insult and is likely the cause of the observed resistance.

3.4.4 Supermetalation: Cd4-β-rhMT 1a and Cd8-βα-rhMT 1a
Supermetalated forms of metallothionein were also observed for both the β- and the
β-proteins studied, where we define supermetalation as metalation in excess of
traditionally measured values. In the case of Cd3-β-rhMT and Cd7-βα-rhMT, addition of
excess Cd2+ led to the formation of Cd4-β-rhMT and Cd8-βα-rhMT, respectively. These
results complement well with the previously discovered supermetalated Cd5-α-rhMT,
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which was postulated to be a metal-exchange intermediate essential for MT’s ability to
maintain metal ion homeostasis (39).
Supermetalation of the β-domain has been previously postulated following analysis of
CD and UV-visible absorption spectral data (49). Capdevila et al. have postulated from
their spectral data, with excess Cd2+, that Cd4-β-rhMT subsequently unwound to form
Cd9-β-rhMT in a cooperative manner. It was proposed the unwinding required addition
of 9 excess equivalents of Cd2+. The ESI-MS data described here demonstrates that the
mechanism is noncooperative for metalation of apo-β-rhMT to Cd3-β-rhMT, Figure 3-2,
and subsequently excess Cd2+ forms only Cd4-β-rhMT.
Interestingly, based on the supermetalated data of the isolated domains we would
predict that supermetalation of the full MT protein would lead to the formation of Cd9βα-rhMT and not Cd8-βα-rhMT. Based solely on the ESI-mass spectral evidence two
possibilities exist: 1) supermetalation of one of the two domains inhibits supermetalation
of the other, or 2) coordination of the additional Cd2+ metal ion requires cysteine residues
from both domains. Meloni and Vasak recently determined that there exists an eighth
metal ion binding site in MT-3 (50).

In the case of MT-3, the formation of

supermetalated Cd8-βα-hMT-3 results in a decrease in the Stoke’s radius of the protein,
which suggests the mutual approach of the two domains. Based on both this data, and the
existence of Cd8-βα-rhMT and not Cd9-βα-rhMT in our ESI-mass spectra titration, we
predict that supermetalation involves both domains.

3.5 Conclusion
In summary, addition of Cd2+ to β-rhMT and βα-rhMT results in noncooperative
binding of to both. It can now be conclusively stated that the metalation of MT 1a with
Cd2+ occurs in a noncooperative manner for both the isolated domains and the full MT
protein. It was also shown that addition of excess Cd2+ to Cd3-β-rhMT and Cd7-βα-rhMT
leads to the formation of Cd4-β-rhMT and Cd8-βα-rhMT, respectively. This result was
surprising, since previous supermetalation studies of the isolated α-domain have also
shown an additional Cd2+ ion is capable of binding to form Cd5-α-rhMT and one would
predict that supermetalation of the full MT protein would be merely the sum of the
supermetalated isolated domains (Cd9-βα-rhMT). Based on ESI-mass spectral evidence,

70
it is unclear if the additional Cd2+ ion coordinates to a single domain in Cd7-βα-rhMT or
involves both domains. The model of metal binding in metallothionein is now clearly
more complex than previously thought, with the existence of partially- as well as supermetalated species. With the elucidation of noncooperative metalation of mammalian
metallothionein, determination of both the presence and function of intermediate species
are now possible.
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Chapter 4.

Single domain MT: Evidence for the onset

of clustered metal binding domains4
4.1 Introduction
Metallothionein (MT) is a small cysteine rich protein found in all organisms. MT
coordinates a variety of metals including the biologically essential Zn2+ and Cu+, as well
as toxic Cd2+, Hg2+ and As3+ (1-2). These metal ions are capable of coordinating in a
number of geometries, including digonal, trigonal, and tetrahedral (3). For Zn2+ and Cd2+
tetrahedral coordination by a mixture of terminal (binding to only a single metal-ion) and
bridging cysteine residues (Cys) is critical to the metal binding site structure. As a
consequence, we find ‘magic numbers’ for metal binding, formally defined as the
stoichiometric ratios that appear to represent stable saturated clusters, that range from 7 to
18 metal ions per MT protein (4). While the exact in vivo functions of MT are unknown,
MT has been implicated in toxic metal detoxification, metal ion homeostasis and as a
protective agent against oxidative stress. All of these processes rely on MT’s dynamic
ability to bind and release metal ions within the cellular environment. The key to
understanding the different roles of MTs is in a precise description of the metalation
reactions – this allows a definitive description of the allowed metalation states possible
for MTs and therefore an assessment of the functional metalation states. In previous
studies, 7 Zn2+ is known as the ‘fully metalated’ state, while loss of 1 or 2 Zn2+ ions
meant the protein had available binding sites and the cysteine residues not bound to Zn2+
would be exposed to oxidation. The result presented here show that the 5 Zn2+ metalation
state is the protective level leaving no accessible cysteine residues.
The most well characterized members of the MT family are the mammalian MTs
(Figure 4-1), for which X-ray diffraction and NMR studies of the fully metalated protein
show that metal ions form two essentially isolated and distinct metal-thiolate clustered
binding domains using the 20 cysteine residues of the protein. The N-terminal β-domain
is capable of binding 3 Zn2+ , 3 Cd2+ or 6 Cu+ metal ions using 9 cysteine residues, while

4
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the C-terminal α-domain is capable of binding 4 Zn2+ , 4 Cd2+ or 6 Cu+ metal ions using
11 cysteine residues (5-7). The current view of these domains is that each acts as an
effectively isolated metal-thiolate cluster. This view has been supported by a number of
NMR studies of mammalian MT, where no inter-domain peaks associated with the
nuclear overhauser effect (NOEs) were found (7-8). Since NOEs are a through space
phenomenon it has been inferred that the two domains are not physically near one
another. The sole exception to this observation is supermetalation of MT, where addition
of excess Cd2+ results in formation of a single Cd8Cys20 ‘super-domain’ (9-10). Based on
a combination of electrospray ionization mass spectrometry (ESI-MS) and absorption,
circular dichroism and NMR spectroscopy it was determined that the addition of the 8th
Cd2+ ion resulted in rearrangement of all 8 Cd2+ ions to form a single clustered Cd8-S20βα-rhMT domain.
One important feature in many of the MT's studied is the existence of multiple, often
2, isolated domains that are reported to coordinate both different numbers and different
types of metal ions. It has been suggested that the existence of the two domain structure
present in many MTs allows the protein to function simultaneously in both Zn2+ and Cu+
chemistries (11-12). The potential for MT to be able to spatially separate metal ion
chemistry into different domains has significant consequences for our understanding of
the role of MT in metal ion homeostasis and as a protective agent against oxidative stress.
For instance, MT-3 has been proposed to play an important role in maintaining the
balance of metals in the brain (13) and it has been reported to be downregulated in
patients with Alzheimer’s disease. A recent paper has shown that Zn7-βα-MT 3 is
capable of metal exchange with the copper bound amyloid-β-peptide (Aβ1-40-Cu2+) (14).
The exchange reaction and subsequent reduction to Cu+ leads to the formation of Cu4Zn4βα-MT 3. This process eliminates the production of reactive oxygen species and related
toxic effects, and it is thought to somewhat protect the individual from Alzheimer’s
disease. While the exact structure of this Cu4-motif is not known, it has been reported as
a stable folding intermediate leading towards the complete metalation of MT (Cu12-βαMT) (15).
Currently, little is known about the exact mechanism of the metalation of MT.
However, it has been demonstrated through ESI-MS that MT binds Cd2+ and As3+ in a

76

noncooperative manner, meaning that in addition to apo- and holo-MT, partially
metalated species may also exist in vivo (2, 16-18). Furthermore these partially metalated
species may be critical in the metal-exchange reactions necessary for maintenance of
metal-ion homeostasis.
While the fully metalated proteins have been studied in detail by numerous methods,
there are few studies that specifically focus on the metal binding reaction to the apometal-free protein other than the recent As3+ kinetic data (2, 18). A key feature of the
conclusions from those As3+ data was that each As3+ ion was bound to exactly 3 cysteinyl
thiolates, meaning that no clustering took place.
With the noncooperative mechanism of metalation recently established, it is now
crucial to determine the structural features of MT in the early stages of metalation (before
the protein is saturated) with Zn2+, the key biologically significant metal. The importance
of determining the 'holding point' for MT, that is the minimum 'safe' metalation point
against oxidative stress, is to answer the question of what is the naturally-metalated state
and the effects expected from demetalation when MT is part of a redox cycle.
In this chapter, we report on a series of Zn2+ competition experiments performed using
the metal-free isolated fragments apo-β- and apo-α- and the metal-free full protein apoβα-rhMT 1a. Individual titrations of both the isolated domains and the full MT protein
demonstrated that Zn2+ metalation occurs in a noncooperative manner. Competition
experiments using the very slight differences in the formation constants (KF) introduced
by co-metallating the isolated fragments containing the individual β- and α-domains, and
the isolated domains and the full MT protein probe the metalation reaction in detail not
previously reported. The data show that KF is sensitive to the metalation status and
particularly to the onset of clustering. We interpret the ESI-MS results to indicate that
initial metalation of MT does not occur in a domain specific manner, rather the
availability of up to 20 cysteines means that Zn2+ up to and including 5 bind tetrahedrally
to four terminal cysteinyl thiolates (each cysteine residue coordinates only a single metal
ion) that do not bridge in a ‘beaded necklace’-like fashion. Only then does clustering
take place via bridging interactions and a concomitant reduction in KF for those sites.
The subsequent metalation of the full protein to Zn6- and Zn7-βα-rhMT 1a requires a
complete structural rearrangement, loss of the single domain structure, together with
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development of the clusters associated with the formation of the more traditional Zn3and Zn4-domains.

Figure 4-1. Structure of MT 1a. (A) A space filling structure of Cd7-βα-rhMT 1a.
The N-terminal β-domain is located on the left hand side, while the C-terminal α-domain
is located on the right hand side. (B) Cadmium-cysteinyl-thiolate clusters of Cd7-βαrhMT 1a presented as a ball and stick model: β-domain (left) and α-domain (right). (C)
A connectivity diagram of MT 1a, which shows each of the seven cadmium atoms
connected to exactly four cysteine amino acids. The connectivity diagram has been
renumbered from the original to accommodate the amino acids glycine and serine, both
of which are a product of S-tag cleavage with thrombin, located on the N-terminal of the
β-domain. Numbering of the Cd-thiolate centers is based on the NMR assignment by
Messerle et al. (7). Data from Chan et al. were used to produce the molecular models
seen in (A) and (B) (19).

4.2 Experimental Methods
Chemicals: cadmium sulfate (Fisher Scientific); zinc sulfate (Caledon Laboratory
Chemicals);

ThrombinCleanCleaveTM

Kit

(Sigma);

Tris,

tris(hydroxymethyl)aminomethane (EMD Chemicals/VWR); ammonium hydroxide
(Caledon Laboratory Chemicals); formic acid (Caledon Laboratory Chemicals); and
hydrochloric acid (Caledon Laboratory Chemicals). All solutions were made with >16
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MΩ·cm deionized water (Barnstead Nanopure Infinity). HiTrapTM SP HP ion exchange
columns (Amersham Biosciences/ GE Healthcare), superfine G-25 Sephadex (Amersham
Biosciences/ GE Healthcare), stirred ultrafiltration cell Model 8200 (Amicon
Bioseparations/Millipore) with a YM-3 membrane (3000 MWCO) were used in protein
preparation steps.
Protein preparation: The expression and purification methods have been previously
reported (19). β-rhMT, α-rhMT and βα-rhMT 1a proteins used in this study were based
on the 38-residue, 41-residue, and 72-residue sequences, respectively: β-rhMT
MGKAAAACSC

ATGGSCTCTG

SCKCKECKCN

SCKKAAAA,

α-rhMT

MGKAAAAC CSCCPMSCAK CAQGCVCKGA SEKCSCCKKA AAA, βα-rhMT
MGKAAAACSC ATGGSCTCTG SCKCKECKCN SCKKAAAACC SCCPMSCAKC
AQGCVCKGAS EKCSCCKKAA AA. There are 9, 11, and 20 cysteine residues present
in β-rhMT, α-rhMT and βα-rhMT, respectively, and no disulfide bonds. The expression
system included, for stability purposes, an N-terminal S-tag (MKETAAAKFE
RQHMDSPDLG TLVPRGS). Recombinant proteins were expressed in BL21(DE3)
Escherichia coli. All cell lines were transformed using the pET29a plasmid. Removal of
S-tag was performed using a Thrombin CleanCleaveTM Kit (Sigma). To impede oxidation
of the cysteine residues to disulfide bonds, all protein samples were argon saturated and
rigorously evacuated to remove any residual oxygen that may be present in the solution.
Concentrated hydrochloric acid was used to demetalate protein samples, followed by
desalting on a G-25 (Sephadex) column.
ESI MS procedures: Protein solutions were prepared in dilute formic acid in deionized
water (pH 2.7). Final ESI MS solutions were pH adjusted using concentrated ammonium
hydroxide. A small aliquot of protein was remetalated with cadmium to determined the
protein concentration by UV absorption spectroscopy using the absorbance at 250 nm,
which corresponds to the ligand-to-metal charge transfer transition generated by the
metal-thiolate bond (Ɛβ250= 36,000 M-1cm-1; Ɛα250= 45,000 M-1cm-1; Ɛβα250= 89,000 M1

cm-1). Zinc sulfate was prepared in deionized water. The concentration of zinc sulfate

and all molar equivalents added to MT solutions were measured through calibration of
the Zn2+ content using atomic absorption spectrometry (AAS).
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All data were collected on an electrospray-ionization time-of-flight (ESI-TOF) mass
spectrometer (Bruker Daltonics) in the positive ion mode. NaI was used as the calibrant.
The scan conditions for the spectrometer were: end plate offset, -500V; capillary, +4200
V; nebulizer, 2.0 bar; dry gas flow, 8.0 L/min; dry temperature, 80ᵒC; capillary exit, 180
V; skimmer 1, 22.0 V; hexapole 1, 22.5 V; hexapole RF, 600 Vpp; skimmer 2, 22 V; lens
1 transfer, 88 µs; lens 1 pre pulse storage 23 µs. The range was 500.0–3000.0 m/z,
averaging 2 × 0.5 Hz.

Spectra were deconvoluted using the Bruker Compass

DataAnalysis software package.
Molecular Model: MM3 and MD calculations parameterized using the modified force
field described by Chan et al. and the dielectric constant for water (78.4) were carried out
to obtain the minimum-energy structure for apo-βα-rhMT 1a to Zn7-βα-rhMT 1a (20).
All MM3 and MD calculations and model-structure rendering were carried out using
CAChe WorkSystem Pro 6.1.1 software (Fujitsu America). The original Cd7-βα-rhMT
1a was modified to produce molecular models for Zn5-βα-rhMT 1a (19). The structure
was energy minimized using the MM3 calculation followed by the MD simulation at 300
K for 5000 ps.

4.3 Results
4.3.1 Noncooperative metalation of isolated apo-β and apo-α- and
apo-βα-rhMT 1a by Zn2+
The mass spectral data recorded during the titration apo-β-rhMT 1a, apo-α-rhMT 1a,
and apo-βα-rhMT 1a with Zn2+ are shown in Figure 4-2 with their corresponding
deconvoluted spectra (right hand columns). Stepwise metalation of apo-β-rhMT (A-E)
leads to the formation of partially metalated species (Zn1-, Zn2-β-rhMT 1a) at
substoichiometric equivalents (β < 3 Zn2+).

Complete metalation occurs when 3.5

equivalents of Zn2+/β-rhMT 1a are added to solution. From the data it can be clearly seen
that the dominant metalation state is a direct result of the number of equivalents of Zn2+
added to solution: at 1.7 eq. Zn2+ the dominant species is Zn1-β-rhMT 1a, while at 2.6 eq.
Zn2+ the two most abundant species are fully metalated Zn3-β-rhMT 1a and partially
metalated Zn2-β-rhMT 1a.

Metal free apo-β-rhMT 1a exhibits charge states
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corresponding to 4+, 3+ and 2+ at 0.1 eq. Zn2+. The most significant change in the
charge state profile is the decrease in intensity of the 2+ charge state at 1.7 equivalents of
Zn2+ added to solution. There is also a 20% decrease in the intensity of the 3+ relative to
the 4+ charge state when comparing apo-β-rhMT 1a to Zn3-β-rhMT 1a. Taken together,
these results suggest that the addition of the first two metal ions stabilize a slightly more
open conformation of apo-β-rhMT 1a.
Stepwise metalation of apo-α-rhMT (F-J) leads to the formation of partially metalated
species (Zn1-, Zn2-, Zn3-α-rhMT 1a) at substoichiometric equivalents (α < 4 Zn2+). The
dominant metalation state is a direct result of the number of equivalents of Zn2+ added to
solution: at 2.2 eq. Zn2+ the dominant species is Zn1-α-rhMT 1a, while at 3.7 and 3.9 eq.
Zn2+ the dominant species are Zn2- and Zn3-α-rhMT 1a, respectively.

Complete

metalation is observed at 4.1 eq. Zn2+ added to solution, however, there still exists a
relatively small (~15% of total species present) population of Zn3-α-rhMT 1a, which we
attributes to slight errors in the calculation of the equivalents of Zn2+ added. Much like
the β-domain, apo-α-rhMT 1a exhibits significant changes in the 4+, 3+ and 2+ charge
state distribution when even a low stoichiometric ratio of Zn2+ has been added (e.g. 0.4).
Also like apo-β-rhMT 1a, the 2+ and 3+ charge state decrease in intensity upon addition
of one equivalent or more Zn2+, relative to the 4+ charge state (compare the ESI-mass
spectral data of apo-α-rhMT to Zn4-α-rhMT). These changes in the overall charge state
profile demonstrate that the metalated forms of both β- and α-rhMT, while similar to that
of the apo-forms of the protein, occupy a somewhat larger volume.
The mass spectral data recorded during the titration of apo-βα-rhMT 1a with Zn2+ and
the corresponding deconvoluted spectra are shown in Figure 4-2 (K-O). As is the case
for both the β- and α-domain, stepwise metalation of apo-βα-rhMT leads to the formation
of partially metalated species (from Zn1 to Zn6) at substoichiometric equivalents (βα < 7
Zn2+) confirming the noncooperative nature of the metalation reaction. The endpoint of
the titration occurs after 7 equivalents of Zn2+ have been added to the solution. In each
step of the titration, the dominant metalation state is a direct result of the number of
equivalents of Zn2+ added to solution. Apo-βα-rhMT 1a exhibits a charge state profile
that ranges from +8 to +3. The increase in the total number of charge states, as compared
to the isolated domains, is because the full protein occupies a larger volume than either of
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the two isolated domains. At 2.7 equivalents of Zn2+, the dominant metalation states are
Zn2- and Zn3-βα-rhMT 1a. A significant reduction in the intensity of the +7 charge state,
as well as the disappearance of the +8 charge state is also observed at this point. These
changes to the charge state envelope suggest that the first metal ion must significantly
restrict the motion of the protein reducing its volume. Beyond 2.7 eq. Zn2+, there is very
little change in the +6, +5, +4 and +3 charge state distribution indicating that further
metalation does not substantially alter the folding of the protein.
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Figure 4-2. ESI mass spectra recorded during the titration of apo-β-rhMT, apo-αrhMT and apo-βα-rhMT, with ZnSO4. In each column the ESI mass spectral data
(left) and their deconvolted counterparts (right) were recorded as Zn(II) was added to the
solution. Dotted lines follow metal binding. (A-E) The titration of apo-β-rhMT, 29.2
µM at pH 9.2, with ZnSO4. (F-J) The titration of apo-α-rhMT, 34.1 µM at pH 9.5, with
ZnSO4. (K-O) The titration of βα-rhMT, 29.2 μM at pH 9.1, with ZnSO4.
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4.3.2 Competitive metalation with Zn2+ of the isolated fragments
containing the β- and α-domains of MT 1a
The metal binding specificity of each of the two metal binding domains of MT has
been the subject of many studies. Yet, no step-wise metalation data have been published
showing the development of the fully metalated protein from the metal-free apo-protein
that identifies clearly any specific domain specificity for a metal. This was determined
by competitively metalating both the isolated domains with Zn2+. This competitive
metalation experiment of the isolated β- and α-domains using Zn2+ was monitored with
ESI-MS.

The value of this technique over those previously used in competition

experiments is that the exact metalation status of each domain can be monitored for all
equivalents added during a single titration. This experimental setup also allows the
interpretation of results in the context of a noncooperative mechanism of metalation,
which allows for partial metalation and a continuum of metalated states to exist. In this
way one can determine the average metalation of MT and also the exact distribution at
each step of the titration. Other competition experiments, such as copper luminescent
experiments (12), provide only an averaged measure of metalation and not the exact
speciation over all sites in each domain. Consequently, it is possible to determine the
relative affinity of each site in each domain for Zn2+ binding from the metalation status.
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Figure 4-3. ESI mass spectra recorded during the competitive titration of apo-βand apo-α-rhMT with ZnSO4. Both species were at a concentration of 29.2 µM and at
a pH of 9.2. ESI mass spectral data (left) and their deconvoluted counterparts (right)
were recorded at Zn(II) molar equivalents of 0.4, 2.1, 3.5, 5.4, 7.6, and 8.0. Dotted lines
follow metal binding in both β- and α-rhMT. The most intense species for both the βand α-domain have been normalized to 100% relative abundance.

87
Figure 4-3 (A-F) shows the ESI-MS monitored competition experiment for Zn2+
between the isolated β- and α-domains of MT. Both domains are present in equal
concentrations and their metalation status is a function of Zn2+ added to solution. It
should be noted that there exists a slight Zn2+ contaminant, ~0.3 equivalents of total
protein. The charge state data (left) have been deconvoluted to obtain the neutral parent
species (right). Because two domains are present and each exhibits several metalation
states, the charge state data are complicated and the deconvolution data fall into two sets
reflecting the different chain lengths of the β and α fragments. To our knowledge this is
the first report of a competition experiment in which metalation data from both domains
can be monitored at the same time. Figures 4-4 and 4-5 extract and condense these data
to show the information contained as function of number of Zn2+ equivalents added. The
equivalents of Zn2+ added to the solution are relative to the total protein concentration of
a given domain (β-domain plus α-domain). In this way, one would expect 7 molar
equivalents to be necessary to fully metalate both domains. At 0.4 equivalents of Zn2+
added to the solution, it can be seen that metal free (apo-) β-rhMT dominates, but there
also exists significant Zn1-β-rhMT (relative abundance compared to the most abundant
metalated species (RA): 70%) and Zn2-β-rhMT (RA: 20%) present in solution. In the
case of the α-domain, apo-α-rhMT dominates, but unlike the β-domain, there is very little
Zn1-α-rhMT (20%). This strongly suggests that initially metalation of the β-domain is, in
fact, favored over that of the α-domain when the fragments are studied. At the 3.5 Zn2+
point, (Figure 4-3C) the dominant metalated species are Zn2-β-rhMT and Zn1-α-rhMT,
respectively. The metalated profiles observed at 5.4 Zn2+ added (Figure 4-3D) are similar
for both domains. Prior to this point in the titration, the β-domain consistently binds
more Zn2+ than the α-domain, so this equalizing of the metalated species would suggests
that the KF for the third binding site for the β-domain, that is the conversion of the Zn2-βrhMT with its terminal-Cys-bonded Zn2+ (no bridging interactions) to the clustered Zn3β-rhMT, is substantially weaker than the previous two.
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Figure 4-4. The normalized metalation properties of the β- and α-domains. (A)
The % metalation of the individual isolated domains (B) The % metalation of the isolated
domains present in direct competition with each other for metal ions. The associated
metalation data for the β-domain is labelled with a solid line (
), while the αdomain is labelled with a dashed lined (
).
This interpretation is based on the uniquely rich nature of these data in which almost
identical cysteine binding sites compete for the same metal. In addition, the distribution
of the Zn2+ (1-bound, 2-bound, etc.) provides a much greater resolution of the binding
pathway than a simple average and leads to the step-wise data shown below. The change
in metalation status of the β-domain can be interpreted as resulting from the necessity for
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the onset of cluster formation that involves three bridging cysteine residues (Fig 1B)
when its 9 cysteine residues accommodate all three Zn2+ ions. In sharp contrast, the αdomain, with 11 cysteine residues, requires only a single shared cysteine residue to bind
three Zn2+ ions. Complete metalation of the β-domain occurs at 7.6 Zn2+ added (Figure
4-3E), at which point the α-domain still exists as a mixture of Zn2-, Zn3- and Zn4-αrhMT. Complete metalation of the α-domain is observed at 8.0 eq Zn2+ added (Figure 43F) at which point 5 cysteines are bridging (Figure 4-1).
Figure 4-4 shows the normalized metalation of the fragments with the isolated
domains as a function of added Zn2+. In these plots, the fully metalated protein status is
100% (that is, 3 Zn2+ for β and 4 Zn2+ for α). Figure 4-4A depicts the relative metalation
of the isolated domains with Zn2+ in the absence of any competitor - that is simply the
metalation of the domains themselves. Clearly, both domains have similar metalation
properties, although the β-domain has an advantage over the α-domain. The 60% mark
for the β-domain represents the binding of 2 Zn2+ and the change in slope may be
interpreted as the effect of the extensive bridging required to add the 3rd Zn2+. The α
domain can add 3 Zn2+ (75% mark) before significant bridging is required.
Figure 4-4B shows the normalized metalation of the two domains when in direct
competition for the added Zn2+.

This Figure 4-4 demonstrates that the β-domain

dominates the titration, completely metalating before the α-domain.

The pause in

metalation for the α domain at about the 80% mark represents the change from 3 Zn2+ to
4 Zn2+ bound. These plots highlight the importance of the competition reaction in
determining the relative metalation of the two domains. The data suggest that when
sufficient Zn2+ is added, the β domain simply competes directly with the α domain and
continues to complete metalation.

4.3.3 Speciation of the β and α fragments with isolated domainseffect of domain competition
Figure 4-5 shows the relative abundances of each individual Zn-species formed during
the metalation of the two isolated fragments and during the competitive metalation
reaction extracted from the experimental data shown in Figures 4-2 and 4-3 above. The
top row of plots (A, C, E) represent the individual Zn-loading as a function of Zn2+ added
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for the β domain and the results of modeling the KF's for each of the three steps. The
bottom row of plots (B, D, F) represent the individual Zn-containing species as a function
of Zn2+ added for the α domain and the results of modeling the KF's for each of the four
steps. For the isolated fragments (A, B), that is for metalation with no competitor (see
Figure 4-2 A-E and F-J) we see that the increasingly metalated species coexist throughout
the metalation reaction until metalation is complete at 100%. For the β domain, Zn2overlaps Zn1-, followed by almost 100% formation of Zn3-. On the other hand, the α
domain metalates stepwise with even the Zn4- species forming while a mixture of Zn2and Zn3- have appreciable content.
The effect of competition for the Zn2+ by the two domains (C, D) is of critical
importance because the two peptides offer slightly different KF`s for the specific Zn2+
binding so these data allow resolution of each individual step in the metalation pathway.
Clearly, the data in Figure 4-5 C and D show that the metalation steps are spread out
compared with A and B - this means that there is direct competition for the Zn2+ as the KF
decreasing as the number of Zn2+ ions bound increases. For example, at the Zn2+ added
point of 4 in (C) there is a mixture of Zn2 (50%), Zn1(25%), Zn3 (25%) - compare this
mixture with the Zn2+ added point of 2 (as the molar ratios of the Zn2+ added are scaled
for the presence of both fragments, 4 approximately scales to 2) for the isolated domain
in (A): here Zn1 is 60%, Zn2 is 10% and apo is still 20%. Similar data are observed for
the α domain (D).
A model was produced in which the competing sites, each with their own KF values,
were metalated (Figure 4-5). The dependence of the individual metalated species on the
amount of Zn2+ ions added to solution are shown for the β-domain, as (E), and the αdomain, as (F). The appearance and disappearance of the individual Zn-species was
modeled by a series of declining KF's for the 7 Zn2+-binding steps (E,F), based upon the
KF values reported by Krezel and Maret (21). The model emphasizes a steeper decline in
KF when terminal Cys have been exhausted (at 2 Zn2+ bound for the  domain and 3 Zn2+
bound for the α domain) arguing that terminal coordination (a cysteine residue that does
not bridge) is thermodynamically preferred as is expected and now confirmed
experimentally.
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Figure 4-5. ESI-MS relative abundances for the metalation chemistry of the two
isolated domains. Metalation of apo-β-rhMT (A), apo-α-rhMT (B), as well as their
respective metalation under competitive conditions (C) and (D), respectively, using Zn2+
to form Znn, where n corresponds to the number of metals bound. Simulation of the
metalation of both the β- and α-rhMT domains were also performed, in which the
log10(KF) association constants for the α-domain were 10.4, 9.8, 9.3 and 8.6, while the βdomain was 10.4, 9.9 and 9.2. Each line corresponds to a different metalation state: Zn0(
), Zn1(
), Zn2 (
), Zn3(
), and Zn4(
).

4.3.4 Competitive metalation of the isolated β- and α-domains and full
protein of MT 1a using Zn2+
Figure 4-6 shows the experimental ESI mass spectral data when the metal-free β and α
fragments are mixed with the full βα-protein and Zn2+ is added incrementally. This
experimental arrangement allows comparison of the relative binding constants of the 14
individual Zn2+ binding sites spread over the two fragments and the full protein. The
mass spectral data in Figure 4-6 (A-G) are complicated as there is a superposition of the
charge states for each of the two fragments and the full protein for each metalated state.
The deconvolution data (on the right hand side) provides greater clarity, and we have
added guideline for each of the three protein species showing the metalation state. From
these data further data sets can be extracted (i) the 'life' of each metalated species up to
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full saturation, Figure 4-7, and (ii) the average saturation for each species as a function of
added Zn2+ during competition, Figure 4-8. Those fractional loadings were modeled
quite accurately based on the 14 KF values, Figure 4-9.
The transient life of each metalated species in the three-protein competition
experiment is shown in Figure 4-7.

The data in (A), (B) and (C) are the species

dependence for the isolated β-fragment, the α-fragment and the full βα-protein in the
absence of competitors, as described earlier from Figure 4-5 and included here to allow
direct comparison of the effect of competitive binding. Figures 4-7 (D, E, F) show that
the individually metalated species exist for a wider range of added Zn2+. Interestingly,
Zn1- and Zn2- for both β- and α- form synchronously. Zn3-β-MT is formed completely
before Zn3-α-MT and therefore, before Zn4-α-MT.

Panel (F) shows the sequential

metalation of the βα-apo-MT. A number of important points can be made. First, Zn1-,
Zn2-, and Zn3-βα-rhMT all form when just the Zn1- of the isolated domains forms. This
is predicted by the As-analysis of Ngu, et al. because there are simply more available
sites in the βα-MT than in the isolated domains so the KF's of these first 3 sites of the full
protein dominate. Zn4- in (F) exists over a wide range of added Zn2+ (2, 18, 22). Zn5-6-7
form over a relatively narrow range of added Zn2+ once the two domains are completely
metalated.
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Figure 4-6. ESI mass spectra recorded during the competitive titration of a
solution containing equimolar concentrations of apo-β-, apo-α-, and apo-βα-rhMT
with ZnSO4 at pH 7.8. ESI mass spectral data (left) and the deconvoluted counterparts
(right) were recorded as aliquots of Zn(II) were added to the protein at molar equivalents
of 1.8, 4.6, 6.4, 9.3, 10.3 and 12.5. Dotted lines follow metal binding in both β-, α- and
βα-rhMT. The most intense species for both the β- and α-domain have been normalized
to 100% relative abundance.
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The model was applied to the 3-protein metalation (Figure 4-6) to produce Figure 4-7
as (G), (H), and (I). The traces shown are the predictions for the simultaneous formation
of the metalated species based on 14 coupled KF values. The model requires the KF
values to decline as a function of metalated number as expected for non-cooperative
binding.

The very close alignment of the simulation with the very complicated

experimental data strongly supports the model: that there are declining KF values and
especially, a sharper reduction when the terminal Cys (cysteine residues bound to one
metal ion) are exhausted for each protein and cluster formation begins using bridged Cys.

Figure 4-7. ESI MS relative abundance for the metalation chemistry of the two
isolated domains and full MT protein. Metalation of apo-β-rhMT (A), apo-α-rhMT
(B), apo-βα-rhMT (C), as well as their respective metalation under competitive
conditions (D) and (E), and (F), respectively, using Zn2+ to form Znn, where n
corresponds to the number of metals bound. A simulation of the metalation of both
domains and the full MT protein was also performed, in which the log10(KF) of the
association constants for the α-domain were 10.4, 9.8, 9.3 and 8.6, while for the β-domain
were 10.4, 9.9 and 9.2, and finally for the full MT protein were 11.8, 11.2, 10.6, 10.0, 9.4,
8.8 and 8.2. Each line corresponds to a different metalation state: Zn0(
), Zn1(
), Zn2(
), Zn3(
), Zn4(
), Zn5(
), Zn6(
) and Zn7(
).
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Figure 4-8.
Average metalation properties of the isolated β- and α-domains and
the full MT protein as a function of added Zn2+. (A) The average number of metals
bound to all three species: β-domain (
), the α-domain (
) and, finally,
the full MT protein (
) in separate solutions (based on data in Figure 4-2). (B)
The average number of metals bound in the competition reaction between the isolated
fragment domains and full MT protein (based on data in Figure 4-6). (C) Comparison
between the sum of the average Zn2+ metalated states of the two isolated domains as a
function of added Zn2+when competing with the full protein (
) and the average
2+
Zn metalated state of the full MT protein (
). The lines show that the full
MT protein is able to outcompete the sum of the isolated domains up until it has bound 4
Zn2+ ions. After that point, the two isolated domains outcompete the full MT protein.
Figure 4-8 provides the average metalation data for two experiments: first metalation
of the two isolated fragments and the full protein, and second the single competition
experiment in which the full MT protein and the isolated fragments compete for the same
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Zn2+ as described above. Figure 4-8A demonstrates that for metalation in the absence of
a competitor, metalation of both the isolated domains and full MT protein proceeds in a
similar manner initially.

In isolation, the only observable change in the slope of

metalation occurs at approximately the 2 molar equivalents of Zn2+ added to solution for
the β domain, 3 for the α domain, and 5 for the full βα-protein. These changes can be
interpreted as arising from the onset of cluster formation - that is the points at which
cysteine residue bridging must occur for metalation to continue. However, when a
competitor is present (Figure 4-8B), significant differences in the affinity of each
component of the solution become apparent because now, first the β- clearly outperforms
the α- domain but also, they both metalate at a lower fraction than the full protein. Figure
4-8B shows that at each molar equivalent of Zn2+ added to the solution up to 4, the full
MT protein has bound more metal ions than the sum of the two isolated domains.
Significantly, when the metalation status of the isolated domains is summed (Figure 48C) so that the total of Zn2+ bound in sites on the isolated fragment domains can be
compared directly with the Zn2+ bound in the full protein, we see that, in fact, the full
protein dominates at added Zn2+ molar equivalents <8; after this point the sum of the
isolated domains dominates.
This result is surprising, since it has been a traditional view of metallothionein
chemistry that the two domains of mammalian MT act in isolation, and consequently that
the metalation of the isolated domains should be equal to that of the full MT protein - that
is the two domains in the full protein are expected to perform like the two domains in
isolation. Our interpretation of this result is that the 5-Zn-species using all 20 Cys with
no bridging interactions must now rearrange significantly to allow the 6th Zn2+ to be
bound. In effect this is the point at which the domain structure of the metallothionein
first develops. We interpret these results to mean that at the 8 molar equivalents of Zn 2+
added point the full MT protein must have a significant drop in the value of KF for further
metalation (the 6th and 7th Zn2+) compared with KF (Zn3-β-) and KF (Zn3-4-α-). Based on
the distribution of Zn2+ at this stage in the metalation profile (Figure 4-6 F) it is likely
that a Zn5-βα-rhMT 1a species using all 20 cysteine residues exists and must significantly
rearrange to allow a 6th Zn2+ ion to bind.
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The experimental data in Figure 4-8B and 4-8C were modeled based on the KF values
determined by Krezel and Maret (21) and extrapolated following the trends reported by
Ngu et al. (2, 18). Figure 4-9 shows the results of this modeling. The calculated
metalation not only predicts the crossover in metalation loading between the full protein
and the sum of the two isolated domains correctly simulated but also the unusual trends
between 0 and 4 molar equivalents of Zn2+ added to solution. Most importantly, the KF
values used for this model are based on the assumption that the requirement for bridging
Cys leads to a significant decrease in KF for each step after 5 Zn2+ have bound to all 20
cysteines in a terminal fashion (bound to only one metal ion). Most significantly, the
data show that it is the 6th Zn2+ ion that forces the two domain structure to form.

Figure 4-9.
A model of the average metalation properties of the β- and α-domains
and the full MT protein as a function of added Zn 2+. The calculated average number
of metals bound to all three species taken from Figure 4-7 (G, H, I): β-domain (blue), the
α-domain (green) and finally the full MT protein (magenta), as well as the sum of the
average Zn2+ metalated states of the two domains (black). The modeled lines are based
upon log10(KF) values for the α-domain of 10.4, 9.8, 9.3 and 8.6, while for the β-domain
of 10.4, 9.9 and 9.2, and finally for the full MT protein of 11.8, 11.2, 10.6, 10.0, 9.4, 8.8
and 8.2. Significantly, the full MT protein outcompetes the sum of the isolated domains
in the first part of the titration (<8.5 equivalents of Zn2+ added to solution), while after
this point the sum of the isolated domains dominates. In addition, the crossover between
the modeled full MT and sum of the isolated domains is at an average number of metals
bound of 4.5.
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4.4 Discussion
To understand the role of metal binding in MT, a large number of metalation,
demetalation and metal replacement experiments have been reported under both
equilibrium and kinetic conditions (1-2, 18, 23-24). Several of these studies have used
competitive chelators to determine the affinity of MT for its metal ions (21, 25). To date
no single experiment has studied the simultaneous competition reaction between the βand α-domains and the full MT protein yet one of the most important questions about the
metalation properties of metallothioneins concerns the role of the two domains. ESI mass
spectrometric studies have focused on both the mechanism of metalation of MT,
determined for Cd2+, As3+ and Bi3+, and the kinetics of metalation, specifically As3+
metalation (17-18, 26-27).
In the study described here, we have used the very similar K F values of the Zn2+
binding sites in the isolated fragments containing the β and α domains to compete for the
incoming Zn2+ binding to the two-domain, βα-full protein.

We show in the data

presented in this study the discriminating power of ESI-mass spectrometry to provide
both simultaneous and detailed information about all three species and their respective
dynamic metalation states. By using both the full MT protein and its isolated fragments
as competitors, the relative metal binding affinity of each species is shown. These results
are important, since they provide insight into the possible structures that exist and take
part in cellular chemistry.
Initially the metalation properties of the isolated fragments and full protein were
determined separately (Figure 4-2). Through an analysis of the changes in the charge
state profile, and their respective deconvoluted spectra, the effect of metals on protein
folding can be determined. The two isolated domains both possess similar charge state
envelopes throughout the titration, with a slight increase in size upon binding of the first
Zn2+ ion following which the charge state distributions remains constant with the 4+ state
dominating both fragments when fully metalated with Zn2+. The prominent charge state
for the apo-two-domain βα-MT is 5+ with about equal contributions from 6+ and 4+.
Metalation results in an increase in 6+ and a reduction in 4+ suggesting that the apo- and
metalated proteins are of similar, but not identical, volume. Additionally, the data in
Figure 4-2 show clearly that Zn2+ metalation takes place step-wise. These results are
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fundamental because they establish that metalation of MT and its fragments using the
biologically relevant Zn2+ occur in a noncooperative manner.
Under a noncooperative mechanism of metalation, partially metalated species may be
stable and able to take part in cellular chemistry. Consequently, instances in which
partially metalated forms of the protein have been purified could in fact represent the
biologically relevant in vivo forms of the protein. For example, mouse heart MT has
been isolated from the organism in a partially oxidized form, where the formation of
disulfide bonds has been implicated in zinc release necessary to combat the oxidative
pressures (28). The twenty cysteine residues present in mammalian MT have long made
it an attractive agent to combat oxidative stress with concomitant formation of disulfide
bonds (29). Under this new mechanism of metalation, MT can now be understood to
combat oxidative stress in a dynamic way, where progressive oxidation of MT leads to
the sequential release of Zn2+ ions and eventually complete oxidation (or thionin
formation). This released Zn2+ can then bind to the metal response element binding
transcription factor 1 (MTF-1) (30). Zn-MTF-1 leads to an upregulation of MT, and
other associated proteins, thus combating the oxidative stress.
The competition experiments provide a detailed view of the Zn2+ binding because the
distribution of the Zn2+ between sites is governed by the relative magnitudes of KF. Our
interpretation of the data presented here is that when the isolated β- and α-domains
compete for metals, the β-domain preferentially binds the first Zn2+ ion added to solution.
There appears to be a decrease in the affinity of the β-domain, relative to the α-domain,
for the third Zn2+ ion to form Zn3-β-rhMT (Figure 4-3). This decrease in relative affinity
is likely the result of the 3 bridging interactions necessary to form Zn3Cys9 in the βdomain, whereas the α-domain only requires 1 bridging interaction to form Zn3Cys11.
This result was surprising, because Cd-NMR metalation studies by Good et al. using
rabbit liver MT 2 suggested that the α-domain binds the first four Cd2+ ions, after which,
any additional metal ions populate the β-domain (31). This paper also showed the
presence of a broad
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Cd-NMR signal centered at 684 ppm. This peak, which was not

identified, could be the result of submetalated species (Cd1-3-rlMT 2), in which the
abundance of free cysteinyl-thiols allows for tetrahedral coordination to terminal thiols
for all Cd2+ ions.

In NMR studies, the signals associated with the α-domain are
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significantly more intense than those associated with the β-domain, which is due to an
increase in fluctionality of the β-domain. It could be that these weaker signals of Cd3cluster could not be detected leading to the conclusion that the α-domain clusters first
(32). Based on our interpretation, we modeled the competition reaction for the two
isolated domains. Figure 4-5 E and F shows the formation of the individual metalated
states. The model very closely matches the experimental data and supports the formation
of the Zn-β species with at least similar KF(n) values for n=1 and 2 compared with the αdomain.
The more challenging experiment allowed for all three species to compete for the
Zn2+. This pitted the relative values of 14 Zn2+ sites with 14 distinct KF values. The ESIMS data allow for the first time the observation of all the metalated species
simultaneously. Significantly, and fundamental to the conclusions of this paper, the data
show that the full protein exhibits higher relative KF values for the first 4-5 Zn2+ than the
isolated domains. The KF values of all three proteins are essentially in balance and
therefore equal when the fifth Zn2+ ion binds to the -MT (Figures 4-7 and 4-8). After
this point, the isolated fragments metalate at the expense of the full protein.
In previous metalation studies,
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Cd-NMR data have shown that the chemical shifts

observed for the α-domain of MT are not affected by either the digestion of the β-domain
by subtilisin (33) or the identity of the metal ions in the β-domain (either Cd2+ or Cu+)
(11). In addition, MT structures have been determined from several sources and in no
case were interdomain NOEs observed (7-8, 34). Not until very recently has this view
been challenged with reports of metalation in excess of traditional levels forming a single
Cd8Cys20 cluster (9-10, 35-36).
Previous metal binding studies of β-, α-, and βα-MT with arsenic by Ngu et al.
demonstrated the affinity of MT for metal ions is directly dependent on the number of
still-available binding sites (2, 18, 22). The same trend is observed here with initial
metalation of MT by Zn2+ being dominated by the full protein and not the isolated
domains that individually contain fewer metal binding sites. These results are critical
because they show that 1) there is no domain preference for Zn2+ until terminal thiolates
bridge, 2) bridging interactions lead to a significant decrease in the KF values observed,
3) KF are directly proportional to the number of available binding sites.
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From our results, we can see that the proposal by Ngu et al. is followed up to the 4-5
2+

Zn

added point, afterwhich the sum of the zinc bound by the isolated domains exceeds

that in the full MT protein (2, 18, 22). The key species is the formation of Zn5-βα-rhMT.
Binding of the fifth Zn2+ ion can only occur in one location, thus locking a submetalated
MT structure that consists of solely terminal Cys thiols. Additional metalation to Zn6-βαrhMT requires bridging interactions that must occur and lead to the eventual formation of
the traditional Zn7-βα-rhMT, where neither domain interacts. The significant decrease in
KF (Zn6, Zn7) past Zn5-βα-rhMT, compared to the sum of the two domains, is strong
evidence for the existence of a single domain up to the Zn5- point and the complete
rearrangement of the binding site to the conventional, two-domain structure for Zn6- and
Zn7-. Unlike the two isolated domains, the full MT protein contains a total of 20 cysteine
residues, which could potentially bind 5 Zn2+ ions without any bridging interactions. If
this is the case, then a metal binding ‘islet of stability’ should exist for Zn5-βα-rhMT,
where KF for the conversion of Zn5-βα-rhMT to Zn6-βα-rhMT is sufficiently low to allow
near quantitative formation of Zn5-βα-rhMT. The presence of Zn5-βα-rhMT would help
to explain inconsistencies observed between the activity of the isolated fragments and the
full protein. For example, the recovery of mice whose cortex had been cryoinjured
occurred at different rates when exposed to either of the isolated domains, or the full
protein (37). In fact, maximal recovery was only observed for the full protein, while the
isolated α-domain demonstrated some detrimental effects. If the metalation properties
and related functions are simply the sum of the two domains, then it is odd that the in
vivo recovery rates were not merely the summation of the two isolated clusters.
Because Zn2+ is spectroscopically silent, it is difficult to determine the exact
metalation state that leads to cluster formation spectroscopically (38-40). However, Co2+
with its rich spectroscopic properties has been extensively used to mimic Zn2+ binding to
MT because of its characteristic tetrahedral coordination with thiols. Uniquely, the
electron paramagnetic resonance (EPR) spectroscopic intensity of Co2+ is directly related
to not only the number of Co2+ atoms present in MT, but also to the number of
nonclustered Co2+ centers (39). In seminal work by Vasak and Kagi, MT was titrated
with Co2+ and the EPR signal measured. Analysis of the data when plotted as a function
of added Co2+ showed an increase in the number of free spins until 4 molar equivalents
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of Co2+ had been added, after which it was proposed that antiferromagnetic coupling led
to a decrease in the signal intensity reaching near zero at the 7 added Co2+ point. These
data were interpreted as cluster formation occurring after 4 metal ions have been added.
We have mimicked the EPR experiment using our data that shows the exact distribution
of metals in nonclustered (up to 5 Zn2+ bound) and clustered (6 and 7 Zn2+ bound)
binding sites assigning a spin to the nonbridging Zn2+ ions in a Co2+ fashion, while
cancelling the spins when clustering occurs (Figure 4-10). We should note that the ESImass spectral data provide the exact speciation and fraction making up the average
loading, information absent in the Co-binding experiments where the average was
assumed to represent a single speciation. We used the following rules to simulate the
observed magnetic moment: Zn1- through Zn5-MT are formed without any bridging
interactions, and consequently increase the EPR signal, after which the formation Zn6and Zn7-MT require four and eight bridging interactions, respectively, and consequently
decrease the signal due to antiferromagnetic coupling. The simulated EPR data, Figure
4-10, closely resemble the original Co2+ data with identical maxima at 4. Interestingly by
using these rules, our data also show maximal intensity at an average of four filled
binding sites.

While we would intuitively predict 5 molar equivalents would be

necessary for maximal intensity, the noncooperative nature of metalation requires that
some M6-MT must also exist at this metal loading. In the Co2+ titration, this species
would greatly decrease the signal intensity. We suggest that the close similarity between
our modeled data and the original Co2+ data, supports our interpretation of the ESI-MS
data that clustering does not occur until the 6th metal ion is added and that Zn5-rhMT is a
single domain species that does not involve bridging Cys.
A recent paper by Krezel and Maret demonstrated the presence of three sets of binding
affinities: four Zn2+ ions that bind strongly (logK = 11.8), two with intermediate affinity
(logK~10) and finally a single weakly bound Zn2+ (logK = 7.7) (21). The strong affinity
sites were interpreted as binding to the α-domain and the weaker sites to the β-domain.
The data presented here suggest that the large KF’s are associated with Zn1-Zn4 formation
and the two smaller values with Zn5 and Zn6, and finally the weakest is associated with
Zn7. For the modeling presented herein (Figure 4-5, 4-7, 4-9), we have based our
modeling calculations on these previously reported association constants. However, in
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addition to these values, we have also incorporated the metalation work by Ngu et al.,
which states the affinity for metal ions is directly related to the number of available
binding sites (2, 18, 22). The final result is a series of association constants that decrease
as the number of Zn2+ ions bound increases, and is related to the maximum and minimum
previously determined association constants. These differences in affinity suggest that
under oxidative stress, MT may lose metal ions in order to deactivate the toxic insult.
MT is often cited as a protective agent against oxidative stress, where the balance of
metalated MT to metal free MT mediates the redox chemistry of the cell (29, 41-42).
This view however, does not take into account the noncooperative nature of the
metalation of metallothionein. It is likely that the average metal load of MT is what
dictates the oxidative environment of the cell. DFT calculations of the reactivity of
polynuclear zinc-thiolate sites have shown the mononuclear ZnCys4 moiety to be more
nucleophilic than either of the two fully metalated Zn3Cys9- and Zn4Cys11-clusters (43).
Given this information and the work presented here, even though Zn5-βα-rhMT possesses
no free thiol groups, it should be able to take part in cellular chemistry as a protecting
agent against oxidative stress.
Figure 4-11 shows the results of a series of molecular dynamics calculations that
illustrate the structural changes that occur during the progressive metalation by Zn2+ of
apo-βα-rhMT to the intermediate Zn5-βα-rhMT, and finally Zn7-βα-rhMT. In the case of
apo-βα-rhMT (A), the minimized (5,000 ps) structure resembles that reported by Rigby et
al. showing a collapse of the traditional dumbbell shape of metalated MT into a more
globular structure with the free thiols of the 20 cysteines aligned on the surface (44-46).
Tetrahedral Zn2+ coordination by terminal Cys was arranged for the first five Zn2+ ions
forming a single 5-Zn-20-SCYS binding domain. The significant feature of the model is
that with 5 Zn2+ all 20 Cys are terminal ligands, yet despite the lack of cluster formation
the overall three-dimensional structure of the protein closely resembles that of the fully
metalated protein with 7 Zn2+. The ramification of this is many techniques will not detect
the change from non-clustered to the clustered domains as a function of metalation status.
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Figure 4-10. Simulated EPR titration. Simulated spin magnitude calculated by
assuming the Zn2+ have the same spin as Co2+. Metal ion speciation was obtained from
the titration of MT with Zn2+ based on the data shown in Figure 4-2. The average
number of simulated spins was determined from the following rules: 1) From M1-βαrhMT to M5-βα-rhMT, the number of metal ions present is equal to the number of
unpaired spins; 2) the number of spins associated with the M6-βα-rhMT species is equal
to that of M5-βα-rhMT minus 4 due to the bridging interactions required for clustering of
the α-domain; 3) formation of M7-βα-rhMT leads to a complete spin pairing as a result of
full clustering of both domains. In the original Co2+ titration of MT the loss of signal was
associated with antiferromagnetic coupling required for cluster formation (39).
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Figure 4-11. Molecular models of the metalation of MT from apo- to Zn7. Ribbons
show the backbone, with the zinc atoms represented as green spheres and sulfur atoms as
yellow spheres. The N-terminal β domain is located on the left hand side, while the Cterminal α domain is located on the right-hand side. (A) Metal-free, apo- βα-rhMT
showing an essentially spherical structure with the cysteinyl sulfurs on the outside. (B)
The single domain Zn5-βα-rhMT structure. The structure was created by assigning a
single Zn2+ ion to every 4 consecutive cysteine residues with respect to the sequence. (C)
Development of the two-domain structure with cluster formation in the α domain (right
lobe) in Zn6-βα-rhMT; (D) Formation of the filled two-domain cluster structure with
addition of the 7th Zn2+ into the β domain in Zn7-βα-rhMT. Structures were calculated
using a locally modified force-field with MM3/MD methods for molecular modeling
(20). Minimization of the structures was carried out for 5000 ps at 300 K. The conformer
with the lowest energy is presented above. The initial structure of the Cd7-βα-rhMT 1a,
modified for all subsequent structures, was provided by Chan et al. (19).
It is interesting to note that even when there are no bridging Cys present, the model of
Zn5-βα-rhMT shows that the two Zn2+ bonded to the β-domain Cys (ie within residues 1-
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36, Figure 4-1) and the three Zn2+ bonded to the α-domain Cys (ie within residues 37-74)
are spatially close to one another. This likely facilitates cluster formation upon further
metalation to the more traditional two-isolated domains of Zn7-βα-rhMT.

4.5 Conclusion
In this study, we demonstrate that Zn2+ metalation occurs in a noncooperative manner
in the same way as for Cd2+ and As3+ reported previously for the human MT 1a protein.
Further, in detailed studies of the metalation reaction itself, we show that with the onset
of cluster formation, which is defined by the use of bridging Cys thiolate ligands rather
than terminal Cys, that there is a significant decrease in the Zn2+ binding affinity to MT
and its domains for further metalation. The switch from terminal to bridging Cys to
accommodate an increase in Zn2+ in the binding sites reduces the binding affinity. The
individual metalated states can be identified and followed in the ESI-mass spectral data
and in competition experiments in which the two isolated fragments compete for the
same metal as the full protein, that the full MT protein has a superior ability to initially
bind Zn2+ (Zn2+< 4) but upon binding of the fifth metal ion, the sum of Zn 2+-bound to the
isolated domains dominates. These mass spectral data allow us to conclude for the full
MT protein that the decreasing association constants necessary for a noncooperative
mechanism of metalation allow formation of a stable Zn5-βα-rhMT species, which
contains no bridging interactions.

This is a single binding site domain and is

mechanistically a key member of the metalation pathway from apo-MT to the fully
metalated Zn7-MT. Our recently published study on the supermetalation of MT 1a,
where addition of an 8th Cd2+ ion leads to the coalescence of the two domains to form one
‘super-domain’ (9), suggests a fundamentally altered view of the metalation properties of
MT from that of maintaining two-domains, regardless of metal depletion, to a new
structural characterization of MT, where MT exists as a flexible, single domain protein
during initial metalation (<5 eq.) and metalation in excess of traditional levels.
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Chapter 5.

Supermetalation of the beta domain of
human MT 1a5

5.1 Introduction
Metallothionein (MT), first characterized in 1957 (1), is a cysteine rich protein
implicated in heavy metal detoxification, metal ion homeostasis and protection against
oxidative stress (2-3). However, despite half a century of intensive research, specific
roles for MT in living organisms are still largely unknown. One of the reasons for the
uncertainty of function is that until very recently the mechanism of metalation of
metallothionein was thought to proceed in a cooperative manner (4-5), in which the
binding of one metal acts to facilitate the binding of subsequent metals. Under this model
the only structures of biological significance would be the fully metalated or completely
demetalated species, and any partially metalated species would likely be too unstable to
have a specific role.

However, new studies have shown metalation to occur in a

noncoooperative manner for Cd2+ and Zn2+ (6-8), as well as As3+ (9-10).

Most

significantly, a noncooperative mechanism allows for partially metalated and metal
exchange intermediates to be stable and, therefore, to be able to take part in cellular
chemistry.
To further complicate matters recent papers have proposed the existence of
supermetalated forms of metallothionein, that is proteins where metalation is in excess of
normal maximum levels, calling into question the so-called “magic numbers” of metal
binding (11-12).

Supermetalated forms have been reported for a single additional

cadmium ion binding to both the isolated α domain of human MT-1a (Cd5-α-rhMT 1a)
(13) and the full human MT-3 protein (Cd8-βα-hMT 3) (14). Because the cadmium ions
in MT-1 and -2 isomorphously replace zinc ions, these results suggest that this additional
metal site may be involved with metal ion homeostasis and may be considered as a model
for metal-exchange intermediates. In addition, the supermetalated site may also be
5

A version of this work has been published:
Reproduced with permission from D.E.K. Sutherland, M.J. Willans and M.J. Stillman
Biochemistry 49 (2010) 3593-3601. Copyright 2010 American Chemical Society.
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connected with the mechanism for binding of incoming metals with binding affinities
greater than the resident zinc, for example the essential copper(I) and the toxic
cadmium(II). To account for the supermetalation of hMT-3, Meloni et al. have proposed
the involvement of both the α and β domains in stabilizing the additional metal ion (14).
However, previous studies involving the oxidation of hMT-3 with nitric oxide (15), as
well as the lack of long range interdomain peaks associated with the nuclear overhauser
effect (NOEs) in the solution structure of hMT-3 (16), in fact suggest that little domain
interaction is involved. Taken together, these metalation properties emphasize the need
for precise information on the specific properties of the individual domains in defining
the function of MT as a whole.
The many members of the metallothionein family have each developed unique metalbinding sites and domain structures, with different metal binding properties. Mammalian
metallothionein consists of a total of 20 cysteine residues (9 in the N-terminal β domain
capable of binding 3 Zn2+/Cd2+ and 11 in the C-terminal α domain capable of binding 4
Zn2+ or Cd2+) (17). While the seaweed Fucus vesiculosus contains a total of 16 cysteine
residues (7 in an as yet uncharacterized N-terminal γ domain and 9 in the C-terminal β
domain, both able to bind 3 Zn2+ or Cd2+) (18). Each of these proteins uses the thiolate
sulfur of cysteine residues to coordinate the bound metals. Other coordinating amino
acids have also been identified, with bacterial metallothionein SmtA binding four Zn2+
atoms through 9 cysteine and 2 histidine residues (19). Furthermore, the Zn2+ atom
coordinated to the two histidine residues was inert to metal exchange and it was
postulated that this stable metal allowed maintenance of the structure during metal
depletion. Recently the C-terminal βE domain of Tricium aestivum, a common wheat
consisting of a two metal-thiolate domain structure with 17 cysteine residues (6 in the Nterminal domain capable of binding 2 Zn2+ or Cd2+ and 11 in the βE domain capable of
binding 4 Zn2+ or Cd2+), was found to have both a traditional β like domain and a fourth
zinc coordinated to two cysteine and two histidine residues in close proximity (20). Of
significant interest is human metallothionein-3 (hMT-3) with approximately 70%
sequence homology with hMT-2, is expressed predominantly in the central nervous
system and inhibits neuronal growth (21). The addition of a single threonine (Thr5) in a
TCPCP motif (22), and a glutamate-rich hexapeptide (23) near the C-terminal have been
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shown to be critical to the function and the labilization of Zn2+ atoms, respectively.
Interestingly, Romero-Isart et al. were able to engineer neuronal activity of hMT-3 into
hMT-1 by addition of the TCPCP inset, which suggests the two isoforms may only differ
in the slight cluster arrangements brought about by 3 distinct mutations (22). Analysis of
the isolated domains demonstrated that the ability to inhibit neuronal growth resides in
the β domain alone, and that this ability results from its unique sequence suggesting
preferential interaction with target proteins (24). These β domain centered proteinprotein interactions have not been well characterized due to a general lack of information
available about this domain for all metallothionein isoforms.
Human metallothionein 1a, Figure 5-1A, consists of two independent domains each
encapsulating a metal-thiolate core, Figure 5-1B.

The sequence of the cleaved

recombinant β domain human metallothionein 1a (β-rhMT 1a), shown in Figure 5-1C,
with cadmium atoms coloured green and cysteine residues yellow, contains both a
glycine and serine residue from the thrombin cleavage reaction.

This fragment

encompasses residues starting from Cys5 to Lys31 of human metallothionein 1a.
Numbering of the cadmium-thiolate core is cross referenced to the original naming
conventions based on the order of the NMR bands in the mammalian MT 2a spectra (25),
while numbering the cysteine residues has been adjusted to accommodate both the
additional amino acids from thrombin cleavage (res. 1 and 2), as well as a series of amino
acids meant to aid in protein expression (res. 3 to res. 9). The β-MT polypeptide
backbone wrapping of the metal-thiolate core proceeds in a right-handed manner, as
opposed to the left-handed wrapping of α-MT. While properties of the α metal binding
site, Cd4-α-rhMT, have been well documented through structural studies of both the
isolated domain (8, 25) and as part of the whole protein (17), far less structural
information has been reported for the isolated β metal binding site, Cd3-β-rhMT.
Analysis of the NMR data for β-rhMT in human metallothionein suggested that
fluctionality causes a decrease in intensity of the 1D 113Cd signals. Further compounding
this problem is the inability of metallothionein to readily crystallize. To date, only two
crystal structures have been reported, including rat Cd5Zn2-MT 2 and much later a Cu8yeast metallothionein (17, 26). In order to determine such basic in vivo data as protein
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binding partners and metalation status, the complete metalation properties of β-MT must
be fully characterized, particularly when one considers the β-centered reactions in hMT 3.
The metal transfer function in MT has been well documented with Zn(II) transfer
taking place from the fully metalated Zn7-βα-MT to m-aconitase (27), carbonic anhydrase
(28), and the prototypical transcription factor, Gal4 (29). These studies have shown the
importance of protein-protein interactions. However, no zinc-exchange intermediate has
been characterized that provides insight into the actual mechanism of metal transfer.
In this study, we present evidence that the isolated β domain of human metallothionein
1a, Cd3-β-rhMT 1a, is capable of binding an additional cadmium atom forming Cd4-βrhMT 1a. Exact metal speciation was monitored using ESI-mass spectrometry (ESI-MS),
which allowed for a direct correlation between the number of cadmium atoms bound to
the protein and changes observed in the UV and CD spectroscopies. To ensure that the
metal was interacting directly with the metal-thiolate cluster, both direct and indirect
113

Cd NMR spectroscopy was used. Addition of excess Cd2+, in the form of solid
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CdCl2, produced four cadmium signals in the range of 600-700 ppm, which

corresponds to the chemical shift region expected for cadmium bound to the thiolates.
When considering these results in the context of the supermetalated Cd5-α-rhMT 1a (13)
and Cd8-βα-hMT 3 (14), two possible scenarios arise: 1) both domains, when present,
work in concert to accept an additional cadmium atom or 2) both domains are
individually capable of supermetalation. In either case, supermetalation must be fully
characterized to understand its chemical implications that will have consequences at a
cellular level.
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Figure 5-1. Molecular model of MT. (A) A space filling structure of Cd7-βα-rhMT
1a calculated using molecular modeling. The N-terminal β-domain is located on the left
hand side, while the C-terminal α-domain is located on the right hand side. (B) The
cadmium-cysteinyl-thiolate clusters of Cd7-βα-rhMT 1a presented as a ball and stick
model: β-domain (left) and α-domain (right). (C) A connectivity diagram of the βdomain of human metallothionein 1a, which shows that each of the three cadmium atoms
is connected to exactly four cysteine amino acids. The connectivity diagram has been
renumbered to allow for the amino acids glycine and serine, a product of S-tag cleavage
with thrombin, located on the N-terminal of the domain. Numbering of the Cd-thiolate
centers is based on the NMR assignment by Messerle et al. (30). Molecular modeling
data from Chan et al. (31).

5.2 Experimental Methods
5.2.1 Chemicals
Chemicals used: cadmium sulfate (Fisher Scientific); cadmium(113) chloride (Trace
Sciences International Inc.); deuterium oxide (Cambridge Isotopes Laboratories, Inc.);
tris(2-carboxyethyl)phosphine (PIERCE); ThrombinCleanCleaveTM Kit (Sigma) Tris
buffer, tris(hydroxymethyl)aminomethane (EMD Chemicals/VWR); ammonium formate
buffer (JT Baker); ammonium hydroxide (Caledon Laboratory Chemicals); formic acid
(Caledon Laboratory Chemicals); and hydrochloric acid (Caledon Laboratory
Chemicals). All solutions were made with >16 MΩcm deionized water (Barnstead
Nanopure Infinity). HiTrapTM SP HP ion exchange columns (Amersham Biosciences/GE
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Healthcare), superfine G-25 Sephadex (Amersham Biosciences/GE Healthcare), stirred
ultrafiltration cell Model 8010 and 8200 (Amicon Bioseparations/Millipore) with YM-3
membrane (3,000 MWCO) were used in the protein purification steps.

5.2.2 Protein sample preparation for CD spectroscopic and ESI mass
spectrometric studies
The recombinant Cd3-β-rhMT 1a was prepared by over-expression in E. coli as
described in detail in Chapter 2. A solution of Cd3-β-rhMT 1a was prepared in 5 mM
ammonium formate (pH 9.0) to a concentration of 24.4 µM for CD, UV spectroscopic
and ESI-mass spectrometric studies. The protein concentrations was confirmed by UV
absorption spectroscopy using the absorbance at 250 nm, which corresponds to the
ligand-to-metal charge transfer transition generated by the metal-thiolate bond (ɛ250 =
36,000 M-1cm-1). To ensure accuracy, all measurements were performed on the same
sample for a given excess molar equivalents excess of Cd2+. Cadmium sulfate was
prepared in H2O to a final concentration of 11.4 mM. The concentrations of both the
cadmium sulfate solution and the cadmium content of all β-rhMT 1a solutions were
determined through calibration of Cd2+ content using atomic absorption spectroscopy
(AAS).

5.2.3 Protein sample preparation for NMR spectroscopic studies
β-rhMT 1a NMR samples were prepared by pooling protein from five-4 L
recombinant preparations following thrombin-cleavage of the S-tag.
abundance of NMR active
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The natural

Cd is 12.75%, consequently an eight-fold enhancement of

signal can be achieved by isotopic enrichment of the NMR sample. To that end, pooled
Cd3-β-rhMT 1a of natural
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Cd2+ abundance was demetalated using formic acid. The

protein was then desalted on a G-25 Sephadex column into deionized water, which had
been adjusted to a pH =2.7 using formic acid, to remove the natural abundance Cd2+. To
impede the oxidation of the protein, tris(2-carboxyethyl)phosphine (TCEP) was added to
the solution. Isotopically enriched Cadmium(113) chloride ( > 95%) was then added to
the solution followed by neutralization using ammonium hydroxide with concomitant
metal binding of 113Cd2+ to the protein. The solution was then concentrated to 10 mL and
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desalted into 10 mM ammonium formate buffer using a G-25 Sephadex column at pH 7.5
in order to remove any excess cadmium(113). Concentration and D2O exchange was
performed using stirred ultrafiltration cell models 8200 and 8010, respectively. The final
protein concentration was determined to be 7-8 mM based on UV absorption
spectroscopy using the 250-nm peak (ɛ250 = 36,000 M-1cm-1). The sample was Arsaturated and sealed in a 5 mm NMR tube for analysis. Following acquisition of 113Cd3/4β-rhMT excess cadmium(113) was added as a solid to produce
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Cd4-β-rhMT 1a used

for both the 1D and 2D NMR spectra.

5.2.4 Experimental details for the titration of excess Cd2+ into a
sample of Cd3-β-rhMT 1a
CD and UV absorption spectroscopy and ESI mass spectrometry
Spectra were acquired for the Cd3-β-rhMT 1a solution (24.4 µM) in 5 mM ammonium
formate buffer (pH 9.0) and for a solution from the same stock of Cd3-β-rhMT 1a to
which 4.4 excess molar equivalent of Cd2+ were added, forming (as we show in the ESIMass spectral data) Cd4-β-rhMT 1a.

5.2.5 Instrumental parameters
CD spectroscopy
CD spectra were acquired on a Jasco J810 spectropolarimeter in a 1-cm quartz cuvette
at room temperature (22 °C) and recorded using Spectra Manager v.1.52.01 (Jasco)
software. The wavelength range of 200-350 nm was scanned continuously at a rate of 60
nm/min with a band width of 2 nm. The spectral data were organized and plotted using
Origin® v.7.0383. The CD spectra are expressed in the units of A.
UV absorption spectroscopy
UV spectra were acquired on a Cary 5G UV-Vis-NIR spectrophotometer (Varian
Canada, Mississauga, ON, Canada) in a 1-cm quartz cuvette at room temperature (22 °C)
and recorded using the Cary Win UV Scan software application. The wavelength range
of 200-350 nm was scanned continuously. All spectra were baseline corrected. The
spectral data were organized and plotted using Origin® v.7.0383.
ESI mass spectrometry
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ESI-MS measurements were carried out after the UV absorption and CD spectroscopic
experiments had been completed. Mass spectra were acquired on a Micromass LCT
electrospray-ionization time-of-flight (ESI-TOF) mass spectrometer (Waters Micromass)
at room temperature (22 °C) and recorded using the Mass Lynx software package v. 4.0.
The ESI-TOF was calibrated with a solution of NaI.

The scan conditions for the

spectrometer were: capillary, 3000.0 V; sample cone, 15.0 V; extraction cone, 10.0 V; RF
lens, 450.0 V; desolvation temperature, 20.0 oC; source temperature, 80.0 oC; nebulizer
gas flow, 53 L/hr; and desolvation gas flow, 548 L/h. The m/z range was 500.0 to
3000.0, the scan mode was continuum, and interscan delay was 0.10 s. Max Ent 1 from
the Mass Lynx v.4.0 software package (Waters Micromass, Mississauga, ON, Canada)
was used for spectra reconstruction program.
NMR spectroscopy
All NMR spectra were acquired on a Varian Inova 600 NMR spectrometer (νL(1H) =
599.44 MHz, νL(113Cd) = 132.99 MHz) using Varian’s VNMRJ 2.2D software with
Chempack 3.0 add-on. The
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Cd chemical shifts were referenced with respect to an

external 1.0 M solution of CdSO4 in D2O (δ(113Cd) = 0.0 ppm), while 1H chemical shifts
were internally referenced to TMS (δ(1H) = 0.0 ppm) based on the 2H frequency of the
deuterated solvent.
Direct-detect 1D
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Cd{1H} NMR spectra were acquired using a Varian broad-band

5.0mm HX probe, a spectral range from 540 to 740 ppm, and WALTZ-16 1H decoupling
during acquisition only.

For Cd3/4-β-rhMT 1a, a total of 93 000 transients were

accumulated using a 1s relaxation delay and a 16.2 µs 90-degree pulse width with a 1.234
s acquisition time at 10 °C. The data were processed using a line-broadening of 10 Hz.
For Cd4-β-rhMT 1a, a total of 84 000 transients were accumulated using a 2s relaxation
delay and a 10.8 µs 60-degree pulse width with a 0.587 s acquisition time at 25 °C. The
data were processed using a line-broadening of 20 Hz.
Indirect 2D 1H-113Cd HSQC NMR spectra were acquired using a Varian indirectdetection 5.0 mm HCX probe, a 113Cd spectral range from 540 to 740 ppm, a 1H spectral
range from -0.4 to 4.8 ppm, a 0.15 s acquisition time, and a 1 s relaxation delay. Water
suppression was achieved using a selective 1 s presaturation pulse at a power of 4 dB. In
the indirect 113Cd dimension the data was zero-filled to 1024 total points, and a Gaussian
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weighting function was applied. In the direct 1H dimension, the data were zero-filled to
1024 points and a Gaussian weighting function was applied. For Cd3/4-β-rhMT 1a, a total
of 84 transients were accumulated for each of the 128 increments, a forward linear
prediction of 128 points in 113Cd dimension, and the 3J( 113Cd,1H) value was set to 60 Hz
at 30 °C. For Cd4-β-rhMT, a total of 44 transients were accumulated for each of the 256
increments, a forward linear prediction of 256 points in
113

113

Cd dimension, and the 3J(

Cd,1H) value was set to 67 Hz at 25 °C.

5.3

Results

5.3.1 Supermetalation

of

β-rhMT

1a

studied

by

ESI-mass

spectrometry and CD and UV absorption spectroscopies
To determine the effect of the fourth metal on the overall fold of the isolated β
domain, analysis with both CD and UV absorption spectroscopy, coupled with metal
speciation provided by ESI-MS, was carried out. These techniques allowed us to directly
correlate the number of metals bound and observed spectroscopic changes in solution.
The protein used in this set of experiments was taken directly after purification and
desalted into an ESI-MS compatible buffer. This was done to avoid structural changes
that may occur upon acid induced demetalation and to demonstrate that the additional
low affinity site for Cd2+ is not the result of high concentrations found in the NMR
experiment (32).
A solution of Cd3-β-rhMT 1a (Figure 5-2A) was initially measured. Addition of 4.4
excess molar equivalents of Cd2+ produced a solution with a composition of 10% Cd3- βrhMT 1a and 90% Cd4-β-rhMT 1a (Figure 5-2B). The mass of apo--rhMT 1a is 3754
Da (spectra not shown), giving the theoretical masses of Cd3-β-rhMT 1a and Cd4-β-rhMT
1a as 4085 Da and 4195 Da, respectively, which compare well with the experimental
masses of 4085 Da and 4197 Da, respectively. Because of the weaker binding of the
fourth Cd2+ atom to the protein, we attribute this residual 10% Cd3-β-rhMT 1a to MS
induced dissociation of the metal. An approximate equilibrium binding constant of 6.0 ±
0.8 x 104 M-1 was determined, using the ratio of Cd3/Cd4 based on an ESI-MS titration of
apo-β-rhMT for the low affinity site by ESI-MS, a value that is several orders of
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magnitude less than previously reported binding constants for normal binding of both
Cd2+, 6.0x1021 – 1025.6 M-1 (33-34), and Zn2+, 5.0x107 – 6.3x1011 M-1 (35).
To determine the location of the fourth cadmium ion, whether it was either attached to
the cluster or existed as an adduct to other opportunistic amino acids, the UV absorption
and CD spectra for both Cd3-β-rhMT 1a and Cd4-β-rhMT 1a were measured. While the
UV spectra did not change significantly (Figure 5-2C), the CD spectra measured for these
species (Figure 5-2D) showed drastic changes in the extrema. Maxima and minima at
262 and 236 nm, respectively, were observed for Cd3-β-rhMT 1a, while Cd4-β-rhMT 1a
exhibited maxima and minima of 252 nm and 231 nm, respectively. For Cd3-β-rhMT 1a
the maximum at 262 nm was broad suggesting that the traditional structure is flexible and
exists as a mixture of conformations.
Upon addition of excess Cd2+ to solution, the maximum blue shifted to 252 nm and the
intensity increased by 60%. The increase in intensity may be attributed to a decrease in
the conformational flexibility of the protein, while the blue shift can be associated with a
breaking of the exciton coupling between the three Cd2+ of the system as observed when
Cd5-α-rhMT 1a is formed (13). The breaking of exciton coupling strongly suggests that
the fourth Cd2+ atom is involved in the metal-thiolate cluster. A previous analysis of the
β domain using mouse MT-1 demonstrated CD spectral changes between 3 and 12
equivalents of Cd2+ (36), which the author argued was the result of a Cd9-rhβ-MT 1, but
which we postulate to be supermetalated Cd4-β-rhMT 1.
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Figure 5-2. ESI-MS deconvoluted spectra, UV-absorption and CD spectra of Cd3-rhMT 1a and the supermetalated Cd4--rhMT 1a.
(A) ESI-MS deconvoluted
spectrum of Cd3-β-rhMT 1a, showing the mass equal to the apo-protein with 3 Cd2+; (B)
ESI-MS deconvoluted spectrum of supermetalated Cd4-β-rhMT 1a formed following the
addition of 4.4 molar equivalents of CdSO4 to the Cd3-β-rhMT 1a, showing the additional
mass from 1 extra Cd2+. (C) UV absorption and (D) CD spectral changes observed for
Cd3-β-rhMT 1a and the supermetalated Cd4-β-rhMT 1a formed following the addition of
4.4 molar equivalents of CdSO4 to the Cd3-β-rhMT 1a. To ensure accurate speciation,
the same samples of Cd3-β-rhMT 1a and Cd4-β-rhMT 1a were used in all experiments.
All experiments were carried out in 5 mM ammonium formate buffer, at pH 9.0, and at
22 oC.

5.3.2 One dimensional 113Cd NMR spectroscopy of Cd3-β-rhMT 1a and
Cd4-β-rhMT 1a
Direct 1D 113Cd[1H] NMR spectroscopy was used for a mixture of Cd3/4-β-rhMT 1a, a
result of a slight excess of Cd2+ to increase resistance to oxidation, and a pure sample of
Cd4-β-rhMT 1a in order to determine relative speciation of the individual metal binding
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sites as well as the type of coordinating ligands through chemical shift data. Samples
were isotopically enriched with 113CdCl2 in 10 mM ammonium formate pH 7.4, following
demetalation with formic acid, in order to enhance the NMR signal. Signals observed for
Cd3/4-β-rhMT 1a (Figure 5-3A) include 687.9, 674.0, 644.7, 634.5, 629.9, 616.7 and
601.3 ppm, while the observed signals for the pure Cd4-β-rhMT 1a (Figure 5-3B) are
688.8, 650.3, 635.9 and 602.5 ppm. The chemical shift range of all the peaks is between
600 and 700 ppm, which overlaps significantly with the region expected for tetrahedral
cadmium-thiolate clusters (37), traditional of metallothioneins, as well as both trigonal
cadmium thiolate and tetrahedral cadmium-thiolate clusters where a single sulfur has
been replaced by water (38). By comparing the signals from both sets of data, the peaks
for Cd3-β-rhMT 1a can be identified as 674.0, 629.9 and 616.7 ppm. Previous NMR
work on human liver MT 1 have shown chemical shifts of 670.5, 652.0 and 645.8 ppm
for the β domain (25); the differences in the chemical shifts are most likely due to the
lack of the α domain as well as differences in sample conditions.
Direct detection of 113Cd in the binding site allows one to infer the fluctionality of the
individual metal ions.

Analysis of the spectrum in Figure 5-3A shows that peaks

attributed to Cd3-β-rhMT 1a species, with the exception of 674.0 ppm, are significantly
less intense than those we attribute to Cd4-β-rhMT 1a. Previous NMR studies involving
both domains, has suggested that the α domain is less fluctional than the β domain
leading to sharper peaks of greater intensity (25). Upon addition of excess
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Cd2+ to

solution, the observed chemical shifts of Cd3-β-rhMT 1a almost completely disappear
with an increase in intensity of the peaks assigned to Cd4-β-rhMT 1a suggesting an
overall reduction in the fluctionality of Cd4-β-rhMT 1a compared to Cd3-β-rhMT 1a.
There is a slight chemical shift in each of the four peaks, with the most significant shift
being a total of 5.6 ppm involving the movement of 644.7 ppm to 650.3 ppm, attributed
to the increase in chloride ions from
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CdCl2 (39). This peak is also noticeably broader

and less intense than the other three, which are of comparable size, suggesting that this
binding site is more solvent exposed and fluctional. The increase in fluctionality and
solvent exposure of just this site would make this Cd2+ site the most likely candidate for
the metal-exchange intermediate, allowing both the solvent and acceptor/donor proteins
access to the metal. The sharpness of the spectral lines further supports the interpretation
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of CD spectroscopic data that the maxima blue shift between Cd3-β-rhMT 1a and Cd4-βrhMT 1a, with an increase in intensity of 60%, is the result of a reduction in the
fluctionality of the domain overall.

Figure 5-3. Direct 1D 113Cd[1H] NMR spectrum (133 MHz) of (A) mixture of Cd3β-rhMT 1a and Cd4-β-rhMT 1a and (B) Cd4-β-rhMT 1a formed by addition of
excess 113CdCl2. Slight shifts in the ppm values of Cd4-β-rhMT 1a were observed
between the mixture and the pure supermetalated sample. This shift is attributed to the
addition of chloride ions from 113CdCl2, to the solution and is most pronounced in the
least intense Cd4-β-rhMT 1a signal at 644.7 ppm, with a total shift of 5.6 ppm downfield.
The Cd3/4-β-rhMT was prepared in 10 mM ammonium formate pH 7.4 and buffer
exchanged into 90% D2O. Subsequent addition of solid 113CdCl2 to Cd3/4-β-rhMT 1a led
to the formation of Cd4-β-rhMT 1a. Spectra of Cd3/4-β-rhMT 1a and Cd4-β-rhMT 1a
were acquired at 10 °C and 25 °C, respectively.
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5.3.3 Two dimensional 1H[113Cd]HSQC NMR spectroscopy of both
Cd3- and Cd4-β-rhMT 1a
Indirect 1H[113Cd] HSQC NMR spectroscopy was used for both Cd3/4-β-rhMT 1a and
Cd4-β-rhMT 1a (Figure 5-4). Analysis of the β protons of the cysteine residues allowed
determination of peak relatedness as well as a tentative assignment of the metal-thiolate
connectivity. Peaks were interpreted as related based on similarity in both the 1H and
113

Cd chemical shifts. Chemical shifts in the β protons of the cysteine were observed for

all metal sites existing in both Cd3-β-rhMT and Cd4-β-rhMT and it is likely these are the
result of the structural changes necessary for the accommodation of a fourth cadmium
atom in the β metal-thiolate cluster. In Figure 5-4, peak 2* possessed intense signals
observable at both the 2.3 and 2.8 ppm in the 1H dimension, both signals overlapped well
with peaks assigned to 2. Similarity in both the 1H profile as well as their closeness in
the 113Cd chemical shift range suggests that they are related. Peaks 3 and 3*, from Cd3-βrhMT 1a and Cd4-β-rhMT 1a, were interpreted as related with both similar peak shape
and profile from 2.4 to 3.5 ppm. A chemical shift disturbance of a β proton from peaks 3
and 3* is observed in the 3.2 to 3.4 1H range with a slight downfield shift that can be seen
in the Cd4-β-rhMT 1a compared to Cd3-β-rhMT 1a. Assignment of the cadmium center
associated with peaks 4 and 4* was based on the significant similarity in the β protons
region. Additionally, these peaks are equally broad and have comparable intensities in
the 1D
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Cd[1H] NMR spectrum (Figure 5-3a). The new signal, S, is attributed to the

supermetalated site and is significantly upfield from all other cadmium peaks. At 602.5
ppm, this peak may represent a tetrahedral geometry coordinating either four thiolates or
three thiolates and a single water molecule/chloride ion.
Assignment of the HSQC spectrum for Cd3-β-rhMT 1a shows three bridging cysteine
residues (Figure 5-4a), as one would expect from the connectivity (Figure 5-1). Upon
addition of excess cadmium, an additional two bridging interactions are observed.
Interestingly, the new metal appears to coordinate with all other metal centers at the
expense of bridging interactions within the original cluster. It is this loss of original
bridging interactions that may explain the loss of exciton coupling in CD spectroscopy
without any significant change in the ligand-to-metal charge transfer band observed in
UV spectroscopy (Figure 5-2).
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Figure 5-4. Indirect 2D 1H[113Cd] HSQC NMR spectra of (A) Mixture of Cd3-βrhMT 1a and Cd4-β-rhMT 1a and (B) Cd4-β-rhMT 1a produced upon addition of
excess 113CdCl2. The spectra were recorded in the 1H chemical shift range of -0.4 – 4.8
ppm and the 113Cd range of 540-740 ppm (3J = 60 Hz and 67 Hz) for Cd3-β-rhMT 1a and
Cd4-β-rhMT 1a, respectively. Spectra (A) was recorded at 30 °C, while spectra (B) was
recorded at 25 °C. Both spectra were acquired using an inverse single axis z-gradient
HCX probe with X tuned to 113Cd. These spectra were used to aid in the correlating Cd3β-rhMT 1a peaks with Cd4-β-rhMT peaks 1a.
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5.4

Discussion

It has been proposed over the last 50 years that the various different metallothioneins
perform many critical functions concerned with metal homeostasis, metal exchange, and
recently cellular redox status. In the present study, analysis of the spectroscopic data
from metalation of the β domain of human metallothionein 1a has shown that a
supermetalated form of the domain exists, the extra metal ion is located in the metal
thiolate cluster and we propose that this supermetalated form, with a distorted cluster,
may be a model of the metal exchange intermediate.

5.4.1 Location of the fourth Cd2+ ion in Cd4-β-rhMT 1a
Prior to this report it was unclear whether an additional metal was bound to the protein
metal-thiolate core, or if the protein was somehow bound to other ligands. The coupling
of both spectroscopic and spectrometric analyses clearly demonstrates that this additional
Cd2+ ion is coordinated to the metal-thiolate core and that this coordination leads to a
significant rearrangement of the cluster.

It is this fourth Cd2+ ion that breaks the

symmetry of the cluster, as monitored through a loss of exciton coupling (Figure 5-2).
Both direct and indirect
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Cd NMR spectroscopy confirm coordination of the fourth

Cd2+ ion to the metal thiolate core and provide tentative connectivities for the Cd3- and
Cd4-β-rhMT 1a clusters. Interestingly, an increase in the number of bridging interactions
from 3 to 5 was observed. The newly coordinated metal bridges with all three of the
original metals at the cost of cluster symmetry explaining the change in the CD spectrum.
We propose an increase in bridging interactions, which is based upon an addition of
proton-cadmium J-coupling seen as Cd3-βα-rhMT is converted to Cd4-βα-rhMT.
Expansion of the protein cluster, may be critical for the functions of metal ion
homeostasis and toxic metal detoxification because formation of these new bonds may be
the first step in metal insertion, followed by expulsion of one of the originally
coordinated metals.

5.4.2 The proposed mechanism of metal ion homeostasis
An insertion-expulsion mechanism would allow Cd2+, which binds several orders of
magnitude more tightly than Zn2+,

to exchange with Zn2+ bound metallothionein
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simultaneous acting to sequester toxic Cd2+ and releasing free Zn2+ into the cellular
environment.

The net effect would be upregulation of metallothionein allowing an

organism to effectively combat toxic metal exposure. A regulator of metallothionein
transcription, the metal-responsive-element-binding transcription factor-1 (MTF-1), has
been shown to upregulate metallothionein upon binding to Zn2+ (40). MTF-1 has been
implicated in cellular responses including toxic metal detoxification and oxidative stress,
both of which are implicated functions of metallothionein. The metal binding site of this
transcription factor includes six Cys2His2 zinc fingers making it exceptionally sensitive
to an organism’s zinc load. For this reason supermetalation, in the context of toxic
metals, may be a critical transient species in the regulation of transcription of the protein.
An incoming toxic metal, such as cadmium, could coordinate in a supermetalated
position allowing both sequestration of the toxic metal and release of a zinc ion. This
zinc ion would consequently lead to the upregulation of MT, through the zinc binding
motifs of MTF-1, allowing an organism to effectively combat toxic metals. Through this
mechanism, supermetalation of metallothionein, the organism would be able to control
cellular metal load.

5.4.3 Reports of supermetalated metallothionein in the literature
Supermetalation has now been reported in the α domain, Cd5-α-rhMT 1a, the β
domain, Cd4-β-rhMT 1a and the full MT protein, Cd8-βα-rhMT 1a, of human
metallothionein 1a (7-8, 31). In the case of the α domain of human MT-1, analysis of
113

Cd NMR spectra provided data suggesting that the supermetalated form, Cd5-α-rhMT

1a, included two bridging interactions through a crevice located on the α domain (13).
ESI-MS titrations have also provided evidence that a supermetalated Cd8-βα-rhMT 1a
may exist in a dynamic equilibrium with Cd7-βα-rhMT (7).

Chan et al. attributed

supermetalation of the full protein to supermetalation of the α domain, with the β domain
remaining intact (31). Currently no competition experiments between the two isolated
domains have been performed that would allow the determination of the relative affinity
of Cd2+ to form supermetalated species, however the NMR chemical shifts would suggest
that supermetalation first occurs in the β domain. By comparison, supermetalation of the
α domain produces a peak at 224 ppm, while supermetalation of the β domain produces a
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peak at 602 ppm. The dramatic difference in peak locations suggests that there are more
cysteine residues coordinating the Cd2+ involved in the supermetalated β domain than
there are in the α domain.

These cysteine residues would act to stabilize the

supermetalated structure, leading to an increase in the affinity of the β domain for
Cd2+/Zn2+ metal ions.

Figure 5-5.
Comparison of the 113Cd NMR resonances for the human MTs: Cd7βα-MT 3 (16), Cd7-βα-MT 2 (25), Cd7-βα-MT 1 (25), supermetalated Cd4--rhMT 1a
(this work), Cd3--rhMT 1a (this work), Cd4--rhMT 1a (13), and supermetalated Cd5-rhMT 1a (13).
Supermetalation of the brain specific MT-3 to produce Cd8-βα-MT 3 has also been
observed (14). Unlike supermetalation of MT-1, Meloni et al. have suggested that both
domains bridge together to accommodate the eighth cadmium atom.

Interestingly,

comparison of the metallothionein isoforms MT-2 and MT-3 demonstrated that while
MT-3 was capable of accepting an additional metal ion, MT-2 was not. However, both
MT-1 and MT-2 are more closely related than MT-3, the former having diverged before
distinction of the mammalian orders while the latter, more structurally distinct, evolved
much earlier (41). Surprisingly Romero-Isart et al. demonstrated the ability to confer
neuroinhibitory MT-3 activity onto MT-1, through a series of mutations to the β domain
(22). We postulate that supermetalation, a property only observed in distantly related
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MT-1 and MT-3, may be a factor that leads to the differentiation of each isoform into
specific functions in cellular chemistry.
One important aspect, which must be examined further, is the exact location of the low
affinity binding site(s) on the Cd8-βα-MT (1 or 2) protein. Figure 5-5 compares the NMR
spectral data for human Cd7-βα-MT 1, 2 and 3, the two isolated fragments of Cd3-rhMT 1a and Cd4--rhMT 1a, and the supermetalated species, Cd4-β-rhMT 1a and Cd5-rhMT 1a. The value of this figure is to show how the extra metal for the  domain
described here exhibits a typical 113Cd NMR spectral signature that falls within the range
of MT data. Indeed, it is possible that the Cd7-βα-MT 1 spectrum may contain a small
fraction of Cd4-β-MT as indicated by an overlap of the NMR signals of the Cd4-β-MT 1a
with those of Cd7-βα-MT 1. On the other hand, the fifth Cd2+ in the Cd5-α-rhMT 1a
results in a resonance in the region well away from the tetrahedral thiolates. Two
possibilities exist for the location of the low affinity sites on Cd8-βα-MT: 1) each domain
is independently capable of binding an additional metal ion, as supported by
supermetalation of the isolated β and α domains of MT-1, or 2) the two domains work in
concert to bind this additional metal, as supported by the decrease in the Stokes radius of
MT-3 upon supermetalation, which is consistent with the close approach of both clusters.
It is probable that supermetalation of metallothionein is isoform specific, related to
cellular function and mechanisms of metalation must be determined on a case-by-case
basis. Answers to these questions in the future will have consequences for metal ion
homeostasis, as well as toxic metal detoxification and could possibly lead to an
assignment of a specific function for each of the metallothionein isoforms.

5.5

Conclusion

In this study, the β domain of recombinant human MT 1a, which is known to
coordinate 3 Cd2+ ions through 9 cysteine residues, was shown to be able to coordinate an
additional Cd2+ ion to form Cd4-β-rhMT 1a using a combination of CD, UV and NMR
spectroscopy, as well as ESI-mass spectrometry. The CD spectrum of the Cd4-β-rhMT
1a showed a sharp monophasic peak centered at 252 nm as compared to the derivativeshaped spectrum of the Cd3-β-rhMT 1a species with a maximum at 262 nm (+) and a
minium at 236 nm (-). This change in the CD maximum indicates a disruption of the
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exciton coupling between the original 3 Cd2+ ions. The ESI-mass spectrum showed an
increase in mass corresponding to a single Cd2+ ion upon the addition of 4.4 molar
equivalents excess to a solution of Cd3-β-rhMT 1a further confirming the existence of
this low affinity binding site.
Both direct and indirect
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Cd NMR spectroscopic techniques were used to probe the

coordination environment of the additional Cd2+ ion. The signal detected in the 1-D
NMR spectrum associated with the supermetalated Cd2+ ion was located at 602 ppm.
This location is typical of both trigonal cadmium thiolate and tetrahedral cadmiumthiolate clusters where a single sulfur ligand has been replaced by water (38). Evidence
from the 2-D NMR spectra suggest that binding of the additional Cd2+ ion significantly
perturbs the cluster leading to an increase of bridging interactions from 3 to 5. These
enhanced interactions are likely the cause of the loss of exciton coupling observed in the
CD spectrum as Cd3-β-rhMT 1a is converted into Cd4-β-rhMT 1a. Based upon the
significant difference between the NMR chemical shift range of the supermetalated peak
in Cd4-β- and Cd5-α-rhMT 1a (602 ppm vs. 224 ppm respectively), it is likely that
supermetalation of the β-domain dominants the full MT protein. Future research will
involve the characterization of supermetalated Cd8-βα-rhMT 1a to determine the exact
location of this additional Cd2+ ion.
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Chapter 6.

Single domain metallothioneins:

Supermetalation of human MT 1a6
6.1 Introduction
Metallothioneins (MTs), first isolated by Margoshes and Vallee in 1957 (1), are a
family of small metalloproteins characterized by their high cysteine content, absence of
disulfide bonds, and a lack of aromatic amino acids (2). MT is ubiquitous to living
organisms and since its discovery, members of the MT family have been isolated from a
wide range of sources including all animal phyla, fungi, plants, as well as cyanobacteria
(3-6). Owing to the significant number of cysteine residues in the sequence (~30% of all
amino acids) (7), the function(s) of MT have been postulated to include toxic metal
detoxification, protection against oxidative stress and as a metallochaperone involved in
the metal ion homeostasis of essential Zn2+ and Cu+ (8). However, despite more than
sixty years of intense research, the exact in vivo role(s) of MT are still largely unknown.
Mammalian MTs are the most well studied members of the MT family and consist of
20 cysteine residues that act to encapsulate two metal-thiolate cores. Figure 6-1A shows
a space filling model of human MT 1a coordinated to 7 Cd2+ ions, Cd7-βα-rhMT 1a
(mammalian isoforms other than 1a will be noted specifically). In the X-ray structure of
rat liver MT 2 (Zn2Cd5-MT 2) (9), and NMR studies from other variants (10-11), the
metal ions exist with two independent domains: an N-terminal β-domain and a Cterminal α-domain. The β-domain is capable of binding 3 Zn2+ or Cd2+ ions through 9
cysteine residues, while the α-domain is capable of binding 4 Zn2+ or Cd2+ ions through
11 cysteine residues (Figure 6-1B). Significantly, the structural data has only been
reported from metal-saturated proteins. It is important to note that both Zn2+ and Cd2+
bind to metallothionein in an isostructural manner, and that the overall molecular
architecture of the protein, when coordinated to either Zn2+ or Cd2+, is identical (11). The
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sequence of the cleaved recombinant βα-rhMT coordinated to seven divalent metal ions
is shown in Figure 6-1C, with the metal ions colored green and cysteine residues colored
yellow. The numbering of the cadmium-thiolate core is cross referenced to the original
naming conventions based on the order of the NMR bands in the mammalian Cd7-MT 2a
spectra (10), while the numbering of the cysteine residues has been adjusted to
accommodate both the additional amino acids from thrombin cleavage (residues 1 and 2)
and a series of amino acids meant to aid in protein expression (residues 3-9).
Mammalian MT can be subdivided into four distinct subfamilies (MT-1, -2, -3 and -4),
each of which contain twenty cysteine residues coordinating seven divalent metals.
However, different patterns of expression suggest specific in vivo roles for each
subfamily. For example, both MT-1 and -2, found in abundance in the liver and kidneys,
are induced by a number of stimuli, including metal ions, glucocorticoids, cytokines and
oxidative stress (3, 12-13), while MT-3, found primarily in the central nervous system
(14), and MT-4, found in stratified squamous epithelial tissues, are more tightly
controlled (15). These differences in expression, both causal and spatial, of the MT
subfamilies are likely the result of the unique biological functions of each member. In
fact, it has been shown that disruption of the natural expression of MT-3, through ectopic
expression in mice, has led to the development of pancreatic acinar cell necrosis and
death (16). These results highlight the fact that a dysregulation in the expression of MT
can lead to a diseased state and eventual death. However, little is known regarding the
structural differences of these MT subfamilies that must underlie their functional
differences.
One reason for the difficulty in determining structure-function relationships for MT is
that it is notoriously difficult to crystallize. To date only two X-ray structures have been
reported: the first from rat (9), Cd5Zn2-MT 2, and the second from yeast (17), Cu8-MT.
In the first case, both cadmium and zinc metal centers were tetrahedrally coordinated by
four thiolate groups into two distinct binding domains, while in the second case a
combination of both trigonal and digonal coordination was observed for a single domain
Cu-thiolate cluster. Much of the structural information known for mammalian MT is a
result of the many NMR-based studies (10, 18-21). While NMR studies can provide the
solution structure of MT, analysis has been limited to the spin ½ nuclei, namely 111Cd and
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Cd. Unfortunately, because of an absence of interdomain peaks associated with the

nuclear overhauser effect (NOEs), NMR studies can only provide the absolute
connectivities of atoms in a specific domain and their spatial relationship within that
domain’s metal-thiolate core. While the X-ray structure of the rat liver Zn2Cd5-MT 2 did
provide the alignment of the interdomain linkage, the lack of interdomain NOEs has led
to the assumption that both domains essentially act independently of each other. Further,
subsequent studies have also generally assumed that the metal-based chemistry of each
domain must also be independent and significantly that MT will adopt a two domain
structure at all metal loading levels.

Figure 6-1. Molecular model of MT. (A) A space filling structure of Cd7-βα-rhMT
1a. The N-terminal β-domain is located on the left hand side, while the C-terminal αdomain is located on the right hand side. (B) Cadmium-cysteinyl-thiolate clusters of Cd7βα-rhMT 1a presented as a ball and stick model: β-domain (left) and α-domain (right).
(C) A connectivity diagram of MT 1a, which shows that each of the seven cadmium
atoms is connected to exactly four cysteine amino acids. The connectivity diagram has
been renumbered to accommodate the amino acids glycine and serine, both of which are
a product of S-tag cleavage with Thrombin, located on the N-terminal of the β-domain.
Numbering of the Cd-thiolate centers is based on the NMR assignment by Messerle et al.
(10). Molecular modeling data from Chan et al. (22).
The assumption of domain independence has significant consequences for the metal
exchange properties of metallothionein. Specifically, the β-domain of MT has been
associated with a preference for Cu+ coordination, while the α-domain has been
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associated with a preference for Zn2+ or Cd2+ coordination (23-25).

The question

remains, however, if the domains do not interact with one another, then how does the
metal binding reaction reach equilibrium? This problem is further complicated by the
fact that MT is capable of binding a very wide range of metals, with differing geometries
that are dependent on the stoichiometries of the associated metal, for example As6-MT,
Cd7- or Zn7-MT, Cu12- or Ag12-MT, and Hg18-MT (26-29). A recent study with As-MT
has shown that As3+ distribution between the full protein and the domain fragments
occurred by protein-protein interactions, and not by an dissociative-associative
mechanism (30). While not conclusive, these results support the existence of domaindomain interactions as the driving force behind metal-ion equilibration.
Another reason for the difficulty in determining the function of MT is that until
recently, MT was thought to coordinate metals in a cooperative fashion, where the
binding of one metal facilitates the binding of subsequent metals (31). However, recent
studies have shown that metalation of MT by Cd2+, Zn2+, As3+, and Bi3+ occurs in a
noncooperative fashion (26, 32-36). A noncooperative mechanism allows for partially
metalated, as well as metal exchange intermediates, to be stable and able to take part in
cellular chemistry. Significantly, Krezel and Maret have shown from their competition
experiments that there exist at least three classes of Zn2+ binding site, with log K values
of 11.8, ~10 and 7.7 corresponding to the binding of four, two and one metal ion,
respectively (37). This range of binding affinities shows that MT can act as a dynamic
metallochaperone, capable of donating and accepting metal ions over a range of cellular
concentrations.
Finally MT has been shown to bind metals in excess of traditional levels. These
supermetalated states have been reported for both of the isolated α- and β-domains
forming Cd5-α-rhMT (38) and Cd4-β-rhMT (39), respectively. This level of metalation
has also been reported in human MT-3, Cd8-βα-hMT 3 (40). In the case of MT-1 and
MT-2, Cd2+ ions are known to isomorphously replace Zn2+ ions (41), which suggests the
involvement of these supermetalated structures in the metal-exchange reactions that must
occur for the binding of incoming metals with binding affinities greater than that of the
resident zinc, for example, the essential Cu+ and the toxic Cd2+. Indeed, metal transfer
reactions in MT have been well documented, for example the Zn2+ transfer of fully
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metalated Zn7-βα-MT to m-aconitase (42), carbonic anhydrase (43), and the prototypical
transcription factor Gal4 (44). Interestingly, a recent study involving the incubation of
Aβ1-40-Cu2+, a producer of reactive oxygen critical to Alzheimer’s disease, with Zn7-βαMT 3 demonstrated that MT readily exchanged Zn2+ for Cu2+, with subsequent reduction
to Cu+ and coordination to the remaining reduced thiols, thereby deactivating the Aβ1-40peptide (45). While these studies highlight the importance of protein-protein interactions,
no exchange intermediates have been characterized that provide insight into the actual
mechanism of metal transfer.
In this paper, we present evidence that human metallothionein, Cd7-βα-rhMT, is
capable of binding an additional cadmium atom to form Cd8-βα-rhMT. Exact metal
speciation was monitored using ESI-mass spectrometry (ESI-MS), which allowed for a
direct correlation between the number of cadmium atoms bound to the protein and
observed changes in the UV absorption and CD spectra. Direct and indirect
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Cd NMR

spectroscopies were used to ensure that the incoming metal was structurally significant
and involved direct interaction with the metal-thiolate cluster. Possible implications of
these results with respect to metal ion homeostasis and metal ion domain selectivity are
discussed both of which have significant consequences for the in vivo function of MT in
an organism.

6.2 Experimental Methods
6.2.1 Chemicals
Cadmium sulfate (Fisher Scientific); cadmium(113) chloride (Trace Sciences
International Inc.); deuterium oxide (Cambridge Isotopes Laboratories, Inc.); tris(2carboxyethyl)phosphine (PIERCE); ThrombinCleanCleaveTM Kit (Sigma) Tris buffer,
tris(hydroxymethyl)aminomethane (EMD Chemicals/VWR); ammonium formate buffer
(JT Baker); ammonium hydroxide (Caledon Laboratory Chemicals); formic acid
(Caledon Laboratory Chemicals); and hydrochloric acid (Caledon Laboratory
Chemicals). All solutions were made with >16 M  cm-1 deionized water (Barnstead
Nanopure Infinity). HiTrapTM SP HP ion exchange columns (Amersham Biosciences/GE
Healthcare), superfine G-25 Sephadex (Amersham Biosciences/GE Healthcare), stirred
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ultrafiltration cell Model 8010 and 8200 (Amicon Bioseparations/Millipore) with YM-3
membrane (3,000 MWCO) were used in the protein purification steps.

6.2.2 Protein sample preparation for CD spectroscopic and ESI mass
spectrometric studies
The expression and purification of recombinant βα-rhMT has been previously reported
(22) and is described in detail in Chapter 2. The βα-rhMT used in this study was based on
the

72-residue

sequence

MGKAAAACSC

ATGGSCTCTG

SCKCKECKCN

SCKKAAAACC SCCPMSCAKC AQGCVCKGAS EKCSCCKKAA AA with no
disulfide bonds present in the system. The expression system included, for stability
purposes, an N-terminal S-tag (MKETAAAKFE RQHMDSPDLG TLVPRGS).
Recombinant βα-rhMT 1a was expressed in BL21(DE3) Escherichia coli (E. coli)
transformed using the pET29a plasmid. Removal of S-tag was performed using a
Thrombin CleanCleaveTM Kit. To impede oxidation of the cysteine residues to disulfide
bonds, all protein samples were rigorously evacuated and then argon saturated to remove
any residual oxygen that may be present in the solution.

6.2.3 Protein sample preparation for NMR spectroscopic studies
Samples of Cd-bound βα-rhMT for NMR analysis were prepared by pooling protein
product from five 4 L recombinant preparations following thrombin-cleavage of the Stag. The
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Cd7-βα-rhMT used for acquisition of all NMR spectra was prepared by

addition of concentrated formic acid to demetalate the protein, followed by desalting on a
G-25 Sephadex column at which point tris(2-carboxyethyl)phosphine (TCEP) was added
to the solution to impede oxidation. Isotopically pure (>95%) cadmium(113) chloride
was added to the solution followed by neutralization using ammonium hydroxide. The
solution was then concentrated to 10 mL and desalted into 10 mM ammonium formate
buffer using a G-25 Sephadex column at pH 7.5 in order to remove any excess
cadmium(113). Concentration, and D2O exchange to 30% total volume, was performed
using Amicon stirred ultrafiltration cell models 8200 and 8010, respectively. The final
protein concentration was determined to be 5.3 mM based on UV absorption
spectroscopy using the 250-nm peak (ɛ250 = 89,000 M-1cm-1). The buffer used for this
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sample was 5 mM ammonium formate (pH 8.3). The sample was Ar-saturated and sealed
in a 5 mm NMR tube for analysis. Following acquisition of
cadmium(113) was added to produce

113

113

Cd7/8-βα-rhMT excess

Cd8-βα-rhMT, which was used for both the 1D

and 2D NMR spectra.

6.2.4 Experimental details for the titration of excess Cd 2+ into a
sample of Cd8-βα-rhMT 1a
CD and UV absorption spectroscopy and ESI mass spectrometry
All protein concentrations were confirmed by UV absorption spectroscopy using the
absorbance at 250 nm, which corresponds to the ligand-to-metal charge transfer transition
generated by the metal-thiolate bond (ε250= 89 000 M-1cm-1).
CD spectra were recorded on a Jasco J810 spectropolarimeter in a 1 cm quartz cuvette
at room temperature (22 °C) using Spectra Manager version 1.52.01 (Jasco).

The

wavelength range of 200-350 nm was scanned continuously at a rate of 50 nm/min with a
bandwidth of 2 nm. The spectral data were organized and plotted using Origin version
7.0383. The CD spectra are expressed in units of ΔA. For the CD titration a solution of
Cd7-βα-rhMT was prepared in 5 mM ammonium formate (pH 8.1) to a concentration of
7.8 μM. This solution was then titrated in a stepwise manner with increasing amounts of
Cd2+ using both 0.17 mM and 1.02 mM CdSO4 in order to produce a solution of Cd8-βαrhMT 1a.
UV absorption spectra were recorded on a Cary 5G UV–vis–NIR spectrophotometer
(Varian) in a 1 mm quartz cuvette at room temperature (22 °C) using the Cary Win UV
Scan software application.

The wavelength range of 200-350 nm was scanned

continuously. All spectra were baseline-corrected. The spectral data were organized and
plotted using Origin version 7.0383. The sample was measured in a 5 mM ammonium
formate buffer at pH 8.1 with a protein concentration of 28 μM. This same sample was
used in the ESI-MS titration. The extinction coefficient used for Cd8-βα-rhMT 1a was 89
000 M-1cm-1
ESI-MS spectra were recorded on a micrOTOF II MS (Bruker).

The operating

parameters were as follows: End plate offset -500 V; Capillary 4200 V; Nebulizer 2.0
Bar; Dry gas 8 L/min; Dry temperature 80 ⁰C; Capillary exit 180 V; Hexapole RF 600
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Vpp; Mass range 500 to 3000 m/z. Spectra were acquired as a rolling average of 2×0.5
Hz. A solution of Cd7-βα-rhMT was prepared in 5 mM ammonium formate (pH 8.1) to a
concentration of 27.0 μM for MS measurements of Cd7-βα-rhMT and Cd8-βα-rhMT.

6.2.5 Instrumental parameters
CD spectroscopy
CD spectra were recorded on a Jasco J810 spectropolarimeter in a 1 cm quartz cuvette
at room temperature (22 °C) using Spectra Manager version 1.52.01 (Jasco).

The

wavelength range of 200-350 nm was scanned continuously at a rate of 50 nm/min with a
bandwidth of 2 nm. The spectral data were organized and plotted using Origin version
7.0383. The CD spectra are expressed in units of ΔA. For the CD titration a solution of
Cd7-βα-rhMT was prepared in 5 mM ammonium formate (pH 8.1) to a concentration of
7.8 μM. This solution was then titrated in a stepwise manner with increasing amounts of
Cd2+ using both 0.17 mM and 1.02 mM CdSO4 in order to produce a solution of Cd8-βαrhMT 1a.
UV absorption spectroscopy
UV absorption spectra were recorded on a Cary 5G UV–vis–NIR spectrophotometer
(Varian) in a 1 mm quartz cuvette at room temperature (22 °C) using the Cary Win UV
Scan software application.

The wavelength range of 200-350 nm was scanned

continuously. All spectra were baseline-corrected. The spectral data were organized and
plotted using Origin version 7.0383. The sample was measured in a 5 mM ammonium
formate buffer at pH 8.1 with a protein concentration of 28 μM. This same sample was
used in the ESI-MS titration. The extinction coefficient used for Cd8-βα-rhMT 1a was 89
000 M-1cm-1.
ESI mass spectrometry
ESI-MS spectra were recorded on a micrOTOF II MS (Bruker).

The operating

parameters were as follows: End plate offset -500 V; Capillary 4200 V; Nebulizer 2.0
Bar; Dry gas 8 L/min; Dry temperature 80 ⁰C; Capillary exit 180 V; Hexapole RF 600
Vpp; Mass range 500 to 3000 m/z. Spectra were acquired as a rolling average of 2×0.5
Hz. A solution of Cd7-βα-rhMT was prepared in 5 mM ammonium formate (pH 8.1) to a
concentration of 27.0 μM for MS measurements of Cd7-βα-rhMT and Cd8-βα-rhMT.
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NMR spectroscopy
All NMR spectra were acquired on a Varian Inova 600 NMR spectrometer (νL(1H) =
599.44 MHz, νL(113Cd) = 132.99 MHz) using Varian’s VNMRJ 2.2D software with
Chempack 3.0 add-on. The
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Cd chemical shifts were referenced with respect to an

external 1.0 M solution of CdSO4 in D2O (δ(113Cd) = 0.0 ppm), while 1H chemical shifts
were internally referenced to TMS (δ(1H) = 0.0 ppm) based on the 2H frequency of the
deuterated solvent.
Direct-detect 1D

113

Cd{1H} NMR spectra were acquired using a Varian broad-band

5.0 mm HX probe, a spectral range from 540 to 720 ppm, and WALTZ-16 1H decoupling
during acquisition only.

For Cd7/8-βα-rhMT 1a, a total of 39 000 transients were

accumulated, while Cd8-βα-rhMT 1a had a total of 30 176 transients accumulated. Both
used a 7 s relaxation delay and a 5.33 µs 60-degree pulse width with a 0.684 s acquisition
time at room temperature. The data were processed using a line-broadening of 10 Hz.
Indirect 2D 1H-113Cd HSQC NMR spectra were acquired using a Varian indirectdetection 5.0 mm HCX probe, a 113Cd spectral range from 540 to 720 ppm, a 1H spectral
range from -0.5 to 10 ppm, a 0.291s acquisition time, and a 2s relaxation delay. Water
suppression was achieved using a selective 2s presaturation pulse at a power of 13 dB. In
the indirect 113Cd dimension the data was zero-filled to 1024 total points, and a Gaussian
weighting function was applied. In the direct 1H dimension, the data were zero-filled to
1024 points and a Gaussian weighting function was applied. For both Cd7/8-βα-rhMT 1a
and Cd8-βα-rhMT 1a, a total of 80 transients were accumulated for each of the 128
increments, a forward linear prediction of 128 points in
113

113

Cd dimension, and the 3J(

Cd,1H) value was set to 67 Hz at room temperature.
Molecular Model
MM3/MD calculations parameterized using the modified force field described by

Chan et al. and the dielectric constant for water (78.4) were carried out to obtain the
minimum-energy structure of Cd8-βα-rhMT 1a (46). All MM3/MD calculations and
model-structure rendering were carried out using CAChe WorkSystem Pro 6.1.1
Software (Fujitsu America). The original Cd7-βα-rhMT 1a was modified using CAChe to
produce molecular models for Cd8-βα-rhMT 1a. The structure was energy-minimized as
follows: 1) the structure was energy minimized using the MM3 calculation followed by
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the MD simulation at 500 K for 1000 ps. 2) The lowest structure was taken and again
minimized at 300K for 5000 ps.

6.3

Results

6.3.1 Supermetalation

of

βα-rhMT

1a

studied

by

ESI-mass

spectrometry and CD and UV absorption spectroscopies
To determine the effect of the 8th metal on the overall fold of the protein, analysis with
both CD and UV absorption spectroscopy, coupled with metal speciation provided by
ESI-MS, were used. These techniques correlate the number of metals bound to the
observed spectroscopic changes in solution. The protein used in these experiments was
taken directly after purification and desalted into an ESI-MS compatible buffer. This was
carried out in order to avoid structural changes that may occur upon acid induced
demetalation and to demonstrate that the additional low affinity site for Cd2+ is not the
result of high concentrations found in the NMR experiment (47).
A solution of Cd7-βα-rhMT (Figure 6-2A) was initially measured. Addition of 2.8
excess molar equivalents of Cd2+ quantitatively converted Cd7-βα-rhMT to Cd8-βα-rhMT
(Figure 6-2B). In the MS spectra, two sets of truncated βα-rhMT were detected: one in
which the N-terminal G residue and C-terminal AA residues were truncated, and a second
in which the N-terminal GSMGK as well as A from either the N-terminal or C-terminal
were truncated.

None of the metal-binding cysteine residues were affected.

This

truncation has been previously reported, and it does not affect the metal binding
properties of the protein (32). The former truncation is of greater intensity and was used
for all metal binding analyses. The theoretical m/z values of Cd7-βα-rhMT are 1275.5
m/z for +6, 1530.4 m/z for +5 and 1912.7 m/z for +4, while the theoretical mass is 7,647
Da. These theoretical data are essentially identical to the experimental results of 1275.8
m/z for +6, 1530.6 m/z for +5 and 1913.2 m/z for +4 and a mass of 7,649 Da. The
theoretical m/z values of Cd8-βα-rhMT are 1293.9 m/z for +6, 1552.5 m/z for +5 and
1940.4 m/z for +4, while the theoretical mass is 7,757 Da. These theoretical values also
compare well with the experimental results of 1294.5 m/z for +6, 1552.8 m/z for +5 and
1940.7 m/z for +4 and a mass of 7,759 Da. Of significance, is that the conversion of Cd7-
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βα-rhMT into Cd8-βα-rhMT leads to an increase in the relative intensity of the +6 charge
state from 38% to 55% and a decrease in the absolute intensity of the +5 charge state.
These changes in intensity may be attributed to an increase in the overall volume of the
protein necessary to accommodate the binding the 8th Cd2+ ion (48-49).
The effect of the addition of the 8th cadmium ion was also analyzed using both UV
absorption and CD spectroscopy to determine the effects of this additional ion on the
metal-thiolate cores.

The UV absorption spectrum did not change significantly upon

formation of Cd8-βα-rhMT (Figure 6-2C).

This was observed previously for the

formation of the supermetalated Cd4-β-rhMT and Cd5-α-rhMT (38-39). The lack of
change in the UV absorption profile with the addition of an 8th Cd2+ ion is likely related
to the necessity for the formation of only bridging interactions.
Addition of 1 molar equivalent Cd2+ led to significant changes in the CD spectrum
(Figure 6-2D). The original maxima and minima of 260 and 239 nm observed for Cd 7βα-rhMT were replaced by maxima and minima of 252 nm and 238 nm, respectively.
Significant reduction in the intensity of the maxima located at 225 nm was also observed.
Two isodichroic points are observed throughout the titration at 260 and 241 nm and
provide evidence for the direct conversion of Cd7-βα-rhMT to Cd8-βα-rhMT. For Cd7βα-rhMT the maximum at 260 nm was broad suggesting that the traditional structure is
flexible and exists as a mixture of conformations. However, upon supermetalation of
Cd7-βα-rhMT to form Cd8-βα-rhMT the maximum blue shifted to 252 nm and the
intensity increased by 50%. The increase in intensity may be attributed to a decrease in
the conformational flexibility of the protein, while the blue shift can be associated with
the metal ion directly interacting with the metal-thiolate core. These changes to the CD
envelope provide strong evidence that the 8th Cd2+ atom coordinates to both the β- and αdomain.
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Figure 6-2. Spectrometric and spectroscopic evidence for the existence of Cd8-βαrhMT. ESI-MS spectra of (A) Cd7-βα-rhMT and (B) Cd8-βα-rhMT with 0.0 and 2.8
excess molar equivalents of CdSO4, respectively. The charge states marked with an
asterisk(*) are the result of a small fraction of truncated protein. (C) UV absorption
spectra of Cd7-βα-rhMT and Cd8-βα-rhMT with 0.0 and 2.8 excess molar equivalents of
CdSO4, respectively. (D) CD spectral changes observed during the incremental titration
of Cd7-βα-rhMT with CdSO4 to form Cd8-βα-rhMT. Aliquots of CdSO4 were added to
solution in mole equivalents (based on the whole protein) of 0.00, 0.03, 0.06, 0.13, 0.19,
0.44, 0.62, 0.80, 0.99 and 1.35. The inset (D) shows the change in absorbance at 252 nm
as a function of Cd2+ added to solution. Past the addition of one molar equivalent Cd2+,
there is no change in the CD spectrum.
The inset in the CD titration (Figure 6-2D) shows that no change in the absorbance at
252 nm is observed after a single molar equivalent of Cd2+ has been added to solution of
Cd7rhMT. We interpret the maxima at 252 nm to be exclusively the result of the Cd 8-βαrhMT species. Cd7-βα-rhMT binds the additional Cd2+ ion with a significantly greater
affinity than either Cd3-β-rhMT or Cd4-α-rhMT binds the additional Cd2+ to form their
respective supermetalated species (38-39).
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6.3.2 One dimensional

113

Cd NMR spectroscopy of Cd7- and Cd8-βα-

rhMT 1a
Direct 1D

113

Cd[1H] NMR spectra were measured for a mixture of Cd7/8-βα-rhMT, a

result of a slight excess of Cd2+ to increase resistance to oxidation, and a pure sample of
Cd8-βα-rhMT in order to determine the relative speciation of the individual metal binding
sites as well as the type of coordinating ligands through chemical shift data. In the Cd 7/8βα-rhMT spectrum, peaks 1, 5, 5’, 6 and 7 correspond to the α-domain, while peaks 2, 3
and 4 correspond to the β-domain (50). Signals observed for Cd7/8-βα-rhMT (Figure 63A) include resonances at 673, 668, 650, 647, 631, 629 and 621 ppm, where the
resonances at 673, 631, 629 and 621 ppm result from the α-domain and 668, 650 and 647
ppm result from the β-domain. An additional peak labeled(*) and located at 680 ppm has
been previously observed and is likely the result of the presence of some metal-based
heterogeneity in the Cd7-βα-rhMT. This assignment is based, in part, on previous NMR
work of human liver Cd-MT 1 by Boulanger and Armitage (50). The observed signals
for the pure Cd8-βα-rhMT (Figure 6-3B) are 690, 647, 637 and 595 ppm. The chemical
shift range of all the peaks is between 590 and 700 ppm, which overlaps significantly
with the region expected for tetrahedral cadmium-thiolate clusters (51). This region is
commonly found for the NMR spectra of Cd-metallothioneins, as well as both trigonal
cadmium thiolate and tetrahedral cadmium-thiolate clusters where a single sulfur has
been replaced by water, or opportunistic chloride ion (52). No signals in the range of 200
to 250 nm were observed, which had been previously observed for supermetalated Cd5-αrhMT (38).
Direct detection of 113Cd in the binding site allows one to infer the fluctionality of the
individual metal sites. Analysis of the spectrum in Figure 6-3A shows that resonances
attributed to the β-cluster are significantly less intense than those attributed to the αcluster. Previous NMR studies involving both domains have shown the α-domain is less
fluctional than the β domain leading to sharper peaks of greater intensity for the αdomain (50). Addition of excess

113

Cd2+ eliminates the spectral complexity associated

with the two isolated domains. The loss of all seven unique Cd2+ signals associated with
the Cd7-MT and the formation of four unique peaks, strongly suggests that the addition of
the singular Cd2+ to Cd7-βα-rhMT leads to the loss of the isolated clusters in favor of a
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coalesced, single domain of a ‘super cluster’. While all four peaks are of similar size,
and intensity, the signal located at 647 ppm is slightly broader and less intense. This
suggests that the metal-ion associated with this binding site is more solvent exposed and
fluxional. Consequently, it is likely that this smaller broader peak is the most likely
candidate for the site of metal loss in the metal-exchange intermediate, allowing both the
solvent and acceptor/donor proteins access to the metal-ion.

The sharpness of the

spectral lines further supports the interpretation of CD spectroscopic data that the maxima
blue shift between Cd7-βα-rhMT and Cd8-βα-rhMT, with an increase in intensity of 50%,
is the result of a reduction in the fluctionality of the protein.

Figure 6-3. Direct 1D 113Cd[1H] NMR spectrum (133 MHz) of (A) a mixture of
Cd7-βα-rhMT and Cd8-βα-rhMT and (B) Cd8-βα-rhMT formed by addition of
excess 113CdCl2. The Cd7/8-βα-rhMT was prepared in 5 mM ammonium formate pH 8.3
and buffer exchanged into 30% D2O. Because of the slight excess of 113Cd2+, a portion of
the sample has been converted to Cd8-βα-rhMT leading to the formation of additional
peaks at 682 and 595 ppm. Subsequent addition of crystalline 113CdCl2 to Cd7/8-βα-rhMT
led to the formation of Cd8-βα-rhMT, which greatly simplifies the spectra reducing it to 4
peaks. Spectra of Cd7/8-β-rhMT and Cd8-β-rhMT were acquired at room temperature.
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6.3.3 Two dimensional 1H[113Cd]HSQC NMR spectroscopy of both
Cd7- and Cd8-βα-rhMT 1a
Indirect 1H[113Cd] HSQC NMR spectra were measured for both Cd7-βα-rhMT and
Cd8-βα-rhMT (Figure 6-4). Analysis of the β protons of the cysteine residues allowed
determination of peak relatedness. Peaks were interpreted as related based on similarity
in both the 1H and 113Cd chemical shifts. In the case of Cd7-βα-rhMT (Figure 6-4A), both
signals 1 and 2 have the same overall profile as those of the isolated domains, and are
attributed to the α- and β-domain, respectively. Signals 3 and 4 result from the remaining
two cadmium ions found in the β-domain and are significantly downfield compared to
their counterparts found in the isolated domains (isolated β-domain 630 and 616 ppm
compared with the full protein 650 and 647 ppm) (39). We interpret this difference as the
result of the effect of the α-domain on the chemical shifts of the β-domain. Signals 5 and
5’ are both attributed to the same cadmium atom found in the α-domain and have a
similar cysteine β proton profile. Signals 6 and 7 both correspond to α-domain and have
similar chemical shifts to those of the isolated α-domain (isolated α-domain 626 and 611
ppm compared with the full protein 629 and 621 ppm) (38).
The loss of cluster identity when Cd7- is converted into Cd8-βα-rhMT (Figure 6-4B)
significantly simplifies the spectra and the addition of the 8th metal ion results in dramatic
changes to the β proton profile of all peaks. These changes indicate that there are
significant structural rearrangements taking place to accommodate all metal ions.
Interestingly, no signal was observed in the 245-215 ppm region that had previously been
assigned to the supermetalated Cd(RS)2(OH2)4 of the α-domain. This suggests that the
supermetalated cadmium ion found in Cd8-βα-rhMT is directly coordinated to at least 3
cysteine residues. With the exception of the previously mentioned Cd(RS)2(OH2)4, the
previously reported

113

Cd NMR data for the

supermetalated isolated domains have

exactly four 113Cd2+ signals located between 700-600 ppm and the tentative assignment of
peak identity for the Cd8-rhMT 1 was based upon this similarity (38-39).
Note that supermetalation of the β-domain leads to an inversion of the location of the
3 and 4 peak, such that 4 is found further downfield than 3. The β proton profile of Cd 8βα-rhMT is somewhat more complex than either isolated domain, indicating overlap of
the profiles of both domains. It should be noted at this time that there are two reasons
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why we have not assigned a specific cysteine residue to each 2-D signal: the first is that
signals associated with the β-domain are significantly less intense than those associated
with the α-domain and their overlap further complicates the spectra, the second reason is
that in order to conclusively assign the identity of the peaks, one would require a
complete backbone assignment. This type of assignment has been not been carried out
yet for human MT-1a.
Figure 6-5 provides a graphical comparison of the NMR data for MT isoforms 1-3, as
well as the supermetalated data for both Cd-MT and its isolated domains. The value of
this figure is that it shows the NMR range where MT-cadmium-thiolate clusters are
found. The presence of the 8th cadmium atom causes both the β- and α-domains to adopt
supermetalated character.

This is strong evidence that this 8th cadmium atom is

coordinated to Cys previously in both domains. Also important to this figure is the
observation that all NMR peaks, with the exception of supermetalated Cd5-α-rhMT, fall
between 700 and 590 ppm. It can be clearly seen that Cd8-βα-rhMT, Cd5-α-rhMT and
Cd4-β-rhMT all exhibit nearly identical 113Cd signals in the 700-590 ppm range. This was
a surprising result since it had been previously thought that supermetalation of the full
protein would lead to either 9 unique signals, indicative of Cd9-βα-rhMT 1a, or
alternatively would only alter the metal binding sites of one of the two domains. We
interpret this overlap to mean that supermetalation of the isolated domains is in fact the
result of residual metal binding capacity. This is supported by CD titrations of all three,
where the isolated β- and α-domains require an excess of Cd2+ to supermetalate and the
full protein is completely supermetalated at exactly 1 equivalent (Figure 6-2).
Consequently, we propose based on these experimental results, that Cd8-βα-rhMT 1a
adopts a new MT structural motif that requires the coalescence of both domains to a
single binding domain.
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Figure 6-4. Indirect 2D 1H[113Cd] HSQC NMR of (A) Cd7-βα-rhMT 1a and (B)
Cd8-βα-rhMT 1a formed by addition of excess 113CdCl2. While a total of eight peaks
exist for Cd7-βα-rhMT, it can be clearly seen that 5 and 5’ have similar proton profiles.
This heterogeneity has been previously reported by Boulanger and Armitage and is
attributed to a slight difference in two structural conformers of the protein (50). The
signals in (B) are the labeled based upon the assignments of the isolated Cd4-β-rhMT and
Cd5-α-rhMT (38-39). The peak labeled 7/S is what we consider to be the site of
supermetalation and we believe that this may represent a tetrahedral geometry
coordinating either four thiolates or three thiolates and a single water molecule/chloride
ion.
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Figure 6-5. Comparison of the 113Cd NMR resonances for the human MTs: Cd7βα-MT 3 (21), Cd7-βα-MT 2 (50), Cd7-βα-MT 1a (50), supermetalated Cd8-βα-rhMT 1a
(this work), Cd3--rhMT 1a (39), supermetalated Cd4--rhMT 1a, Cd4--rhMT 1a and
supermetalated Cd5--rhMT 1a (38). Note the significant overlap in the location of
signals associated with both isolated domains of MT and the full protein. The sole
exception to this similarity is the presence of a single peak at 224 ppm associated with
supermetalated Cd5--rhMT, which is both absent from supermetalated Cd4--rhMT and
supermetalated Cd8-βα-rhMT.

6.4

Discussion

For the last sixty years, MT has been proposed to be involved in metal homeostasis,
toxic metal detoxification and in the protection of organisms against oxidative stress (8).
And while it is likely that MT is involved in all three of these processes, the exact cellular
function(s) have never been determined. Critical to these roles are MT’s ability to act as
a metallochaperone capable of coordinating incoming metal ions and exchanging them
with the cellular environment. Indeed several studies have demonstrated the importance
of MT in both donating to and accepting metal ions from other metalloproteins (42-44).
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These studies have highlighted the importance of protein-protein interactions, but a
metal-exchange intermediate has not been observed. Several studies have documented
the preference of the β-domain for Cu+ ions and the α-domain for Zn2+/ Cd2+ ions (23, 45,
53). Since Zn2+ coordination dominates mammalian MT (54), an incoming metal of
higher binding affinity (Cd2+ or Cu+) must either 1) coordinate in a domain specific
manner, or 2) coordinate through either domain with a subsequent redistribution of
metals leading to the observed metal-domain preferences. Copper luminescent studies of
MT have provided evidence for a fluctional model of the protein, in which initial
metalation occurs in a distributed manner, statistically across both domains, followed by
a rearrangement of both clusters to their lowest energy conformers (25, 28). However,
this model would require an intraprotein intermediate, in which both domains exchange
metals with each other. To date both the β- and α-domains of fully metalated MT are
considered isolated, because of both a lack of interdomain NOEs and the independence of
their respective 113Cd signals in NMR studies (10, 20, 55).

6.4.1 Location of the eighth Cd2+ ion in Cd8-βα-rhMT 1a
We report here, for the first time, conclusive evidence for the presence of domaindomain interactions in fully metalated MT from experimental observation of a species in
which one Cd2+ is proposed to bridge both domains. Formation of Cd8-MT species
results in the loss of specific  and  domain character and the formation of a single,
Cd8Cys20 domain.

This supermetalated species provides evidence for the type of

intermediate that is critically important in the metal exchange pathway necessary for the
observed domain selectivity of metal ions. Implicit in this structure is the existence of a
‘super domain’, where both domains contribute cysteine residues to produce a single
Cd8Cys20 cluster in MT 1a. This supermetalated structure has been effectively ‘frozen’
by the higher binding constant of Cd2+, compared with Zn2+, and is likely critical in the
metal exchange reactions necessary for MTs role as a metallochaperone.
Initial ESI-MS studies of the apo-protein of MT provided the first evidence that the
Cd7-βα-rhMT species was able to supermetalate to form Cd8-βα-rhMT (32). However,
prior to this report it was unclear whether this additional metal was bound to either metalthiolate core found in the protein, or if the 8th Cd2+ was somehow bound to other ligands.
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The coupling of both spectroscopic and spectrometric analyses (Figure 6-2) demonstrates
that the addition of only a single equivalent of Cd2+ to the fully metalated Cd7-rhMT
protein causes structural changes, which lead to a significant changes in the symmetry of
the eight Cd2+ bound in the cluster. This rearrangement breaks the symmetry of both
original clusters, observed from the simultaneous loss of exciton coupling in the CD
spectrum, but with little change in the ligand-to-metal charge transfer profile. ESI-MS
spectral data also show that only a single Cd2+ ion is found to coordinate to the protein,
and further that this additional metal ion causes an increase in the relative intensity of the
+6 charge state compared with the +5 charge state. This suggests that the protein must
adopt a significantly larger structure to accommodate the additional metal ion. The
observation of two simultaneous isodichroic points during the CD titration of Cd7-βαrhMT with Cd2+ is evidence for the direct conversion of Cd7-βα-rhMT to Cd8-βα-rhMT
with no intermediate structures (Figure 6-2D). The location of the

113

Cd-NMR chemical

shifts demonstrates conclusively that the additional metal directly interacts with the
metal-thiolate core and that this metal ion greatly simplifies the seven unique Cd2+ sites
to four unique Cd2+ sites. Taken together these results demonstrate that supermetalation
of MT 1a with Cd2+ leads solely to the formation a bridged Cd8Cys20 structure as the final
product of metalation.
Based on the previous stoichiometric data for the isolated supermetalated domains of
Cd4-β-MT and Cd5-α-MT it would be reasonable to predict that the supermetalated full
protein would involve 9 Cd2+ ions. However, only Cd8-MT was actually formed. This
now allows us to propose that the two-domain structure does not exist generally for all
metal loadings, rather only for specific metal loadings. For Zn2+ and Cd2+ this would
occur at 7 metals per MT protein.
In addition to Cd-hMT-1a, Cd-hMT-3 has also been confirmed to supermetalate by 1D
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Cd NMR spectroscopy (40). Cd-hMT-3 is primarily found in the central nervous

system and, unlike MT-1a and -2, its expression is strictly controlled (12-13). In the
central nervous system MT-3 is thought to control metal ion homeostasis and has been
shown to be downregulated in some Alzheimer’s patients (14). Unlike Cd-hMT-1a, the
supermetalated NMR spectra of Cd-hMT-3 does not simplify to four peaks. Moreover,
the CD spectrum of MT-3 does not exhibit a loss of exciton coupling found in the
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supermetalation of MT-1a. However, the formation of supermetalated Cd-hMT-3 does
result in a decrease in the Stoke’s radius of this protein, which suggests the mutual
approach of the two domains. We should note that neither Meloni et al. studying Zn7MT-2 using both spectroscopic and spectrometric techniques (40) nor Stillman et al.
studying rabbit liver Cd7MT 2a by CD spectroscopy (56) found that MT-2 was capable of
supermetalation. These differences between isoforms may be critical to the cellular role
of each MT isoform. It is probable that supermetalated structures of Cd-hMT-1a and -3
are different. Based on these observations, we postulate that the ability of an MT isoform
to supermetalate and the subsequent structure formed from this process are factors that
lead to the differentiation of each isoform (MT-1a,-2,-3 and -4) into specific functions in
cellular chemistry.

6.4.2 The proposed mechanism of metal ion homeostasis
This metal exchange structure could have significant consequences for both the metal
ion homeostasis and toxic meal detoxification properties of an organism.

Previous

studies, using CD, UV and NMR spectroscopies have shown that Cd2+ binding to both
apo-MT or Zn7-MT leads to the formation of Cd7-MT with almost identical absorption
and CD properties (23, 56-57). These experiments suggest that regardless of initial status
of the MT it is capable of assuming the same conformation when fully metalated. When
the protein is fully metalated, such as Zn7-MT, the incoming metal ion must be able to
coordinate and expel a previously bound Zn2+. In the case of Zn7-MT, the formation of a
transient M1Zn7-βα-rhMT 1a can be envisioned as an exogenous Cd2+, or Cu+, ion
coordinating to Zn7-βα-rhMT 1a, bridging both domains with subsequent rearrangement
and expulsion of a previously bound Zn2+ ion. The net effect would be 1) metal ion
selectivity (for example, Cu+ in the β-domain and Zn2+/Cd2+ in the α-domain) and 2)
upregulation of metallothionein allowing an organism to effectively combat toxic metal
exposure. A regulator of metallothionein transcription, the metal-responsive-elementbinding transcription factor-1 (MTF-1), has been shown to upregulate metallothionein
upon binding to Zn2+ ions (58-59). MTF-1 has been implicated in cellular responses
including toxic metal detoxification and oxidative stress, both of which are implicated
functions of metallothionein. The metal binding site of this transcription factor includes
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six Cys2His2 zinc fingers, making it exceptionally sensitive to an organism’s zinc load.
Cell free transcription experiments have shown a number of stresses, including exposure
to Cd2+, Cu+ and H2O2 function by displacing naturally bound Zn2+ from MT (60).
These free Zn2+ ions bind to MTF-1 leading to a translocation of MTF-1 from the
cytoplasm to the nucleus where the Zn-MTF-1 interacts with metal response elements
(MREs) leading to upregulation of MT. In this way, MT is capable of countering and
deactivating a wide range of insults in order to return an organism to homeostatic
balance.
For this reason, supermetalation, in the context of toxic metals, may be a critical
transient species in the regulation of transcription of the protein. An incoming toxic
metal, such as Cd2+, could coordinate in a supermetalated position allowing both
sequestration of the toxic metal and release of a Zn2+ ion.

This Zn2+ ion would

consequently lead to the upregulation of MT, through the Zn2+ binding motifs of MTF-1,
allowing an organism to effectively combat toxic metals. Through this mechanism,
supermetalation of metallothionein, the organism would be able to control cellular metal
load.
Surprisingly, we did not observe any evidence for the existence of a Cd9-βα-rhMT
species, which had previously been suggested to exist based on the summation of the
metalation status of the individual supermetalated β- and α-domains. These observed
supermetalated states, Cd4-β-rhMT and Cd5-α-rhMT, are likely the result of the residual
metal binding capacity necessary for both domains to work in concert to form Cd 8-βαrhMT. Unlike other metalation studies, which reported the collapse of the two domain
structure, for example Hg- and Ag-MT, supermetalation to Cd8-βα-rhMT does not require
a change in coordination number of the metal ion (29, 61-62).
We have calculated a tentative model based on all eight Cd2+ ions being tetrahedrally
coordinated to four cysteine residues, which leads to a complete collapse of the twodomain structure (Figure 6-6A). While qualitative in nature, the structure presented
shows how the addition of the 8th Cd2+ ion leads to the complete loss of cluster identity
(Figure 6-6B). Through supermetalation, the bridging of both domains provides the
intraprotein interactions necessary for metal ion selectivity. The coordination of the 8th
Cd2+ ion in this model accounts for the absorption, CD and NMR spectral data of Cd8-βα-
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rhMT. In the case of the CD titration, supermetalation of MT essentially locks the two
domains in place resulting in a loss of conformational freedom and explains increased
sharpness of the Cd8-MT spectra. In the case of the NMR spectra, the complete collapse
of the Cd7-MT spectra is the result of loss of cluster identity upon binding of the 8th Cd2+
ion.
Much current research on MT include its interaction with metal based anticancer
drugs, such as cisplatin (63). In these cases, MT has been implicated as a cause for the
development of cisplatin resistant cancers (64-66). Karotki and Vasak have found that
the binding of Pt2+ to MT occurs via a two step reaction and further that the β-domain is
the preferred site of coordination. In the context of supermetalation, initial coordination
likely leads to a coalescence of both domains with subsequent ejection of one of the
previously bound metals of the β-domain (67). These researchers have also characterized
a previously unknown DNA-cis-Pt-MT ternary structure, where coordination of the DNA
bound cisplatin does not lead to the release of significant Zn2+ in Zn7-MT. These results
suggest that coordination occurs in a site specific manner through two sets of solvent
exposed cysteine residues found in the β- and α-domain (68). The role of supermetalation
in the initial coordination of metal-based chemotherapeutics may be of significant
importance for the development of future chemotherapeutics.
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Figure 6-6. Molecular model of a possible structure for supermetalated Cd8-βαrhMT 1a. A) Ribbon structure of the backbone of Cd7-βα-rhMT and Cd8-βα-rhMT with
the cadmium atoms represented as spheres calculated using a locally modified force-field
with MM3/MD methods for molecular modeling. The N-terminal β domain is located on
the left hand side, while the C-terminal α domain is located on the right-hand side. (B)
The cadmium-cysteinyl-thiolate clusters of Cd8-βα-rhMT 1a are presented as a ball-andstick model: β domain (left) and α domain (right). The structure was created by inserting
an additional Cd2+ ion between the two domains, and minimizing the structure in two
steps: 1) 1000 ps at 500 K, and 2) 5000 ps at 300 K. The conformer with the lowest
energy is presented above. The initial structure of the Cd7-βα-rhMT 1a was provided by
Chan et al. (22).
It is now becoming evident that MT has a significant role in the body’s response to
neuroinflammation (69). Recently, a report by Manso et al. has demonstrated that the
full MT-1 was able to improve the performance of MT knockout mice whose cortex had
been damaged through cryoinjury (70).

Most interestingly, the authors report that

exposure of the mice to the isolated MT fragments, β and α, result in markedly different
recovery rates compared to the full βα-protein. While the exact mechanism of action is
not known, it could be postulated that supermetalation of the full protein, which has
significantly greater affinity than either of the two isolated domains, is the causative
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agent in recovery. Thus full MT acts as a superior metallochaperone when compared to
the isolated domains.

6.5 Conclusion
In summary, the collapse in the number of unique

113

Cd-NMR peaks from seven to

four, the significant changes in the CD spectral envelope and the quantitative formation
of Cd8-βα-rhMT, and not Cd9-βα-rhMT, are paradigm shifting with respect to the
structural motifs in metallothionein. The spectroscopic evidence reported in this paper
indicate that the β- and α-clusters act in isolation under only very specific metalation
conditions. The supermetalated Cd8-rhMT 1a protein adopts a novel single domain
structure suggesting that the well-known two-domain structure might be the special case
in the metal-dependent structural landscape of MTs. Further, with these results we are
now able to account for both the ability of MT to exchange metals with the solution and
the observed metal ion selectivity of the individual domains.
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Chapter 7.

Conclusion7

Metallothionein is a small cysteine rich protein, which was first isolated more than
sixty years ago (1). In that time, it has been implicated in a number of roles, including
toxic metal detoxification, metal ion homeostasis, and as a protective agent against
oxidative stress (2). MT is found in all organisms and has been isolated from a number
of sources (3). It is therefore quite surprising that while there exists a significant body of
evidence to support all three roles, the exact in vivo function(s) of MT and its associated
binding partners is not known. Two potential reasons for this lack of specific function(s)
includes: 1) an ambiguous mechanism of metalation, and 2) a lack of metal binding
motifs. In the first case, the mechanism of metal binding seriously impacts both the
ability of MT to act as a dynamic metallochaperone, and the biologically relevant
partially metalated states of the protein. If MT were to coordinate metals in a cooperative
manner, then partially metalated forms of the protein would be unstable and unlikely to
take part in cellular chemistry. As such, only the fully metalated (Zn7-MT) and apo
forms of the protein are biologically relevant. Indeed to address the lack of an exact
function, much research has recently focused on the metalation chemistry of the apo form
of the protein (4-7).
MT has also been traditionally considered a two-domain protein. The structure has
always been thought to contain two independent metal-binding domains: an N-terminal
β-domain, which can bind 3 Zn2+, Cd2+, or 6 Cu+ ions, and a C-terminal α-domain, which
can bind 4 Zn2+, Cd2+, or 6 Cu+ ions. The most well known mammalian form is Zn7-MT
(8-10), and Zn2+ is the dominant metal found in human MT. Cu+ is also found,
particularly in fetal MT, and finally also Cd2+, due to environmental exposure(11). But in
all three cases, metalation is thought to involve two independent metal-binding domains.
Most interestingly, there exists no metal-exchange intermediate to account for these
metalated forms.

7

A version of this work is in preparation
D.E.K. Sutherland, K.L. Summers and M.J. Stillman (2012).
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The research in this thesis demonstrates that the mechanism of metalation is
noncooperative (12-14). Consequently, partially metalated forms of the protein are stable
and may take part in cellular chemistry.

Information regarding the metal-binding

mechanism was extracted from the analysis of the metalated states of the isolated
domains, and full MT protein, in the presence of sub-stoichiometric amounts of Zn2+, or
Cd2+ (12). In this way detection of only the fully metalated and the metal-free protein
would indicate a cooperative mechanism, while the formation of a mixture of
intermediate partially metalated species would indicate a non-cooperative mechanism of
metalation. The results presented in this thesis on the metalation of apo-α-, apo-β and
apo-βα-rhMT 1a with sub-stoichiometric concentrations of Cd2+ , or Zn2+, at slightly
basic pH showed the formation of stable, partially-metalated domain species as detected
by ESI-mass spectrometry (Chapters 3 and 4). These results unequivocally confirmed a
non-cooperative metalation mechanism for both Cd2+ and Zn2+.
The work presented here also provides evidence for the existence of at least 2
additional and previously unknown motifs of metalation. A thorough understanding of
all possible metal binding motifs of MT is essential for a complete understanding of the
in vivo functions of MT. For example, Zn7-MT is often cited as cellular buffer against
toxic metals, Cd2+ and Hg2+. In this case, an incoming metal ion of greater affinity than
the resident zinc will coordinate forming a transient M1Zn7-MT, where M is the incoming
metal ion, with concomitant rearrangement and expulsion of the previously bound Zn2+
ion to form M1Zn6-MT. To date no known metal exchange intermediate has been
discovered and it is unknown exactly how MT reaches equilibrium with the metal ions in
the cell. Furthermore the mechanism by which MT can selectively isolate different metal
ions into both domains (Zn2+ and Cd2+ prefer the α-domain, while Cu+ prefers the βdomain) is not known, but is of critical importance to the function of MT (15-16). This
question also has practical implications since MT overexpression is thought to be a
mechanism that allows cancer cells to overcome metal based chemotherapeutics, for
example cisplatin (17-19). The only partially metalated form that has previously been
described as relevant is one in which the α-domain is completely metalated (4 Zn2+ ions)
and the β-domain is completely demetalated (0 Zn2+ ions) (20).

However, with a

noncooperative mechanism of metalation, all partially metalated structure may be stable,

165

depending on metal ion availability, and a thorough understanding of each is a
prerequisite for a complete understanding of the roles of MT during Zn2+ deficiency. It
is, therefore, highly unlikely that one domain would be filled, while the other remains
empty. More likely is a reversion of the protein to a partially metalated motif, which
could incorporate cysteine residues from both domains to bind the metal ions.
In this thesis, the mechanism of metal binding and the subsequent structural motifs
formed in MT 1a were investigated. Three proposals naturally fall from these results: 1)
The mechanism of metalation is in fact always noncooperative, meaning that the partially
metalated forms of the protein are stable and could potentially take part in cellular
chemistry, and 2) two additional metal binding motifs of MT exist, the first is a
supermetalated form of the protein, where an eighth Cd2+ ion is coordinated to both
domains, and the second is a submetalated form of the protein, where five Zn2+ ions are
each coordinated to four terminal thiol groups, where terminal thiol groups defines a
cysteine residue coordinated to only a single metal ion. Taken together, these results
fundamentally alter our understanding of the metalation properties of the protein by not
only demonstrating that, in fact, all partially metalated forms of the protein are stable and
the dominant species is directly dependent on the concentration of metal ions present, but
also that cluster formation occurs only upon the addition of the sixth Zn2+ ion and further
that addition of excess Cd2+ leads to the formation of a novel Cd8-MT species. This latter
species is of particular interest, since the addition of Cd2+ to Zn7-MT leads to the mixed
metals species until 7.0 molar equivalents have been added at which point Cd7-MT exists.
We postulate that Cd8-MT is in fact a ‘frozen’ metal-exchange intermediate that is
observable due to the higher association constant of Cd2+ compared to Zn2+.
In order of significance we have discussed above: Noncooperativity. This led to the
understanding that partial metalation was stable and, therefore, able to take part in
cellular chemistry.
Sub-saturated metalation. In Chapter 4, we demonstrated that the onset of cluster
formation, which is defined by the use of bridging Cys thiolate ligands rather than
terminal Cys, leads to a significant decrease in the Zn2+ binding affinity to MT and its
domains for further metalation.
accommodate an increase in Zn

2+

The switch from terminal to bridging Cys to

in the binding sites reduces the binding affinity. These
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mass spectral data allow us to conclude for the full MT protein that the decreasing
association constants necessary for a noncooperative mechanism of metalation allow
formation of a stable Zn5-βα-rhMT species, which contains no bridging interactions.
This is a single binding site domain and is mechanistically a key member of the
metalation pathway from apo-MT to the fully metalated Zn7-MT. In addition, we have
used this model to reinterpret the Co2+ titration of MT(21). By allowing for the existence
of a non-clustered Zn5-MT intermediate, we were able to reproduce the data presented by
Vasak and Kagi, and more importantly, reinterpret their data in the context of a
noncooperative mechanism of metalation.
Supermetalation. To date, all reports regarding the speciation of the mammalian MT
protein state a maximum of seven Cd2+ or Zn2+ ions coordinating 20 cysteinyl thiolate
ligands. These metal ions are divided between the β-domain (3 Cd2+ or Zn2+) and αdomain (4 Cd2+ or Zn2+). The work in Chapters 5 and 6, as well as a previous report By
Rigby-Duncan et al. (22), have shown that human MT-1a isoform is capable of
expanding its cluster to accommodate an eighth Cd2+ ion by the addition of 1.0 molar
equivalents excess of Cd2+ ions to solution (Chapter 6)(23). Based upon the chemical
shift range of the NMR spectra, the coordination geometry of this eighth site is predicted
to include tetrahedral geometry coordinating cysteine residues from both domains. In
addition, the breaking of exciton coupling in the CD spectra would suggest that this
eighth metal ion is directly interacting with the metal-thiolate clusters of both domains.
The existence of a supermetalated state for the α-domain had been previously determined
(24). When combined with the ability of the β-domain to supermetalate, it had been
previously predicted that supermetalation of the full protein would include two additional
Cd2+ ions binding to both domains. It was therefore quite surprising that only a single
Cd2+ ion bound to form Cd8-MT. This result is critically important because this structure,
for the first time, provides definitive evidence for the existence of domain-domain
interactions. When the protein is fully metalated, such as Zn7-MT, the incoming metal
ion must be able to coordinate and expel a previously bound Zn2+. These interactions
provide a rationale for two important features of MT: metal ion equilibration with cellular
environment, and the ability for each domain to discriminate between metal ions (Zn2+
and Cd2+ in the α-domain, and Cu+ in the β-domain).

167

Figure 7-1. Molecular models of the metalation of apo- to Zn7-MT, then to Cd8MT. The first four structures represent the sequential metalation of apo-MT using Zn2+,
while the last structure demonstrates the effect of the addition of 8 equivalents of Cd2+.
The traditional two-domain structure of MT is observed in Zn6- and Zn7-MT. However,
prior to 6 molar equivalents of Zn2+ added, and following the addition of 8 molar
equivalents of Cd2+, the two domain structure collapses. Zn5-MT was created by
coordinating 1 Zn2+ ion to every 4 consecutive cysteine residues with respect to the
sequence. Zn6-MT was created by removing a Zn2+ ion from the β-domain of MT. Cd8MT was created by coordinating an additional 8th Cd2+ ion to the exposed residues of
both domains. All structures were minimized in two steps: 1) 1000 ps at 500 K, and 2)
5000 ps at 300 K. The conformer with the lowest energy is presented above. The initial
structure of the Cd7-βα-rhMT 1a was provided by Chan et al.(25).
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Concluding remarks. The results presented in this thesis support a paradigm altering
view of MT, in which the two-domain nature of metallothionein is, in fact, the
exceptional case. In the early stages of metalation, metal ions, such as Zn 2+, bind MT in
a noncooperative manner. In the new model based on the experimental data described in
this thesis, clustering, a key feature of MT, does not occur until all cysteine residues are
bound terminally, that is after 5 Zn2+ have bound. Following this, bridging occurs to lead
to the more traditional two-domain structure. Consequently, Zn5-MT, where all twenty
cysteine residues of MT are terminally coordinating five Zn2+ ions, will not contain any
free thiol groups. MT is often considered a protective agent against oxidative stress. A
metallothionein redox cycle, connecting oxidants with the redox silent Zn2+, has been
suggested to account for the protective role of MT in the cell. Initially a ROS oxidizes
MT leading to Zn2+ release. This Zn2+ then acts to up regulates Zn-dependent proteins,
through MTF-1, and subsequently reduction of MT using glutathione, or replacement
with de novo synthesized MT and reestablishment of zinc homeostasis(26). With these
results, one can now begin to assess the redox potential of the differently metalated
versions of MT (Zn1- to Zn5-MT), and how metalation of all the cysteine residues,
forming Zn5-MT, affects its ability to act as a protective agent. It is possible that the
subtle control of the redox activity of Zn5-MT controls its biological activity - the change
from terminal Cys to one free Cys (and therefore available SH groups) or additionally to
a bridging Cys may be a low energy reaction allowing for active but controlled redox
properties.
Metallothionein has also been implicated in metal-ion homeostasis, and as a protective
agent against toxic metal insults (2). However, no metal-exchange intermediate has been
isolated. The results presented in this thesis now demonstrate that MT is capable of
binding an additional eighth Cd2+ ion to form Cd8-MT (23, 27). This species is stabilized
due to the higher affinity of Cd2+ ions for thiols, compared with Zn2+ ions. Unique to this
structure is the bridging of both domains to coordinate the eighth metal ion. We propose
that when the protein is fully metalated, such as Zn7-MT, the incoming metal ion must be
able to coordinate and expel a previously bound Zn2+. In the case of Zn7-MT, the
formation of a transient M1Zn7-βα-rhMT 1a can be envisioned as an exogenous Cd2+, or
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Cu+, ion coordinating to Zn7-βα-rhMT 1a, bridging both domains with subsequent
rearrangement and expulsion of a previously bound Zn2+ ion.
Finally, we propose a metalation chart (Figure 7-1), which begins with metal-free MT,
which progressively metalates to Zn5-MT, at which point there are no free thiols.
Following this, the binding of the 6th and 7th Zn2+'s leads to the formation of the more
traditional two-domain structure. MT is capable of coordinating eight structurally unique
Cd2+ ions leading to the formation of Cd8-MT, where the two-domains have collapsed to
form one ‘super-domain.’

The value of this diagram is that it shows progressive

metalation of the protein, and highlights the early stages of metalation (apo- to Zn5-MT),
which are important in the protection of an organism against oxidative stress, as well as
the latter stages of metalation (Zn7- to Cd8-MT), which are important in protecting an
organism against toxic metal insult and in maintain the metal ion homeostasis of an
organism.
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